<SEC-DOCUMENT>0001493152-21-002375.txt : 20210202
<SEC-HEADER>0001493152-21-002375.hdr.sgml : 20210202
<ACCEPTANCE-DATETIME>20210202133019
ACCESSION NUMBER:		0001493152-21-002375
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20210202
DATE AS OF CHANGE:		20210202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JanOne Inc.
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-HOME FURNITURE, FURNISHINGS & EQUIPMENT STORES [5700]
		IRS NUMBER:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-251645
		FILM NUMBER:		21580134

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
    SUPPLEMENT</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    Pursuant to Rule 424(b)(5)</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
    Prospectus dated December 29, 2020)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    No.</B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 333-251645</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_001.jpg" ALT="" STYLE="height: 75px; width: 326px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JanOne
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>571,428
shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering 571,428 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;JAN.&rdquo; On January 28, 2021, the last reported
sale price of our common stock as reported on the Nasdaq Capital Market was $12.99 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. See the section entitled &ldquo;Risk Factors&rdquo; appearing on page S-6 of
this prospectus supplement and elsewhere in this prospectus supplement and the accompanying base prospectus for a discussion of
information that should be considered in connection with an investment in our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged A.G.P./Alliance Global Partners (&ldquo;AGP&rdquo;) to act as our sole placement agent in connection with this offering.
The placement agent has agreed to use its reasonable best efforts to place the securities offered by this prospectus supplement.
We have agreed to pay the placement agent the fees set forth in the table below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Public offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">10.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">5,999,994.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Placement agents&rsquo; fees(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">419,999.58</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Proceeds, before expenses, to us</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.765</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,579,994.42</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, we have agreed to reimburse the placement agent for certain offering-related expenses. See &ldquo;Plan of Distribution.&rdquo;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
of the shares of common stock is expected to be made on or about February 2, 2021, subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole
Placement Agent</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>A.G.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is January 29, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-6</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#m_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION INCORPORATED BY REFERENCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<TD STYLE="vertical-align: bottom; border-bottom: transparent 1.5pt solid">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<TD STYLE="vertical-align: bottom; width: 0.5in; border-bottom: #000000 1.5pt solid">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ABOUT_THIS_PROSPECTUS"><font style="text-decoration:underline;">ABOUT THIS PROSPECTUS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#AVAILABLE_INFORMATION"><font style="text-decoration:underline;">AVAILABLE INFORMATION</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INCORPORATION_CERTAIN_INFORMATION_BY_REF"><font style="text-decoration:underline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FORWARDLOOKING_STATEMENTS"><font style="text-decoration:underline;">FORWARD-LOOKING STATEMENTS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS"><font style="text-decoration:underline;">RISK FACTORS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BUSINESS"><font style="text-decoration:underline;">BUSINESS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SELECTED_CONSOLIDATED_FINANCIAL_DATA"><font style="text-decoration:underline;">SELECTED CONSOLIDATED FINANCIAL DATA</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_SECURITIES_WE_MAY_FER"><font style="text-decoration:underline;">DESCRIPTION OF SECURITIES WE MAY OFFER</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_CAPITAL_STOCK"><font style="text-decoration:underline;">DESCRIPTION OF CAPITAL STOCK</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_PREFERRED_STOCK"><font style="text-decoration:underline;">DESCRIPTION OF PREFERRED STOCK</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_DEBT_SECURITIES"><font style="text-decoration:underline;">DESCRIPTION OF DEBT SECURITIES</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_WARRANTS"><font style="text-decoration:underline;">DESCRIPTION OF WARRANTS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_RIGHTS"><font style="text-decoration:underline;">DESCRIPTION OF RIGHTS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_UNITS"><font style="text-decoration:underline;">DESCRIPTION OF UNITS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS"><font style="text-decoration:underline;">USE OF PROCEEDS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PLAN_DISTRIBUTION"><font style="text-decoration:underline;">PLAN OF DISTRIBUTION</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS"><font style="text-decoration:underline;">LEGAL MATTERS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
<TR STYLE="background-color: White">
<TD STYLE="vertical-align: bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS"><font style="text-decoration:underline;">EXPERTS</font></a></p></td>
<TD STYLE="vertical-align: bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_001"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is in two parts, this prospectus supplement and the accompanying base prospectus, both of which are part of a registration
statement on Form S-3 that we filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo;
registration process. The first part is the prospectus supplement, including the documents incorporated by reference, which describes
the specific terms of this offering. The second part, the accompanying base prospectus, including the documents incorporated by
reference, provides more general information. Before you invest, you should carefully read this prospectus supplement, the accompanying
base prospectus, all information incorporated by reference herein and therein, as well as the additional information described
under &ldquo;<I>Where You Can Find More Information</I>&rdquo; on page S-9 of this prospectus supplement. These documents contain
information you should consider when making your investment decision. This prospectus supplement may add, update, or change information
contained in the accompanying base prospectus. To the extent there is a conflict between the information contained in this prospectus
supplement, on the one hand, and the information contained in the accompanying base prospectus or any document incorporated by
reference therein filed prior to the date of this prospectus supplement, on the other hand, you should rely on the information
in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document
having a later date &mdash; for example, a document filed after the date of this prospectus supplement and incorporated by reference
in this prospectus supplement and the accompanying base prospectus &mdash; the statement in the document having the later date
modifies or supersedes the earlier statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained or incorporated by reference in this prospectus supplement, the accompanying base
prospectus and in any free writing prospectuses we may provide to you in connection with this offering. We have not authorized
any other person to provide you with any information that is different. If anyone provides you with different or inconsistent
information, you should not rely on it. We are offering to sell, and seeking offers to buy, shares of our common stock only in
jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the common
stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus
supplement must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution
of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in
connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement
by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further note that the representations, warranties, and covenants made by us in any agreement that is filed as an exhibit to any
document that is incorporated by reference in the accompanying base prospectus were made solely for the benefit of the parties
to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should
not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were
accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as
accurately representing the current state of our affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
used herein, &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; or &ldquo;our&rdquo; refers to JanOne Inc., a Nevada corporation,
and our subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_002"></A>CAUTIONARY
STATEMENTS REGARDING FORWARD-LOOKING INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information included or incorporated by reference into the base prospectus and this prospectus supplement contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and
Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). These forward-looking statements
that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from any future
results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such
as, but not limited to, &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;targets,&rdquo; &ldquo;likely,&rdquo; &ldquo;aim,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
&ldquo;should,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; and similar expressions or phrases
identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future
events and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial
needs. Actual results may differ materially from those expressed or implied in such forward-looking statements as a result of
various factors. We do not undertake, and we disclaim, any obligation to update any forward-looking statements or to announce
any revisions to any of the forward-looking statements, except as required by law. Certain factors that could cause results to
be materially different from those projected in the forward-looking statements include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    history of losses and working capital deficit;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue as a going concern;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    known and unknown impact of the Covid-19 pandemic on our Company;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dependence
    on our key personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">need
    for additional financing to complete our Phase IIb/IIIa studies for JAN101, which is a potential treatment for Periphery Artery
    Disease;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    and legal uncertainties;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of quarterly results on our common stock price; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dilution
    to our stockholders upon the exercise of outstanding common stock options and restricted stock unit grants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
urge you to consider these factors before investing in our common stock. The forward-looking statements included in this prospectus
supplement, the accompanying base prospectus, and any other offering material, or in the documents incorporated by reference into
this prospectus supplement, the accompanying base prospectus, and any other offering material, are made only as of the date of
the prospectus supplement, the accompanying base prospectus, any other offering material, or the documents incorporated by reference.
For more detail on these and other risks, please see &ldquo;Risk Factors&rdquo; in this prospectus supplement, our Annual Report
on Form 10-K for our fiscal year ended December 28, 2019, filed with the SEC on April 6, 2020, and our other filings with the
SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_003"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following information below is only a summary of more detailed information included elsewhere in, or incorporated by reference
in, this prospectus supplement and the accompanying base prospectus, and should be read together with the information contained
or incorporated by reference in other parts of this prospectus supplement and the accompanying base prospectus. This summary highlights
selected information about us and this offering. This summary may not contain all of the information that may be important to
you. Before making a decision to invest in our common stock, you should read carefully all of the information contained in or
incorporated by reference into this prospectus supplement and the accompanying base prospectus, including the information set
forth under the caption &ldquo;Risk Factors&rdquo; in this prospectus supplement and the accompanying base prospectus, as well
as the documents incorporated herein by reference, which are described under &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Information Incorporated by Reference&rdquo; in this prospectus supplement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 10, 2019, JanOne Inc. (formerly known as Appliance Recycling Centers of America, Inc.) and subsidiaries (collectively,
&ldquo;we,&rdquo; the &ldquo;Company,&rdquo; or &ldquo;JanOne&rdquo;) broadened its business perspectives to being a pharmaceutical
company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving
properties. The Company aims to reduce prescriptions for dangerous opioid drugs by treating underlying diseases that cause severe
pain. Our first drug candidate is a treatment for Peripheral Arterial Disease (&ldquo;PAD&rdquo;), a condition that can cause
severe pain and affects over 8.5 million people in the U.S. alone. In addition, we continue to operate our legacy businesses,
ARCA Recycling, Inc. (&ldquo;ARCA Recycling&rdquo;), in our Recycling segment, and GeoTraq Inc. (&ldquo;GeoTraq&rdquo;), in our
Technology segment. ARCA Recycling recycles major household appliances in North America by providing turnkey appliance recycling
and replacement services for utilities and other sponsors of energy efficiency programs. GeoTraq is engaged in the development,
design, and, ultimately, we expect, the sale of cellular transceiver modules and associated wireless services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biotechnology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on becoming the leader in identifying, acquiring, licensing, developing,
partnering, and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the
treatment of pain. Our initial product candidate, JAN101 (formerly known as TV1001SR) is a potential treatment for Periphery Artery
Disease (&ldquo;PAD&rdquo;), a vascular disease that affects more than 60 million people worldwide. We are also researching the
potential impact our compound JAN101 could have in patients with COVID-19, as many doctors around the world and our Company believe
COVID-19 is a respiratory disease that directly affects the vascular system. We expect to commence Phase 2b clinical trials for
the treatment of PAD in early 2021. It is expected that the Investigational New Drug application (referred to in the industry
as &ldquo;IND&rdquo;) for JAN101 as a COVID-19 vascular complication treatment will be submitted to the U.S. Food and Drug Administration
in the coming weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JAN101</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN101,
formerly known as TV1001SR and/or TV1001, our advanced product candidate, is a patented oral, sustained release pharmaceutical
composition of sodium nitrite and targets poor blood flow to the extremities, such as those with vascular complications of diabetes
or PAD and treats pain. A conclusion from a round of human studies found JAN101 sustained release sodium nitrite prevents the
prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite. In a previous study
of patients with PAD, 40 mg BID treatment with immediate release sodium nitrite led to a statistically significant reduction in
reported pain, while an 80 mg BID treatment had the more pronounced effect on bioactivity and Flow Mediated Dilation, a measure
of vascular function. However, a number of subjects on both treatment groups reported headaches and dizziness following treatment.
Although this did not result in subjects discontinuing treatment, JAN101 was developed to overcome this side effect. JAN101 was
tested in a bridging study of diabetic neuropathy subjects and, during that bridging study, the subjects did not report headaches
or dizziness. Subjects in this bridge study also reported less pain following treatment and improvements in bioactivity (quantitative
sensory testing, a measure of nerve function) were similar to the PAD study, where the 80 mg dose group had the greatest improvement
in Flow Mediated Dilation. The ability to alleviate pain with BID treatment of JAN101 offers promise for a new, non-addictive,
non-sedating treatment of chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recycling</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
started our business in 1976 as a used appliance retailer that reconditioned old appliances to sell in our stores. Under contracts
with national and regional retailers of new appliances, such as Sears Roebuck and Co. and Montgomery Ward Inc., we collected the
replaced appliance from the retailer&rsquo;s customer&rsquo;s residence when one of their stores delivered a new appliance in
the Minneapolis/St. Paul, Miami, or Atlanta market. Any old appliances that we could not sell in our stores were sold to scrap
metal processors. In the late 1980s, stricter environmental regulations began to affect the disposal of unwanted appliances and
we were no longer able to take appliances that contained hazardous components to a scrap metal processor. At that time, we began
to develop systems and equipment to remove the harmful materials so that metal processors would accept the appliance shells for
processing. We then offered our services for disposing of appliances in an environmentally sound manner to appliance manufacturers
and retailers, waste hauling companies, rental property managers, local governments, and the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate 13 recycling centers in the U.S. and Canada to process and recycle old appliances according to all federal, state, provincial,
and local rules and regulations. ARCA Recycling uses U.S. EPA RAD-compliant methods to remove and properly manage hazardous components
and materials, including CFC refrigerants, mercury, polyurethane foam insulation, and recyclable materials, such as ferrous and
nonferrous metals, plastics, and glass. All of our facilities comply with licensing and permitting requirements, and employees
who process appliances receive extensive safety and hazardous materials training.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 18, 2017, in a move to diversify our offering beyond our then-current appliance recycling capabilities, we acquired GeoTraq,
Inc., a Mobile Internet of Things (&ldquo;IoT&rdquo;) technology company that designs innovative wireless modules that provide
Location Based Services (&ldquo;LBS&rdquo;) and connect external sensors to the IoT. GeoTraq is planning to manufacture and sell
wireless transceiver modules and subscription services that will allow connectivity using publicly available global Mobile IoT
networks. GeoTraq addresses the large LBS market segment that is currently under-served with existing solutions due to high deployment
costs (hardware, service, logistics), limited battery life, and large form factors. We believe that there is a large under-served
portion of the LBS market that is not addressed by existing solutions. RFID and Wi-Fi require close proximity for asset tracking,
while GPS is too bulky and power hungry for many needs. GeoTraq addresses the white space in-between by designing wireless transceiver
modules with technology that provides LBS directly from global Mobile IoT networks. GeoTraq&rsquo;s technology allows for a substantially
lower cost solution, extended service life, a small form factor, and even disposable devices, which we believe can significantly
reduce return logistics costs. Additionally, GeoTraq applied for and was granted Patent No. 10,182,402, which covers various aspects
of operation of its Mobile IoT wireless modules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see our Annual Report on Form 10-K for the fiscal year ended December 28, 2019 as filed with the SEC on April 6, 2020, and our
other subsequent filings with the SEC for additional information about our business, operations, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves a high degree of risk. You should carefully consider all of the information in this prospectus and
in the documents incorporated by reference prior to investing in our securities. These risks are discussed more fully in the section
titled &ldquo;Risk Factors&rdquo; herein and in our Annual Report on Form 10-K for the year ended December 28, 2019 and
our Quarterly Reports on Form 10-Q for the periods ended March 28, 2020, June 27, 2020, and September 26, 2020, each of
which is incorporated by reference in this prospectus. These risks and uncertainties include, but are not limited to, the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a history of losses and a working capital deficit;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to continue as a going concern will require us to obtain additional financing to fund our current operations, which
    may be unavailable on acceptable terms, or at all;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business and operations have been adversely impacted by the Covid-19 pandemic and we are unable to predict the ultimate overall
    impact on our company;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are dependent on a limited number of key personnel;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need additional financing to initiate and complete our Phase IIb/IIIa studies for JAN101, which is a potential treatment for
    Periphery Artery Disease;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business is subject to regulatory and legal uncertainties;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    quarterly results will have a material impact on our common stock price; and</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    stockholders will suffer dilution upon the exercise of outstanding common stock options and restricted stock unit grants.</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in Nevada. Our principal executive offices are located at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada
89119, and our telephone number is (702) 997-5968. We report on a 52-or 53-week fiscal year. Our 2020 fiscal year ended on
January 2, 2021. Our 2019 fiscal year ended on December 28, 2019. Our 2018 fiscal year ended on December 29, 2018. We maintain
a corporate website at www.janone.com. Except as specifically set forth herein, the information which appears on our website is
not part of the prospectus or this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_004"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary contains basic information about this offering. The summary is not intended to be complete. You should read
the full text and more specific details contained elsewhere in this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
    Inc.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">571,428
    shares at a purchase price of $10.50 per share.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock outstanding prior to the offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,829,982(1)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock to be outstanding after this offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,401,410
    shares (1)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
    Capital Market symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds from this offering for working capital. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
investment involves a high degree of risk. See &ldquo;Risk Factors&rdquo; and other information included or incorporated by reference
in this prospectus supplement beginning on page S-6 and the accompanying base prospectus beginning on page 4 for a discussion
of certain factors you should carefully consider before deciding to invest in shares of our common stock.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of shares of our common stock outstanding before and after this offering is based on 1,829,982 shares of common stock
    outstanding as of January 28, 2020, and excludes:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,900
    shares of our common stock issuable upon the exercise of outstanding stock options with a weighted average exercise price
    of $11.10 per share;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">346,500
    additional shares of our common stock reserved for future issuance under our equity incentive plans; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,363
    shares issuable upon the exercise of outstanding common stock purchase warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider
the risk factors we describe in this prospectus supplement and in any related free writing prospectus that we may authorize to
be provided to you or in any report incorporated by reference into this prospectus supplement, including our Annual Report on
Form 10-K for the year ended December 28, 2019, or any Quarterly Report on Form 10-Q that is incorporated by reference
into this prospectus supplement. Although we discuss key risks in those risk factor descriptions, additional risks not currently
known to us or that we currently deem immaterial also may impair our business. Our subsequent filings with the SEC may contain
amended and updated discussions of significant risks. We cannot predict future risks or estimate the extent to which they may
affect our financial performance.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our
common stock, you will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase
in this offering. As of September 26, 2020, our net tangible book value was ($9,676,000) or approximately ($5.29) per share.
After giving effect to the sale of 571,428 shares of our common stock at the offering price of $10.50 per share in this offering,
our as adjusted net tangible book value as of September 26, 2020 would have been approximately ($4,096,006),
or approximately ($1.71) per share of outstanding common stock. Based on a public offering price of $10.50 per share of
common stock, and our as adjusted net tangible book value as of September 26, 2020, if you purchase common stock in
this offering, you will suffer immediate and substantial dilution of $12.21 per share with respect to the net tangible book
value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have broad discretion in determining how to use the proceeds from this offering and we cannot assure you that we will be successful
in spending the proceeds in ways which increase our revenues, profitability, or market value, or otherwise yield favorable returns.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to utilize net proceeds of this offering for general working capital. Nevertheless, we will have broad discretion in determining
specific expenditures. You will be entrusting your funds to our management, upon whose judgment you must depend, with limited
information concerning the purposes to which the funds will ultimately be applied. We may not be successful in spending the proceeds
of this offering in ways which increase our profitability or market value, or otherwise yield favorable returns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fluctuations
in the price of our common stock, including as a result of actual or anticipated sales of shares by stockholders, may make our
common stock more difficult to resell.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price and trading volume of our common stock have been and may continue to be subject to significant fluctuations due not
only to general stock market conditions, but also to a change in sentiment in the market regarding the industries in which we
operate, our operations, business prospects, or liquidity or this offering. In addition to the risk factors discussed in our periodic
reports, in the prospectus, and in this prospectus supplement, the price and volume volatility of our common stock may be affected
by actual or anticipated sales of common stock by existing stockholders, including of shares purchased in this offering, whether
in the market or in subsequent public offerings. Stock markets in general may experience extreme volatility that is unrelated
to the operating performance of listed companies. These broad market fluctuations may adversely affect the trading price of our
common stock, regardless of our operating results. As a result, these fluctuations in the market price and trading volume of our
common stock may make it difficult to predict the market price of our common stock in the future, cause the value of your investment
to decline and make it more difficult to resell our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not anticipate paying dividends in the foreseeable future; you should not buy our stock if you expect dividends.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid a dividend on our common stock. The determination of whether to pay dividends on our common stock in the future
will depend on several factors, including without limitation, our earnings, financial condition, and other business and economic
factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, our common stock
may be less valuable because a return on your investment will only occur if our stock price appreciates. We currently intend to
retain our future earnings to support operations and to finance expansion and, therefore, we do not anticipate paying any cash
dividends on our common stock in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could issue preferred stock without stockholder approval with the effect of diluting then current stockholder interests and impairing
their voting rights; and provisions in our charter documents could discourage a takeover that stockholders may consider favorable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
articles of incorporation, as amended, authorize the issuance of up to 2,000,000 shares of &ldquo;blank check&rdquo; preferred
stock with designations, rights and preferences as may be determined from time to time by our board of directors. 259,729 shares
of our preferred stock, designated &ldquo;Series A-1 Convertible Preferred Stock,&rdquo; are issued and outstanding, leaving available
for designation and issuance up to 1,740,271 authorized, but unissued, shares of &ldquo;blank check&rdquo; preferred stock. Our
board of directors is empowered, without stockholder approval, to issue one or more series of preferred stock with dividend, liquidation,
conversion, voting, or other rights that could dilute the interest of, or impair the voting power of, our common stockholders.
The issuance of a series of preferred stock could be used as a method of discouraging, delaying, or preventing a change in control
of us. For example, it would be possible for our board of directors to issue preferred stock with voting or other rights or preferences
that could impede the success of any attempt to change control of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sales
of a significant number of shares of our common stock in the public markets or significant short sales of our common stock, or
the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise
capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock or other equity-related securities in the public markets, could depress
the market price of our common stock. If there are significant short sales of our common stock, the price decline that could result
from this activity may cause the share price to decline more so, which, in turn, may cause long holders of the common stock to
sell their shares, thereby contributing to sales of common stock in the market. Such sales also may impair our ability to raise
capital through the sale of additional equity securities in the future at a time and price that our management deems acceptable,
if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may seek to raise additional funds, finance acquisitions, or develop strategic relationships by issuing securities that would
dilute the ownership of the common stock. Depending on the terms available to us, if these activities result in significant dilution,
they may negatively impact the trading price of our shares of common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our acquisitions and the development of strategic relationships by issuing equity and debt securities and may continue
to do so in the future, which could significantly reduce the percentage ownership of our existing stockholders. Further, any additional
financing that we secure may require the granting of rights, preferences, or privileges senior to, or <I>pari passu</I> with,
those of our common stock. Any issuances by us of equity securities may be at or below the prevailing market price of our common
stock and, in any event, may have a dilutive impact on your ownership interest, which could cause the market price of our common
stock to decline. We may also raise additional funds through the incurrence of debt or the issuance or sale of other securities
or instruments senior to our shares of common stock. The holders of any securities or instruments we may issue may have rights
superior to the rights of our common stockholders. If we experience dilution from issuance of additional securities and we grant
superior rights to new securities over common stockholders, it may negatively impact the trading price of our shares of common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market,
or if they change their recommendations regarding our common stock adversely, our common stock price and trading volume could
decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our shares of common stock will be influenced by many factors, including without limitation, the research reports
that industry or securities analysts may publish about us, our business, our market, or our competitors. As of the date of this
prospectus, no analysts cover us, but, if any were to cover us and then adversely change their recommendation regarding our common
stock, or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any
analyst who may cover us were to cease coverage of our Company or fail to publish reports on us regularly, we could lose visibility
in the financial markets, which in turn could cause our common stock price or trading volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Significant
dilution will occur if outstanding options or warrants are exercised, or restricted stock unit grants vest. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 28, 2021, we had 101,900 shares of our common stock underlying outstanding stock options and 33,363 shares of
our common stock underlying outstanding common stock purchase warrants. If outstanding stock options or warrants are exercised,
dilution will occur to our stockholders, which may be significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the public offering price of $10.50 per share of common stock, we estimate that the net proceeds from the sale of the securities
offered under this prospectus supplement, after deducting placement agents&rsquo; fees and commissions and estimated offering
expenses payable by us will be approximately $5.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently expect to use the net proceeds from this offering for working capital and other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term, investment-grade, interest-bearing instruments and U.S. government securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_007"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
purchaser of our shares of our common stock in this offering will be diluted immediately to the extent of the difference between
the offering price per share and the as adjusted net tangible book value per share of our common stock upon the closing
of this offering. Our historical net tangible book value as of September 26, 2020, was ($9,676,000), or approximately ($5.29)
per share of outstanding common stock, based on 1,829,982 shares of common stock outstanding as of September 26, 2020. Net
tangible book value per share of our common stock is determined at any date by subtracting total liabilities from the amount of
total tangible assets, and dividing this amount by the number of shares of common stock deemed to be outstanding as of that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net tangible book value as of September 26, 2020 was ($9,676,000), or approximately ($5.29) per share of common
stock, based upon 1,829,982 shares outstanding. After giving effect to the issuance and sale of 571,428 shares of
our common stock at the offering price of $10.50 per share in this offering, our as adjusted net tangible book value
as of September 26, 2020 would have been approximately ($4,096,006), or approximately ($1.71) per share of outstanding
common stock. This amount represents an immediate increase in net tangible book value of $3.58 per share of our common
stock to our existing stockholders and an immediate dilution of $12.21 per share of our common stock to new investors
purchasing securities in this offering, as illustrated in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Public offering price per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">10.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Historical net tangible book value per share of common stock as of September 26, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5.29</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in net tangible book value per share of common stock attributable to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">As adjusted net book value per share of common stock, after giving effect to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,096,006</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.71</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dilution per share of common stock to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.21</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing table does not take into account further dilution to new investors that could occur upon the exercise of outstanding
options having a per share exercise price less than the per share offering price to the public in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing table excludes the following as of September 26, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,900
    shares issuable upon the exercise of outstanding stock options;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">346,500
    shares reserved for future issuances under our equity compensation plans; and.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,363
    shares issuable upon the exercise of outstanding common stock purchase warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_008"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not declared or paid cash dividends on our common stock since our inception. Under Nevada law, we are prohibited from paying
dividends if the distribution would result in our Company not being able to pay its debts as they become due in the normal course
of business if our total assets would be less than the sum of our total liabilities plus the amount that would be needed to pay
the dividends, or if we were to be dissolved at the time of distribution to satisfy the preferential rights upon dissolution of
stockholders whose preferential rights are superior to those receiving the distribution. Our board of directors has complete discretion
on whether to pay dividends subject to compliance with applicable Nevada law. Even if our board of directors were to decide to
pay dividends, the form, the frequency, and the amount will depend upon our future operations and earnings, capital requirements
and surplus, general financial condition, contractual restrictions, and other factors that the board of directors may deem relevant.
While our board of directors will make any future decisions regarding dividends, if, when, and as circumstances surrounding us
change, it currently does not anticipate that we will pay any cash dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_009"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./Alliance
Global Partners has agreed to act as sole placement agent in connection with this offering. The placement agent is not purchasing
or selling any of the shares of our common stock offered by this prospectus supplement, but will use its reasonable best efforts
to arrange for the sale of the securities offered by this prospectus supplement. We have entered into a securities purchase agreement
directly with investors in connection with this offering. We will make offers only to a limited number of accredited investors.
The offering is expected to close on or about February 2, 2021, subject to customary closing conditions, without further notice
to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees
and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay the placement agent a placement agent&rsquo;s fee equal to 7.0% of the aggregate purchase price of the shares
of our common stock sold in this offering. The following table shows the per share and total cash placement agent&rsquo;s fees
we will pay to the placement agent in connection with the sale of the shares of our common stock offered pursuant to this prospectus
supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Public offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">10.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">5,999,994.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Placement agents&rsquo; fees(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">419,499.58</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Proceeds, before expenses, to us</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.765</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,579,994.42</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have also agreed to reimburse the placement agent for certain expenses. See below.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have agreed to reimburse the placement agent for accountable legal expenses incurred by it in connection with the
offering of up to $35,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
M</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the shares sold by it while acting as a principal might be deemed to be
underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply
with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities
Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and
sales of shares by the placement agent acting as a principal. Under these rules and regulations, the placement agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    not engage in any stabilization activity in connection with our securities; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than
    as permitted under the Exchange Act, until they have completed their participation in the distribution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
Capital Market Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;JAN.&rdquo; On January 28, 2021, the last reported
sale price of our common stock as reported on the Nasdaq Capital Market was $12.99 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the placement agent and other specified persons against certain civil liabilities, including liabilities
under the Securities Act and the Exchange Act, and to contribute to payments that the placement agent may be required to make
in respect of such liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent or its affiliates may in the future engage in transactions with, and may perform, from time to time, investment
banking and advisory services for us in the ordinary course of their business and for which it would receive customary fees and
expenses. In addition, in the ordinary course of its business activities, the placement agent and its affiliates may make or hold
a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments
(including bank loans) for its own account and for the accounts of its customers. Such investments and securities activities may
involve securities and/or instruments of ours or our affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_010"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clark
Hill PLC, Los Angeles, California, will provide us with opinions as to certain legal matters in connection with the shares of
common stock offered hereby. The placement agent is being represented by Nelson Mullins Riley &amp; Scarborough LLP, Washington,
D.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_011"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audited consolidated balance sheets as of December 28, 2019 and December 29, 2018, and the related consolidated statements of
income, stockholders&rsquo; equity and cash flows for the years ended December 28, 2019 and December 29, 2018 incorporated by
reference in the registration statement of which this prospectus is a part have been audited by WSRP, LLC, independent registered
public accounting firm, and by SingerLewack LLP, independent registered public accounting firm, respectively, as indicated in
their reports with respect thereto, and have been so included in reliance upon the report of such firm given on their authority
as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_012"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly, and other reports, proxy statements, and other information with the SEC. The SEC maintains a website at
<U>www.sec.gov</U> that contains reports, proxy and information statements, and other information regarding issuers such as our
company that file electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate website address is <U>www.janone.com</U>. We make available free of charge, through the Investor section of our website,
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K and amendments to those reports filed
or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="m_013"></A>INFORMATION
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus
supplement, and later information filed with the SEC will update and supersede this information. We incorporate by reference the
documents listed below that we have previously filed with the SEC, except that information furnished under Item 2.02 or Item 7.01
of our Current Reports on Form 8-K or any other filing where we indicate that such information is being furnished and not filed
under the Exchange Act, is not deemed to be filed and not incorporated by reference herein:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on Form 10-K for the year ended December 28, 2019, as filed with the SEC on April 6, 2020;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Reports on Form 10-Q for the quarter ended March 28, 2020, as filed with the SEC on May 12, 2020; June 27, 2020,
    as filed with the SEC on August 10, 2020; and September 26, 2020, as filed with the SEC on November 10, 2020;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K, as filed with the SEC on January 10, 2020, February 7, 2020, April 22, 2020 (as amended
    on April 23, 2020), May 4, 2020, June 18, 2020, June 25, 2020, June 30, 2020, July 8, 2020, July 21, 2020, July 30, 2020,
    August 6, 2020, August 12, 2020, September 3, 2020, September 16, 2020, September 24, 2020, October 2, 2020,
    and January 29, 2021 (excluding any information furnished pursuant to Item 2.02 or Item 7.01 of such Current Reports on Form
    8-K); and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our common stock contained in Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December
    28, 2019, as filed with the SEC on April 6, 2020.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also incorporate by reference into this prospectus supplement additional documents that we may file with the SEC under Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, including all such documents
we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration
statement, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously
filed document incorporated by reference into this prospectus supplement is deemed to be modified or superseded for purposes of
this prospectus supplement to the extent that a statement contained in this prospectus supplement, or in a subsequently filed
document also incorporated by reference herein, modifies or supersedes that statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement may contain information that updates, modifies or is contrary to information in one or more of the documents
incorporated by reference in this prospectus supplement. You should rely only on the information incorporated by reference or
provided in this prospectus supplement. We have not authorized anyone else to provide you with different information. You should
not assume that the information in this prospectus supplement is accurate as of any date other than the date of this prospectus
supplement or the date of the documents incorporated by reference in this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide to each person, including any beneficial owner, to whom this prospectus supplement is delivered, upon written or
oral request, at no cost to the requester, a copy of any and all of the information that is incorporated by reference in this
prospectus supplement. You may request a copy of these filings, at no cost to you, by telephoning us at (702) 997-5968 or by writing
us at the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325
E. Warm Springs Road, Suite 102</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Las
Vegas, Nevada 89119</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Corporate Secretary</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access the documents incorporated by reference in this prospectus supplement through our website at www.janone.com. The
reference to our website is an inactive textual reference only and, except for the specific incorporated documents listed above,
no information available on or through our website shall be deemed to be incorporated in this prospectus supplement, the accompanying
prospectus, or the registration statement of which it forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: normal bold 10pt Times New Roman; text-align: left; margin-bottom: 0pt; margin-top: 0pt; text-transform: none"><B>PROSPECTUS</B></p>
<P STYLE="text-align: center; margin-bottom: 0pt; margin-top: 0pt; font-size: 10pt">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000001.jpg" title="" alt="" style="width:326px;height:75px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$100,000,000</p>
<P STYLE="font: normal 10pt Times New Roman; text-align: center; margin-bottom: 0pt; margin-top: 0pt; text-transform: none">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Debt Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rights</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may offer and sell from time to time shares of our common stock,<font style="color:#000000;"> par value $0.001 per share (our &#8220;Common Stock&#8221;)</font>, shares of our preferred stock<font style="color:#000000;">, par value $0.001 per share (our &#8220;Preferred Stock&#8221;)</font>, debt securities, warrants, rights, and units that include any of these securities. The Preferred Stock or warrants may be convertible into or exercisable for shares of our Common Stock or shares of our Preferred Stock or other of our securities registered hereunder. The debt securities may be convertible into or exchangeable for shares of our Common Stock or shares of our Preferred Stock. Our Common Stock is listed on The Nasdaq Capital Market and trades under the symbol &#8220;JAN.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may offer and sell these securities to or through one or more underwriters, dealers, and agents, or directly to purchasers, on a continuous or delayed basis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The aggregate market value of our outstanding Common Stock held by non-affiliates was approximately $2,186,586, based on 1,829,982 shares of outstanding Common Stock as of December 15, 2020, of which approximately 410,121 shares were held by affiliates, and based on the closing sale price of our Common Stock of $4.62 on November 25, 2020. Pursuant to General Instruction&#160;I.B.6 of Form&#160;S-3, in no event will we sell securities pursuant to this prospectus with a value of more than one-third of the aggregate market value of our Common Stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our Common Stock held by non-affiliates is less than $75,000,000. In the event that, subsequent to the date of this prospectus, the aggregate market value of our outstanding Common Stock held by non-affiliates equals or exceeds $75,000,000, then the one-third limitation on sales shall not apply to additional sales made pursuant to this prospectus. During the prior 12 calendar months prior to, and including, the date of this prospectus, we have not sold any securities pursuant to General Instruction&#160;I.B.6 of Form&#160;S-3.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus describes some of the general terms that may apply to these securities and the general manner in which they may be offered. The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in a supplement to this prospectus. You should read this prospectus and any applicable prospectus supplement carefully before you invest.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">See the &#8220;Risk Factors&#8221; section of this prospectus on page 4, our filings with the SEC, and the applicable prospectus supplement for certain risks that you should consider before investing in our securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">None of the Securities and Exchange Commission, any state securities commission, or any other regulatory body has approved or disapproved of these securities nor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The
date of this prospectus is December 29, 2020.</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:95%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ABOUT_THIS_PROSPECTUS"><font style="text-decoration:underline;">ABOUT THIS PROSPECTUS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#AVAILABLE_INFORMATION"><font style="text-decoration:underline;">AVAILABLE INFORMATION</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INCORPORATION_CERTAIN_INFORMATION_BY_REF"><font style="text-decoration:underline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FORWARDLOOKING_STATEMENTS"><font style="text-decoration:underline;">FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS"><font style="text-decoration:underline;">RISK FACTORS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BUSINESS"><font style="text-decoration:underline;">BUSINESS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SELECTED_CONSOLIDATED_FINANCIAL_DATA"><font style="text-decoration:underline;">SELECTED CONSOLIDATED FINANCIAL DATA</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_SECURITIES_WE_MAY_FER"><font style="text-decoration:underline;">DESCRIPTION OF SECURITIES WE MAY OFFER</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_CAPITAL_STOCK"><font style="text-decoration:underline;">DESCRIPTION OF CAPITAL STOCK</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_PREFERRED_STOCK"><font style="text-decoration:underline;">DESCRIPTION OF PREFERRED STOCK</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_DEBT_SECURITIES"><font style="text-decoration:underline;">DESCRIPTION OF DEBT SECURITIES</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_WARRANTS"><font style="text-decoration:underline;">DESCRIPTION OF WARRANTS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_RIGHTS"><font style="text-decoration:underline;">DESCRIPTION OF RIGHTS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_UNITS"><font style="text-decoration:underline;">DESCRIPTION OF UNITS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS"><font style="text-decoration:underline;">USE OF PROCEEDS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PLAN_DISTRIBUTION"><font style="text-decoration:underline;">PLAN OF DISTRIBUTION</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS"><font style="text-decoration:underline;">LEGAL MATTERS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS"><font style="text-decoration:underline;">EXPERTS</font></a></p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073246"></a>&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ABOUT_THIS_PROSPECTUS"></a><a name="ABOUT_THIS_PROSPECTUS"></a>ABOUT THIS PROSPECTUS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document is called a prospectus and is part of a Registration Statement on Form S-3 that we have filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings in amounts that we will determine from time to time, up to a total dollar amount of $100,000,000.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities described in this prospectus we will provide a prospectus supplement, incorporate information or document by reference into this prospectus or a related free writing prospectus or use other offering materials, as applicable, containing more specific information about the terms of the securities that are then being offered. We may also authorize one or more related free writing prospectuses to be provided to you that may contain material information relating to these offerings and securities. This prospectus, together with applicable prospectus supplements, any information or document incorporated by reference, and any related free writing prospectus or other offering materials, as applicable, we file with the SEC, includes all material information relating to these offerings and securities. We may also add, update, or change in the prospectus supplement any of the information contained in this prospectus or in the documents that we incorporate by reference into this prospectus, including, without limitation, a discussion of any risk factors or other special considerations that apply to these offerings or securities or the specific plan of distribution. If there is any inconsistency between the information in this prospectus and a prospectus supplement or information or document incorporated by reference having a later date, you should rely on the information in that prospectus supplement or incorporated information having a later date. We urge you to read carefully this prospectus, any applicable prospectus supplement, and any related free writing prospectus or other offering materials, as applicable, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information by Reference,&#8221; before buying any of the securities being offered.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should rely only on the information we have provided in, or incorporated by reference into, this prospectus, any applicable prospectus supplement, and any related free writing prospectus or other offering materials, as applicable. We have not authorized anyone to provide you with different information. No dealer, salesperson, or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials, as applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Neither the delivery of this prospectus nor any sale made under it implies that there has not been any change in our business or affairs or that the information in this prospectus is correct as of any date after the date of this prospectus. You should assume that the information in this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials, as applicable, is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials, as applicable, or any sale of a security.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registration Statement containing this prospectus, including exhibits to the Registration Statement, provides additional information about us and the securities offered under this prospectus and any prospectus supplement. We have filed and plan to continue to file other documents with the SEC that contain information about us and our business. Also, we will file legal documents that control the terms of the securities offered by this prospectus as exhibits to the reports that we file with the SEC. The Registration Statement and other reports can be read at the SEC Internet site or at the SEC offices mentioned under the heading &#8220;Available Information.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus contains summaries of certain provisions contained in some of the documents described herein; but, reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed, or will be incorporated by reference as exhibits to the Registration Statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;Available Information.&#8221;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073247"></a><a name="AVAILABLE_INFORMATION"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="AVAILABLE_INFORMATION"></a>AVAILABLE </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have filed with the SEC a Registration Statement on Form&#160;S-3 under the Securities Act with respect to the securities covered by this prospectus. This prospectus, which is a part of that Registration Statement, does not contain all of the information set forth in the Registration Statement or the exhibits and schedules filed therewith. For further information with respect to us and the securities covered by this prospectus, please see the Registration Statement and the exhibits filed with the Registration Statement. A copy of the Registration Statement and the exhibits filed with the Registration Statement may be inspected without charge at the Public Reference Room maintained by the SEC, located at 100 F Street, N.E., Washington,&#160;D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. The SEC also maintains an Internet website that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC. The address of the website is http://www.sec.gov.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the information and periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and, in accordance therewith, we file periodic reports, proxy statements, and other information with the SEC. Such periodic reports, proxy statements, and other information are available for inspection and copying at the Public Reference Room and website of the SEC referred to above. We maintain a website at http://www.janone.com. You may access our Annual Reports on Form&#160;10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed pursuant to Sections&#160;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. Our website and the information contained on that site, or connected to that site, are not incorporated into and are not a part of this prospectus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073248"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="INCORPORATION_CERTAIN_INFORMATION_BY_REF"></a><a name="INCORPORATION_CERTAIN_INFORMATION_BY_REF"></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC&#8217;s rules allow us to incorporate by reference information into this prospectus. This means that we can disclose important information to you by referring you to another document. Any information referred to in this way is considered part of this prospectus from the date we file that document. Any reports filed by us with the SEC after the date of this prospectus and before the date that the offering of the securities by means of this prospectus is terminated will automatically update and, where applicable, supersede any information contained in this prospectus or incorporated by reference in this prospectus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We incorporate by reference into this prospectus the following documents or information filed with the SEC (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our Annual Report on Form 10-K for the year ended December 28, 2019, filed with the SEC on </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020015355/jan-10k_20191228.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">April 6, 2020;</font></a></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our Quarterly Reports on Form 10-Q for the quarters ended March 28, 2020, filed with the SEC on </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020024581/jan-10q_20200328.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">May 12, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, June 27, 2020, filed with the SEC on </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020024581/jan-10q_20200328.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020039002/jan-10q_20200627.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">August 10, 2020</font></a><font style="text-decoration:none;">, and </font><font style="font-size:10pt;color:#000000;">September 26, 2020</font><font style="text-decoration:none;font-size:10pt;">, filed with the SEC on </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020024581/jan-10q_20200328.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020039002/jan-10q_20200627.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020052676/jan-10q_20200926.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">November 10, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our Current Reports on Form 8-K, filed with the SEC on </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">January 10, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">April 22, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (as amended on April 23, 2020), </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">May 4, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">June 18, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">June 25, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">June 30, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">July 8, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020032844/jan-8k_20200721.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">July 21, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020032844/jan-8k_20200721.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020034544/jan-8k_20200714.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">July 30, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020032844/jan-8k_20200721.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020034544/jan-8k_20200714.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020037602/jan-8k_20200806.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">August 6, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020032844/jan-8k_20200721.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020034544/jan-8k_20200714.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020037602/jan-8k_20200806.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020039462/jan-8k_20200812.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">August 12, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020032844/jan-8k_20200721.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020034544/jan-8k_20200714.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020037602/jan-8k_20200806.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020039462/jan-8k_20200812.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020042477/jan-8k_20200903.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">September 3, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020032844/jan-8k_20200721.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020034544/jan-8k_20200714.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020037602/jan-8k_20200806.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020039462/jan-8k_20200812.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020042477/jan-8k_20200903.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020043715/jan-8k_20200915.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">September 16, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020032844/jan-8k_20200721.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020034544/jan-8k_20200714.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020037602/jan-8k_20200806.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020039462/jan-8k_20200812.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020042477/jan-8k_20200903.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020043715/jan-8k_20200915.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020044450/jan-8k_20200924.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">September 24, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020000785/jan-8k_20200106.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020017932/jan-8k_20200416.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020020860/jan-8k_20200501.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020029717/jan-8k_20200618.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020030520/jan-8k_20200625.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031155/jan-8k_20200630.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020031994/jan-8k_20200708.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020032844/jan-8k_20200721.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020034544/jan-8k_20200714.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020037602/jan-8k_20200806.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020039462/jan-8k_20200812.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020042477/jan-8k_20200903.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020043715/jan-8k_20200915.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020044450/jan-8k_20200924.htm"><a href="http://www.sec.gov/Archives/edgar/data/862861/000168316820003334/janone_8k.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">October 2, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (excluding any information furnished pursuant to Item 2.02 or Item 7.01 of such Current Reports on Form 8-K); and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The description of our Common Stock contained filed as Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 28, 2019, filed with the SEC on </font><a href="http://www.sec.gov/Archives/edgar/data/862861/000156459020015355/jan-ex41_182.htm"><font style="font-size:10pt;text-decoration:underline;color:#000000;">April 6, 2020</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, all documents filed by us with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, after (i)&#160;the date of the initial Registration Statement and prior to effectiveness of the Registration Statement and (ii)&#160;the date of this prospectus and before the termination or completion of this offering, shall be deemed to be incorporated by reference into this prospectus from the respective dates of filing of such documents, except that we do not incorporate any document or portion of a document that is &#8220;furnished&#8221; to the SEC, but not deemed &#8220;filed.&#8221; Any information that we subsequently file with the SEC that is incorporated by reference as described above will automatically update and supersede any previous information that is part of this prospectus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written or oral request, a copy of any or all documents referred to above that have been or may be incorporated by reference into this prospectus, excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. Written or telephone requests should be directed to JanOne Inc., 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119, Attention: Corporate Secretary; telephone: (702) 997-5968.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073249"></a><a name="FORWARDLOOKING_STATEMENTS"></a><a name="FORWARDLOOKING_STATEMENTS"></a>FORWARD-LOOKING STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus, including the documents we incorporate by reference into it, contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act, and Section&#160;21E of the Exchange Act, the Private Securities Litigation Reform Act of 1995 (the &#8220;PSLRA&#8221;) or in releases made by the SEC. Such statements include, without limitation, statements regarding our expectations, hopes, or intentions regarding the future. Statements that are not historical fact are forward-looking statements. These forward looking statements can often be identified by their use of words such as &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;outlook,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; and &#8220;assume,&#8221; as well as variations of such words and similar expressions referring to the future. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act, and the PSLRA with the intention of obtaining the benefits of the &#8220;safe harbor&#8221; provisions of such laws.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The forward-looking statements contained in or incorporated by reference into this prospectus are largely based on our expectations, which reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently known market conditions and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain and</font><font style="color:#000000;"> involve certain risks and uncertainties, many of which are beyond our control. If any of those risks and uncertainties materialize, actual results could differ materially from those discussed in any such forward-looking statement. Among the factors that could cause actual results to differ materially from those discussed in forward-looking statements are those discussed under the heading &#8220;Risk Factors&#8221; below, those discussed under the heading &#8220;Risk Factors&#8221; and in other sections of our Annual Report on Form 10-K for the year ended December 28, 2019, as well as in our other reports filed from time to time with the SEC that are incorporated by reference into this prospectus. See &#8220;Available Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; for information about how to obtain copies of those documents.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">All readers are cautioned that the forward-looking statements contained in this prospectus and in the documents incorporated by reference into this prospectus are not guarantees of future performance, and we cannot assure any reader that such statements will be realized or that the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied in the forward-looking statements.</font><font style="color:#000000;"> All forward-looking statements in this prospectus and the documents incorporated by reference into it are made only as of the date of the document in which they are contained, based on information available to us as of the date of that document, and we caution you not to place undue reliance on forward-looking statements in light of the risks and uncertainties associated with them. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073250"></a><a name="RISK_FACTORS"></a><a name="RISK_FACTORS"></a>RISK FACTORS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing in our securities involves significant risks. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in, or incorporated into, the applicable prospectus supplement, any related free writing prospectus, or other offering materials, as applicable, and under similar headings in the other documents that are incorporated by reference herein or therein. Each of the referenced risks and uncertainties could adversely affect our business, operating results, and financial condition, as well as adversely affect the value of an investment in our securities. <font style="Background-color:#FFFFFF;color:#000000;">When we offer and sell any securities pursuant to a prospectus supplement, we may include additional risk factors relevant to such securities in the prospectus supplement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073251"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="BUSINESS"></a><a name="BUSINESS"></a>BUSINESS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 10, 2019, JanOne Inc. (formerly known as Appliance Recycling Centers of America,&#160;Inc.) and subsidiaries (collectively, &#8220;we,&#8221; the &#8220;Company,&#8221; or &#8220;JanOne&#8221;) broadened its business perspectives to being a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.  The Company aims to reduce prescriptions for dangerous opioid drugs by treating underlying diseases that cause severe pain.  Our first drug candidate is a treatment for Peripheral Arterial Disease (&#8220;PAD&#8221;), a condition that can cause severe pain and affects over 8.5 million people in the U.S. alone.&nbsp;&nbsp;In addition, we continue to operate our legacy businesses, ARCA Recycling, Inc. (&#8220;ARCA Recycling&#8221;), in our Recycling segment, and GeoTraq Inc. (&#8220;GeoTraq&#8221;), in our Technology segment.&nbsp;&nbsp;ARCA Recycling recycles major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs.&nbsp;&nbsp;GeoTraq is engaged in the development, design, and, ultimately, we expect, the sale of cellular transceiver modules and associated wireless services.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 10, 2019, <font style="color:#000000;">the Company changed its name from Appliance Recycling Centers of America, Inc. to JanOne Inc. and announced that it intended to broaden its business perspectives to include developing new and highly innovative solutions for ending the opioid epidemic.  From digital technologies to educational advocacy to revolutionary painkilling drugs that address a multibillion dollar a year market, the Company intends to champion new initiatives to combat the opioid crisis, which claims tens of thousands of lives each year.&nbsp;&nbsp;The new name, JanOne, was strategically chosen to express the start of a &#8220;new day&#8221; in the fight against the opioid epidemic.  January First is the first day of a New Year&#8212;a day of optimism, resolution, and hope.  JanOne affirms the Company&#8217;s new strategic commitment to fresh thinking and innovative means to assist in ending the worst drug crisis in our nation&#8217;s history.&nbsp;&nbsp;The Company also adopted a new Nasdaq ticker symbol, NASDAQ: JAN, a new CUSIP number, 03814F403, and a new website address &#8211; www.janone.com.&nbsp;&nbsp;</font><font style="Background-color:#FFFFFF;color:#000000;">The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk35691890"></a>On December 28, 2019, we had 208 employees, of which 199 were full-time employees.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Minnesota in 1983, although, through our predecessors, we began operating our legacy recycling business in 1976.&nbsp;&nbsp;On March 12, 2018, we reincorporated in the State of Nevada. Our principal office is located at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Overview</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company focused on becoming the leader in identifying, acquiring, licensing, developing, partnering and commercializing novel,&#160;non-opioid&#160;and&#160;non-addictive&#160;therapies to address the large unmet medical need for the treatment of pain.&nbsp;&nbsp;Our initial product candidate, JAN101 (formerly known as TV1001SR) is a potential treatment for Periphery Artery Disease (&#8220;PAD&#8221;), a vascular disease that affects more than 60 million people worldwide. We are also researching the potential impact our compound JAN101 could have in patients with COVID-19 as many doctors around the world and our company believes COVID-19 is a respiratory disease that directly affects the vascular system.&nbsp;&nbsp;<font style="Background-color:#FFFFFF;color:#0F0F0F;">We expect to commence Phase 2b clinical trials for the treatment of PAD in early 2021.&nbsp;&nbsp;It is expected that the investigational new drug application (&#8220;IND&#8221;) for JAN101 as a COVID-19 vascular complication treatment will be submitted to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in the coming weeks. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">JAN101 </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Generally</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JAN101, formerly known as TV1001SR and/or TV1001, our advanced product candidate, is a patented oral, sustained release pharmaceutical composition of sodium nitrite and targets poor blood flow to the extremities, such as those with vascular complications of diabetes or PAD and treats pain. A conclusion from a round of human studies found JAN101 sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite. In a previous study of patients with PAD, 40 mg BID treatment with immediate release sodium nitrite led to a statistically significant reduction in reported pain while a 80 mg BID treatment had the more pronounced effect on bioactivity and Flow Mediated Dilation, a measure of vascular function.&nbsp;&nbsp;However, a number of subjects on both treatment groups reported headaches and dizziness following treatment.&nbsp;&nbsp;Although this did not result in subjects discontinuing treatment, JAN101 was developed to overcome this side effect.&nbsp;&nbsp;JAN101 was tested in a bridging study of diabetic neuropathy subjects and during that bridging study, the subjects did not report headaches or dizziness.&nbsp;&nbsp;Subjects in this bridge study also reported less pain following treatment and improvements in bioactivity (quantitative sensory testing, a measure of nerve function) were similar to the PAD study, where the 80 mg dose group had the greatest improvement in Flow Mediated Dilation. The ability to alleviate pain with BID treatment of JAN101 offers promise for a new non-addictive, non-sedating treatment of chronic pain.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical studies in humans JAN101 Attributes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Well established safety profile</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Excellent bioavailability</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Lack of induced tolerance</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Non-narcotic</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JAN1010 does not mask pain, but instead treats the cause of pain by improving tissue and vascular dysfunction.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Benefits of Sodium Nitrite on Vascular Health</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In initial research studies, sodium nitrite effectively restored ischemic tissue blood flow and was effective in a wide range of pathologies involving alterations of angiogenesis - development of new blood vessels - including diabetes, wound healing and tissue necrosis. Beneficial effects included enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis.&nbsp;&nbsp;There is also a strong association between reduced circulating nitrite levels and cardiovascular diseases in humans.&nbsp;&nbsp;We describe some of the associations and beneficial effects of sodium nitrite/nitrite below.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plasma nitrite levels are negatively correlated to cardiovascular disease</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000002.jpg" title="" alt="" style="width:391px;height:174px;"><img src="grk3fpqjsz23000003.jpg" title="" alt="" style="width:144px;height:193px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plasma nitrite levels were inversely related to number of cardiovascular risk factors a subject had and decreased plasma nitrite was associated with decreased flow mediated vasodilation (FMD) and increased intimal medial thickness (IMT) (both indicators of vascular pathology). -Kleinbongard, et al. (2006) Free Radic Biol and Medicine 40:295-302</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plasma nitrite levels are reduced in diabetic and PAD patients&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000004.jpg" title="" alt="" style="width:347px;height:260px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise is a well-known stimulator of e<font style="Background-color:#FFFFFF;color:#4D5156;">ndothelial nitric oxide synthase </font>activity, NO production that leads to increased plasma nitrite. In the study by Allen et al, these authors revealed that baseline plasma levels of nitrite were less in patients with diabetes mellitus (DM) or DM + PAD. Importantly, increases in plasma nitrite levels were not observed in either DM, PAD or DM + PAD patients after supervised exercise. These data reveal that baseline nitrite availability is compromised in DM patients and that supervised exercise is unable to increase plasma nitrite levels but actually results in a decrease<font style="font-weight:bold;font-style:italic;"> </font>in nitrite highlighting a physiological efficiency of this molecule. -Allen et al Nitric Oxide 2009 20:231-237</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Skeletal Muscle Nitrite and Metabolite Levels are Reduced in Critical Limb Ischemia Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000005.jpg" title="" alt="" style="width:387px;height:283px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skeletal muscle nitrite, nitrosothiol, nitric oxide-heme and cGMP are all significantly reduced in CLI patients. Diabetic patients with CLI show even further nitrite reductions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, nitrite levels in various cardiovascular and vascular diseases appear to be inversely related to the severity of the disease in humans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Lower nitrite levels are associated with higher level of heart failure;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Lower nitrite levels are observed in diabetic patients with PAD and are not compensated by exercise; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Nitrite levels are lower in the muscles of patients with critical limb ischemia and are further reduced in diabetic subjects with critical limb ischemia.</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the association between low levels of circulating nitrite and human diseases, supplementation with sodium nitrite has been studied preclinically in animals.&nbsp;&nbsp; Below are summaries of some of the more important findings:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Stimulates wound healing</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Prevents tissue necrosis</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From Arya et al </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nitrite Therapy Selectively Increases Ischemic Tissue Vascular Density in a NO-dependent Manner</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000006.jpg" title="" alt="" style="width:372px;height:535px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic sodium nitrite therapy increases ischemic tissue vascular density in a NO-dependent manner. A and B show representative images of CD31 (red) and DAPI nuclear (blue) staining from sodium nitrite and sodium nitrate ischemic gastrocnemius muscle tissue at day 7. C and D report the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 for 165 &#956;g/kg sodium nitrite and nitrate treatments, respectively. E and F demonstrate the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 from 165 &#956;g/kg sodium nitrite plus carboxy PTIO. (Scale bar, 150 &#956;m.) n = 10 mice per treatment group. Kumar D. et al. PNAS; 2008; 105:7540-7545.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nitrite Therapy Augments Arterial Perfusion of Ischemic Tissue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000007.jpg" title="" alt="" style="width:624px;height:296px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic sodium nitrite therapy acutely increases ischemic tissue blood flow and stimulates arteriogenesis. A and B report 165 &#956;g/kg sodium nitrite-induced acute changes in blood flow of chronically ischemic tissues at various time points with or without cPTIO, respectively. C reports the number of arterial branches between PBS and nitrite therapies. D and E illustrate vascular casting of the arterial vasculature in ischemic hind limbs of day 7 nitrite or PBS-treated mice, respectively. *, P &lt; 0.01 vs. sodium nitrate. n = 10 mice per treatment group. Kumar D. et.al. PNAS;2008; 105:7540-7545</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nitrite Therapy Restores Diabetic Ischemic Hind-Limb Blood Flow and Promotes Wound Heal</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000008.jpg" title="" alt="" style="width:365px;height:385px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unilateral femoral artery ligation was performed on 18-20 week old male Db/Db mice. Mice were randomized to PBS or sodium nitrite (165 &#956;g/kg) therapy twice daily via I.P. injection. Laser doppler flowmetry was performed at the indicated time points. Increased wound dehiscence was noted in the PBS treated animals at day 7 but not in nitrite treated animals. (Bir et al Diabetes 2014, 63(1):270-81)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nitrite Therapy Increases Diabetic Ischemia Induced Angiogenesis</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000009.jpg" title="" alt="" style="width:511px;height:306px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nitrite therapy prevented ischemia mediated endothelial cell density loss in normal C57BL/6J ischemic limbs. Nitrite therapy significantly restored endothelial cell density in ischemic limbs of diabetic mice to normal C57BL/6J levels compared to PBS therapy of non-ischemic and ischemic conditions. These data suggest that nitrite therapy may be useful in attenuating microvascular rarefaction due to loss of nitric oxide that is observed during metabolic dysfunction (Frisbee JC AJP Integr Comp Physiol 2005 289(2):R307-16; Stepp et al Microcirculation 2007 14(4-5): 311-6)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delayed Nitrite Therapy Restores Ischemic Hind-Limb Blood Flow</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000010.jpg" title="" alt="" style="width:548px;height:408px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Studies were performed to determine whether nitrite mediated therapy would be effective in tissue that had been left ischemic for 5 days after femoral artery ligation. Femoral artery ligation was performed in C57BL/6J mice and the animals randomized to either PBS or sodium nitrite therapy 5 days after artery ligation. Treatments were given b.i.d. via I.P. injection. Ischemic limb blood flow was measured using laser doppler flowmetry. (Bir et al Diabetes 2014, 63(1):270-81)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delayed nitrite therapy increases SPY angiogram arteriogenesis</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000011.jpg" title="" alt="" style="width:466px;height:640px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delayed nitrite therapy increases SPY angiogram arteriogenesis. Representative temporal SPY angiogram image stills (3&#8211;6s) are shown at 11 days following ligation and 6 days after beginning therapy (either</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PBS or sodium nitrite). <font style="font-style:italic;">Left</font>: PBS control angiogram. <font style="font-style:italic;">Right</font>: sodium nitrite angiogram following injection of ICG. <font style="font-style:italic;">n </font>= 5 animals per cohort. Circles identify limb anatomical regions of vascular blush, whereas arrows indicate perfused vessels that progressively occur over time.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bir S C et al. Am J Physiol Heart Circ Physiol 2012;303:H178-H188</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nitrite Therapy Prevents Tissue Necrosis in Aged Db/Db Mice</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000012.jpg" title="" alt="" style="width:604px;height:320px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delayed sodium nitrite (165 ug/kg) or control PBS therapy was stated 5 days post femoral artery ligation in 9 month old Db/Db mice. Nitrite therapy significantly prevented tissue necrosis (panel B) compared to control PBS therapy (panel A). Panel D reports tissue necrosis severity as a function of degree of limb and digit involvement. Nitrite therapy but not PBS control or sodium nitrate significantly prevented tissue necrosis. (Bir et al Diabetes 2014, 63(1):270-81)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nitrite and Hind Limb Ischemia Summary</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sodium nitrite has long been known to be a potent vasodilator (transiently increasing blood vessel diameter) that can lead to a drop in blood pressure when given acutely.&nbsp;&nbsp;The above studies indicate that chronic administration at low doses, promotes angiogenesis, unlike single one-time nitrite therapy which does not stimulate angiogenesis. In addition, these studies and a large number of other studies not reviewed above, show:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Nitrite therapy is very specific, acting only in damaged, ischemic tissue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Delayed nitrite therapy effectively restores ischemic tissue blood flow;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Nitrite therapy is effective in a wide range of pathologies involving alterations of angiogenesis including critical limb ischemia, heart failure, and tissue necrosis; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Nitrite supplementation has had positive effects in various diabetes models, including diabetic nephropathy and diabetic wound healing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Beneficial effects center on enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Sustained release nitrite therapy, unlike immediate release therapy, does not lead to vasodilation or a drop in blood pressure.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our Product Candidate JAN101</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidate is designed to treat diseases associated with poor vascular function. The following table summarizes our current product candidate pipeline:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000013.jpg" title="" alt="" style="width:624px;height:149px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutic Area Peripheral Artery Disease Pain COVID-19 Drug JAN101 Pre-IND Phase 1 Phase 2a Phase 2b Phase 3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company intends to file an Investigational IND with the FDA for COVID-19 in the coming weeks and a protocol amendment to carry out a large Phase 2 trial in Peripheral Artery Disease patients early next year.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pain</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pain is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted. The National Institutes of Health (the &#8220;NIH&#8221;) defines chronic pain as pain that persists beyond the normal healing time of an injury or that persists longer than three months. It is estimated that chronic pain affects 100 million individuals in the US and over 1.5 billion people worldwide, thus more people suffer from chronic pain than diabetes, heart disease and cancer combined (Cowen Therapeutic Categories Outlook March 2019).&nbsp;&nbsp;&nbsp;&nbsp;Chronic pain exacts a tremendous cost in terms of direct treatment and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public health problem in the United States that costs society between $560 and $635&#160;billion annually. Despite the magnitude of the pain problem, innovation in the development of therapeutic solutions has been largely absent. Since 2010, there have been 20 approvals by the FDA for the treatment of pain, of which 12 were opioid variants, one was an extended release generic corticosteroid, five were variants of aspirin, and two were variants of other existing drugs. We are developing a novel product candidate designed to overcome the limitations of current treatment options for patients with PAD who suffer from chronic pain. According to a research study by Stanford University more than 24% of patients with PAD are at risk of high opioid use. By treating pain at the source and present patients and physicians with better and safer treatment alternatives we expect to minimize opioids at the prescription pad.&nbsp;&nbsp;Given the properties of JAN101, we have made the strategic decision to initially focus on pain associated with PAD by treating the underlying cause of PAD.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Peripheral artery disease </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peripheral artery disease is a general term for conditions in which arterial blood flow to the limbs are partially blocked. When there is less blood present in the extremities relative to demand, muscle pain and fatigue result, especially in the calf, which is also known as intermittent claudication.&nbsp;&nbsp;In many patients, pain and fatigue are relieved through rest. Roughly half of patients with PAD are asymptomatic. The most common cause of PAD / intermittent claudication is atherosclerosis. Diabetes, chronic kidney disease, hypertension, and smoking are all risk factors which can increase the likelihood of PAD. In atherosclerosis, fat deposits (plaques) build up along arterial walls, resulting in a reduction in blood flow in the legs. This same process can cause strokes if the arteries leading up to the brain are affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the high rate of asymptomatic patients, prevalence figures vary widely. Some estimate that up to 200 million worldwide have PAD, ranging from asymptomatic disease to severe. Prevalence increases as a function of patient age, rising sharply after the age of 60. Thus, in countries with an aging population, it is expected that the prevalence of PAD will only increase.&nbsp;&nbsp;There is also a strong ethnic and racial component to PAD prevalence, which may be due to cultural differences in diet and exercise, along with genetic differences. Some suggest a prevalence of 8-12 million in the US alone, with roughly a third experiencing pain when walking, which improves upon resting. The diagnosis of PAD usually begins with patient complaints of pain in the extremities. If the patient is already being treated or monitored for diabetes or other risk factors, then the physician will check for a weak or absent pulse in the extremity. Decreased blood pressure, poor wound healing, and whooshing sounds in the legs (via stethoscope) are also tell-tale signs of PAD / intermittent claudication. Angiograms, electrocardiograms, and ultrasounds can also be used to image and confirm the diagnosis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000014.jpg" title="" alt="" style="width:624px;height:326px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The non-drug treatment of PAD / intermittent claudication may be divided into four general categories:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Lifestyle </font><font style="font-size:10pt;color:#000000;">&#8211; Primarily changes in diet and smoking cessation.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Exercise </font><font style="font-size:10pt;color:#000000;">&#8211; Patients who walk, cycle, stretch, or swim can experience marked improvement. Formal programs involving treadmills and track walking (usually 3-5 times per week) are frequently provided to patients. However, if the pain is triggered by exercise (claudication) and is significant, it can discourage the patient from exercise.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Angioplasty </font><font style="font-size:10pt;color:#000000;">&#8211; A procedure by which the affected artery is stretched with a balloon-like device. This procedure has limited effectiveness and is reserved for severely blocked arteries.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Bypass Surgery </font><font style="font-size:10pt;color:#000000;">&#8211; Arteries which are beyond angioplasty can be bypassed entirely. This procedure is typically reserved for cases where the blockage is considered very long (~10 centimeters) and nearly complete.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underlying condition, however, is not addressed by surgery. Surgical approaches will not, in the long run, improve exercise capacity and walking distance. Only exercise itself, coupled with lifestyle changes and drug approaches, has this benefit.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prescription drugs for the treatment of the underlying PAD may be divided into multiple categories, depending on the underlying condition and severity:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Cholesterol-Lowering Agents </font><font style="font-size:10pt;color:#000000;">- Statins and bile acid sequestrants.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Antiplatelet Medica1ons </font><font style="font-size:10pt;color:#000000;">&#8211; Aspirin and related drugs, such as clopidogrel. Cilostazol also has antiplatelet properties.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Antihypertensives </font><font style="font-size:10pt;color:#000000;">&#8211; Patients with underlying high blood pressure can and will receive any number of medications to reduce blood pressure, such as ACE inhibitors and diuretics.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Diabetes Therapies </font><font style="font-size:10pt;color:#000000;">&#8211; While a substantial portion of PAD patients may have pre-diabetes or fulminant diabetes, it is unknown of aggressive treatment of diabetes has a positive effect on PAD.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Pain </font><font style="font-size:10pt;color:#000000;">&#8211; To our knowledge, no drugs are specifically indicated for PAD-associated pain. Pentoxifylline, for example, is indicated &#8220;&#8230;for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs.&#8221; (Sanofi-Aventis U.S. LLC, 2010) However, the evidence supporting the effectiveness of pentoxifylline is mixed. Short-term courses of NSAIDs, such as ibuprofen may be used, provided the patient is not on another anticoagulant like aspirin. Non-drug pain relievers, such as TENS and massage, may also be used in these patients. Opioids may also be used which creates a risk for addiction and potential misuse at the medicine cabinet by family members.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="grk3fpqjsz23000015.jpg" title="" alt="" style="width:624px;height:402px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lack of any truly effective treatment of PAD, along with encouraging early trial results using JAN101 on both improving vascular function and reducing pain in PAD patients, has created an opportunity to potentially treat this large unmet medical need.&nbsp;&nbsp;By improving vascular function, JAN101 has the potential to reduce associated pain and improve PAD patients&#8217; quality of life.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment.&#160; Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness.<font style="Background-color:#FFFFFF;color:#424242;"> </font>&#160;The COVID-19 virus spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. At the time of filing this Form 10-K, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments and vaccines. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of the hallmarks of severe cases of COVID-19 is acute respiratory distress syndrome (&#8220;ARDS&#8221;), a rapid, widespread inflammation of the lungs that can lead to respiratory failure and death<font style="Background-color:#FFFFFF;color:#333E48;">.&nbsp;&nbsp;</font>In addition to the widely reported lung injuries associated with COVID-19, clinicians around the world are reporting that the disease also could be causing cardiac injuries in patients that sometimes lead to cardiac arrest.<font style="color:#333E48;"> </font>Kidney damage also is becoming a commonly reported issue among COVID-19 patients.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alan Kliger, a nephrologist at the&#160;Yale School of Medicine, found early data showed 14%&#160;to 30%&#160;of ICU COVID-19 patients in New York and Wuhan, China, lost kidney function and later required dialysis. Similarly, a&#160;study published in the journal&#160;<font style="font-style:italic;">Kidney International</font>&#160;found that nine of 26 people who died of COVID-19 in Wuhan had acute kidney injuries, and seven had units of the new coronavirus in their kidneys. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A study in May, 28 2020 in the New England Journal published research detailing the post-mortem features of seven patients who died of COVID-19 provides critical insights, including evidence of extensive damage to the lining of the blood vessels, abnormal blood vessel growth in the lungs and widespread blood clotting. The study led by Steven Mentzer, HMS professor of surgery at Brigham and Women&#8217;s Hospital, and done in collaboration with a team of international researchers<font style="color:#1E1E1E;"> </font>tissue analysis showed that infection with SARS-CoV-2, the virus that causes COVID-19, caused severe damage to the endothelial cells that line blood vessels and triggered widespread blood clotting.&nbsp;&nbsp;The team also identified signs of a distinctive pattern of vascular disease progression in some cases of COVID-19 compared with patterns seen in equally severe influenza virus infection. The findings highlight these key takeaways:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">While caused by a respiratory virus, COVID-19 manifests as a vascular disease that leads to severe injuries to blood vessels throughout the lungs. The damage to vascular cells may help explain why serious blood clotting has been observed in many patients.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The substantial new blood vessel growth seen in the lungs of COVID-19 patients occurs primarily through a mechanism known as intussusceptive angiogenesis&#8212;the splitting of existing blood vessels to form new ones&#8212;perhaps as a repair response to blood clotting and blood vessel damage, according to the authors.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Damaged blood vessels may also underlie other problems, such as COVID toe, multisystem inflammatory syndrome in children (MIS-C), stroke and other seemingly unrelated problems seen with COVID-19.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our Team</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tony Giordano PhD, our Chief Scientific Officer, joined the company in December 2019. Dr. Giordano joined JanOne from the Cleveland Clinic, the No.2 rated hospital in the country, where he served as Senior Director of Special Projects in the Business Development group. Dr. Giordano has extensive experience in commercialization and drug development, having served as Vice President or President of seven different biotechnology companies he co-founded, including companies developing platform technologies, a cancer vaccine, and Alzheimer&#8217;s Disease and cardiovascular therapies.&#160; He has managed numerous clinical trials and the launch of a medical food product.&nbsp;&nbsp;Dr. Giordano has also served as an Associate Professor and Assistant Dean of Research and Business Development at LSU Health Sciences Center in Shreveport, where he led the licensing efforts at the campus and at Abbott Labs, where in addition to serving as a Senior Research Scientist, he was involved in technology assessment activities.&#160; Dr. Giordano has a PhD focused in Molecular Genetics from Ohio State University and completed Fellowships at the NCI and NIA. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Amol Soin, our Chief Medical Officer, joined the Company in January 2020.&nbsp;&nbsp;Dr. Soin is considered one of the nation's top pain experts and is the Founder and Chairman of the Ohio Pain Clinic. Dr. Soin brings significant expertise for treating neuropathic and chronic pain and extensive research experience for non-opioid, nonaddictive pain solutions to the JanOne management team. In his role as Chief Medical Officer, Dr. Soin will guide JanOne's drug development activities, manage clinical research, set patient safety standards, and ensure regulatory compliance. In addition, Dr. Soin will play an integral role in establishing partnerships and drug candidate selection as the company expands its pipeline.&nbsp;&nbsp;Dr. Soin received his undergraduate degree from&#160;University of Akron, his MBA from&#160;University of Tennessee, his MD from Northeastern Ohio Universities College of Medicine, his master's in science from&#160;Brown University&#160;and also has studied at&#160;Dartmouth College. He is board certified in anesthesiology and pain medicine and a fellow of interventional pain management at the World Institute of Pain, and he served as a pain management fellow at the Cleveland Clinic, the oldest and largest academic pain management department in&#160;the United States. The founder and chairman of the Ohio Pain Clinic, Dr. Soin has also held several prestigious positions including President of the Ohio Society of Interventional Pain Physicians, president of the American Society of Interventional Pain Physicians Foundation, President of the Society of Interventional Pain Management Surgery Centers and president &#8211; elect of TriState Pain Society. He was appointed by Governor Kasich to the Ohio Medical Board in 2012 to two 5 year terms and has served as the Ohio Medical Board's president where he was instrumental in passing statewide rules and guidelines to help the opioid crisis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, we formed a Scientific Board of Advisors (the &#8220;SBA&#8221;) and the following doctors and scientist currently sit on the SBA:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chris Kevil, Ph.D., Chair of the Scientific Advisory Board<font style="font-weight:normal;"> -- Dr. Kevil, an internationally known expert in vascular pathophysiology, PAD, and nitric oxide biology, discovered the role of sodium nitrite in promoting angiogenesis that led to the development of TV1001 now known as Jan101. Dr. Kevil earned his Ph.D. degree from LSU Health Shreveport in Molecular and Cellular Physiology followed by a fellowship at the University of Alabama at Birmingham (UAB) with an emphasis on redox pathophysiology. Returning to LSU Health Shreveport in the Department of Pathology, he established cutting edge research programs regarding redox biology regulation of peripheral vascular diseases. This led to ground-breaking insights on how glutathione, nitrite/nitric oxide, and hydrogen sulfide regulate vascular health during ischemia. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Edgar Ross,<font style="font-weight:normal;"> MD -- Dr. Ross is the current Director of the Pain Management Center at Brigham and Women's Hospital and a professor of anesthesia at Harvard Medical School. Dr. Ross is recognized as Castle Connolly's America's top doctors for the fifth year in a row. In addition to serving as chairman of Pfizer's partnership on pain, Dr. Ross also has served as a member of the Blue Cross and Blue Shield Opioid Prescribing Policy Committee.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rakesh Patel, Ph.D.<font style="font-weight:normal;"> -- Dr. Patel is currently Vice Chair for Research, Department of Pathology, and Director of the Center for Free Radical Biology at the University of Alabama at Birmingham (UAB). Most noted is his research to understand the molecular basis of nitric oxide, and nitrite interactions with organs and red blood cells. Patel is also known for his work to understand the impacts on the biological process associated with blood flow regulation and pulmonary function.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Timothy Ness, MD, Ph.D<font style="font-weight:normal;">. -- Dr. Ness is Professor Emeritus and former Pain Treatment Division Chief, Director of Pain Research and Vice Chair for Clinical Research in the Department of Anesthesiology and Perioperative Medicine at the University of Alabama at Birmingham (UAB) He has served as a clinical research expert on pain for the National Institutes of Health (NIH), Food and Drug Administration (FDA) advisory panels, the Veterans Administration (VA), and various international research institutes. He has served on the American Pain Society and the American Society of Regional Anesthesia and Pain Medicine Board of Directors. He is currently funded by the NIH.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alan Kaye, MD, PhD, DABA, DABPM, DABIPP<font style="font-weight:normal;"> -- Dr Kaye is the Professor and Chairman of the Department of Anesthesiology at LSU Health Sciences Center in New Orleans since January 2005. Before LSU, he was Professor and Chairman of the Texas Tech University Health Sciences Center Department of Anesthesiology in Lubbock, Texas. Prior, he was the Medical Director of the Greater New Orleans Surgical Center, the Director of Resident Recruitment, Acting Program Director and an Attending Staff of the Department of Anesthesiology at Tulane University Medical Center in New Orleans. He received two BS degrees and a MD degree from the University of Arizona. He also completed a pain management fellowship at Texas Tech Health Sciences Center. He is Board </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Certified as a Consultant in Anesthesiology and has a special certificate in Pain Management for the American Board of Anesthesiology. He is also a Diplomate of the American Board of Pain Medicine and the American Board of Interventional Pain Physicians. Dr. Kaye completed his PhD in pharmacology in May 1997. His thesis title was "Pharmacology of Angiotensin Peptides and Nonpeptide Agonists in the Pulmonary Vascular Bed of the Cat and of the Rat." He was awarded first place in the National Student Research Forum as a resident and has authored or co-authored over 150 abstracts and 200 manuscripts and book chapters in the fields of pulmonary vascular pharmacology and anesthesiology. He has had a lifelong interest in education and teaching medical students and residents. He serves on a number of national committees including as a National Board of Directors of ASIPP and ABIPP. He is editor-in-chief of the journal Pain Physicians and is on the FDA Advisory Board on Anesthetics and Analgesics. He was an Associate National Board Examiner in Anesthesiology</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">John Cooke, MD, Ph.D.<font style="font-weight:normal;"> -- is the Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center in Houston, Texas. He trained in cardiovascular medicine and obtained a Ph.D. in physiology at the Mayo Clinic. He was recruited to Harvard Medical School as an assistant professor of medicine. In 1990, he was recruited to Stanford University to spearhead the program in vascular biology and medicine, and was appointed professor in the Division of Cardiovascular Medicine at Stanford University School of Medicine, and associate director of the Stanford Cardiovascular Institute until his recruitment to Houston Methodist in 2013. Dr. Cooke has published over 500 research papers, position papers, reviews, book chapters and patents in the arena of vascular medicine and biology with over 30,000 citations. He has served on national and international committees that deal with cardiovascular diseases, including the American Heart Association, American College of Cardiology, Society for Vascular Medicine, and the National Heart, Lung and Blood Institute. He has served as president of the Society for Vascular Medicine, as a director of the American Board of Vascular Medicine, and as an associate editor of Vascular Medicine.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our Strategy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mission is to develop and commercialize novel,&#160;non-opioid,&#160;and&#160;non-addictive&#160;therapies to safely and effectively address the significant unmet medical need of chronic pain or treat conditions that cause pain. The principal elements of our strategy to achieve this mission are the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">License, acquire, develop, and create novel,&#160;non-opioid&#160;and&#160;non-addictive&#160;therapies by leveraging our understanding of pain biology to address the large and growing problem of pain.</font><font style="font-size:10pt;color:#000000;">&#160;While innovation in medical sciences has led to exciting new treatment options in many disease areas, pain has seen limited innovation in recent years. We have a deep understanding of the pathophysiology of pain and diseases that cause pain. We intend to leverage this understanding to bring innovation in the pain treatment paradigm through targeted acquisitions of companies or assets in development. Our advisors and doctors have years of collective experience in leadership positions at institutions and substantial scientific experience, and understand the complexity of designing and executing clinical trials for and developing therapies.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Advance the development of our lead product candidate, JAN101, designed for the treatment of patients with PAD and pain associated with the disease.</font><font style="font-size:10pt;color:#000000;">&#160;There are limited therapeutic options available for patients with PAD and we believe that JAN101 has the potential to transform the standard of care to a twice a day pill to substantially improve moderate to severe PAD. The company plans to engage a contract research organization (&#8220;CRO&#8221;) in early 2021 and begin enrolling subjects for the first Phase 2b trials for JAN101, and we expect to report topline results promptly following receipt of the data from the CRO. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Leverage clinical activity of JAN101 to expand into new indications, including complications associated with COVID-19. &#160;</font><font style="font-size:10pt;color:#000000;">We believe that JAN101 may have utility in treating vascular complications in patients with COVID-19 as we believe COVID-19 is an endothelial cell disease which manifests its complications in the vascular system and major organ causing complications in recovered patients. In November 2020, we filed an IND for our COVID-19 indication (which was subsequently converted to a pre-IND) and begin our study if and when we receive approval from the FDA. We plan to release more information regarding our COVID-19 study once the FDA has cleared the IND.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Advance our product candidates through clinical development and pursue development of additional product candidates through acquisitions.</font><font style="font-size:10pt;color:#000000;">&#160;Our objective is to build a well-balanced, multi-asset portfolio targeting the large population of patients with chronic and acute pain. To achieve this, in addition to JAN101, we intend to pursue partnerships, licensing agreements, and potential acquisitions of other pharma companies. We continue our search for assets with indications where we believe they could have meaningful impact and address the large unmet medical need. In addition, we may choose to selectively&#160;in-license&#160;or acquire complementary product candidates by leveraging the insights, network, and experience of our team.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Maximize the commercial potential of all our product candidates.&#160;</font><font style="font-size:10pt;color:#000000;">We currently intend to retain all commercial rights to JAN101 in the United States and selectively partner outside of the United States. Because we believe that PAD is an attractive market for many major pharmaceutical companies, we may sub-license or partner certain indications if we believe it may enhance stockholder value. As we continue to build and develop our product portfolio, we may opportunistically pursue strategic partnerships that maximize the value of our pipeline while seeking to develop other indications. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Leverage our management team background and expertise.&#160;</font><font style="font-size:10pt;color:#000000;">We have assembled a team with extensive experience described above. </font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chronic Pain</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NIH defines chronic pain as pain that persists either beyond the normal healing time of an injury or longer than three months. We believe that chronic pain represents a significant public health crisis. In the United States, chronic pain affects approximately 40&#160;million adults annually, which is greater than the annual prevalence of each of heart disease, cancer and diabetes. It is also estimated that pain leads to between $560 and $635&#160;billion in healthcare and lost productivity costs each year. Chronic pain is the leading cause of long-term disability in the United States, and approximately 23&#160;million adults in the United States experience severe pain over a three-month period. Globally the prevalence of chronic pain is even larger, with over 1&#160;billion people worldwide affected each year.<sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup>Common types of chronic pain include those of neuropathic and inflammatory origin and may involve the skin, muscles, joints, bones, tendons, ligaments, and other soft tissues. Chronic pain is associated with a variety of clinical conditions including, but not limited to, arthritis, spinal conditions, cancer, fibromyalgia, diabetes, surgical recovery, visceral injury and general trauma.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pain is a necessary protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses can be mounted. Pain is signaled by specialized cells in the peripheral nervous system called nociceptors, or pain-sensing fibers. These pain-sensing fibers normally transmit information about stimuli that approach or exceed harmful intensity from different locations in the body to the brain, which registers this information as a sensation of pain. In the case of tissue injury due to trauma or infection, pain accompanies the associated inflammation, persists for the duration of the inflammatory response, and aids healing by inhibiting use of the affected body part.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pain also can modify the central nervous system such that the brain becomes sensitized and registers more pain with less provocation. This is called central sensitization. When central sensitization occurs, the nervous system goes through a process called&#160;wind-up&#160;and gets regulated in a persistent state of high reactivity. This persistent, or&#160;up-regulated,&#160;state of reactivity lowers the threshold for what triggers the sensation of pain and can result in the sensation of pain even after the initial injury might have healed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When there is dysfunction in pain signaling, injury to the nervous system, or an unhealed injury, pain becomes no longer just a symptom, but a disease in itself.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Current Therapeutic Approaches to Treating Chronic Pain and Their Limitations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">NSAIDs</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the most widely used therapies to treat chronic inflammatory pain are&#160;non-steroidal&#160;anti-inflammatory&#160;drugs, or NSAIDs. NSAIDs can have significant side effects that include gastrointestinal bleeding, gastritis, high blood pressure, fluid retention, kidney problems, heart problems and rashes. On April&#160;7, 2005, the FDA announced a decision to require boxed warnings of potential cardiovascular risk for all NSAIDs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Corticosteroids</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corticosteroids, or steroids, also possess anti-inflammatory properties and are commonly used in the practice of pain management, either systemically or locally, depending on the condition.&#160;Steroids work by decreasing inflammation and reducing the activity of the immune system. While steroids are commonly used, they may have numerous and serious side effects. These side effects may include allergic or hypersensitivity reactions, increased risk for infection, adrenal insufficiency, diabetes or decreased glucose tolerance, hypertension, loss of bone density, and loss of joint cartilage volume. In addition, steroids should not be administered when there is an infection present because steroids can inhibit the body&#8217;s natural infection-fighting immune response. Also, if a joint is already damaged or is subject to chronic deterioration, IA steroid injections are not likely to provide any long-term restorative benefit. For the above reasons, IA steroid injections are generally recommended to be administered no more often than every six weeks and not more than three to four times per year.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Opioids</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Opioids are some of the most widely prescribed therapeutics for chronic and acute pain, and sales of these drugs have quadrupled between 1999 and 2010.<sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup>According to a National Survey on Drug Use and Health report, in 2016 more than one third of adult Americans were prescribed opioids and 230&#160;million opioid prescriptions were written that year in the United States. Opioids act by binding to specific receptors located on neurons in both the central and peripheral nervous system throughout the body including in the brain, spinal cord and other nervous tissue. Although they can be effective in providing pain relief, the increased medical use of opioids has been accompanied by an increase in the abuse and misuse of prescription opioids. In addition, for most patients, chronic opioid use is a poor option due to an intolerance to the many side effects, including nausea, vomiting, drowsiness and constipation, and the propensity for opioids to become less effective with long-term use. According to the Centers for Disease Control and Prevention, or CDC, almost two million individuals abused or were dependent on prescription opioids in 2014. CDC figures show that the number of opioid-related overdose deaths has quadrupled between 1999 and 2010, and currently approximately 40% of opioid overdose deaths in the United States involve a prescription opioid. This increase in prescription opioid-related deaths in the United States prompted President Trump to declare the opioid crisis a national Public Health Emergency in October 2017. Opioid abuse has become an epidemic in the United States, ranking as the nation&#8217;s second most prevalent illegal drug problem. These major issues create the need to find new approaches to treating chronic pain.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Our Approach to Treating PAD and Chronic Pain</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unmet medical need for treating PAD and chronic pain reflects the historic failure to develop novel classes of analgesics with comparable or greater efficacy, an acceptable level of adverse effects and a lower abuse liability than those currently available. Some of the reasons for this include the heterogeneity of chronic pain and its related conditions, and the complexity and diversity of the underlying pathophysiological mechanisms for pain. However, recent advances in the understanding of the neurobiology of pain are beginning to offer opportunities to identify new drug targets and develop new therapeutic strategies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken an innovative and targeted approach to identifying treatments for chronic pain that leverages our understanding of the pathophysiology of pain. Pain is variable&#8212;for example, it can be inflammatory or neuropathic in nature, and it may be localized to a specific area of the body or it may be generalized throughout. We believe that the most effective way to treat chronic pain is through therapies that specifically target the origin of the pain signal. We strive to maximize each of our product candidate&#8217;s potential based on its unique mechanism of action related to the origin of the pain signal.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic Neuropathy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Background:<font style="font-weight:normal;"> Background: Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Objectives:<font style="font-weight:normal;"> To evaluate the safety and efficacy of 40 and 80 mg, BID, of an oral sustained release formulation of sodium nitrite (SR-nitrite) in patients suffering from diabetic neuropathy, and to determine whether SR-nitrite would reduce the frequency of headaches reported previously by subjects receiving the same doses of an immediate release formulation. Study Design: Phase II, single-center, randomized, double-blind, placebo controlled clinical trial. Setting: The Ohio Pain Clinic and Kettering Medical Center.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Methods:<font style="font-weight:normal;"> Twenty-four patients were randomized to 40 mg or 80 mg SR-nitrite or placebo twice daily for 12 weeks. The primary objective was to determine whether headaches would be reduced using SR-nitrite. The primary efficacy endpoint was the mean difference in the change of the Neuropathic Pain Symptom Inventory (NPSI) pain score from baseline to that reported after 12 weeks of treatment. Secondary endpoints included changes from baseline for the Brief Pain Inventory (BPI) Scale, the RAND 36 questionnaire, Short Form McGill Questionnaire, daily patient reported score for neuropathic pain, changes in HbA1c, PulseOx and quantitative sensory testing. Results: The number of subjects reporting adverse events and the number of adverse events did not change with dose. There were no reports of treatment-related headaches. Although no significant differences were identified in patient responses to the questionnaires, a trend was observed. In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group. A trend was also observed with the BPI total severity score. However, the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores, where the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups. Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity. No changes were observed in HbA1c levels or PulseOx.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations:<font style="font-weight:normal;"> Small sample size.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conclusion:<font style="font-weight:normal;"> Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite. In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study. The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}. The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Microcirculatory injury, which is common in diabetic patients, can lead to a number of problems. Prominent among these is diabetic peripheral neuropathy (DPN) (1,2). About 10% of patients will have evidence of DPN at the time they are initially evaluated, and almost 50% of diabetic patients will ultimately develop DPN. Of diabetic patients with DPN, 40% to 50% suffer from chronic pain as well as paresthesias, sensory loss, and weakness, and have at least an 8-fold increased risk of undergoing a distal lower extremity amputation compared to similar non-diabetics.&nbsp;&nbsp;Endothelial cells play an important part in the regulation of microcirculation, as they maintain vascular tone by secreting both vasodilators and vasoconstrictors. A central feature of diabetic microvascular disease (MVD) is endothelial dysfunction, which, in turn, plays an important role in the development and progression of DPN. The pathophysiological factors leading to endothelial dysfunction in diabetes include chronic hyperglycemia and protein glycolation, insulin resistance, inflammation, and increased oxidative stress. Studies have now shown a close relationship between endothelial dysfunction and diminished nitric oxide (NO) bioavailability. Endogenously produced NO has a half life measured in seconds, and is rapidly oxidized to nitrite (NO2&#8211;) and nitrate (NO3&#8211;&#8211;) end products, the latter of which is biologically inert. In the presence of microcirculatory ischemia and endothelial cell dysfunction, however, endogenous NO production by eNOS is much more limited. In such circumstances, circulating NO2&#8211; can be non-enzymatically reduced to increase NO availability. In addition to serving as a circulating NO reservoir, nitrite itself has also been shown to have direct and potent vasodilatory effects in vitro and in vivo. The findings that NO2&#8211; mediates vasodilatation, both directly and through NO generation, has led to growing interest in the potential effectiveness of nitrite as a therapeutic agent in conditions associated with DPN and endothelial dysfunction. Such conditions include diabetic microvascular disease, DPN, and retinopathy, in which low levels of NO and NO2&#8211;, as well as elevated levels of nitrate (NO3), suggest that the complete oxidation of NO occurs during diabetes with insufficient NO2&#8211; reserves to restore NO bioavailability. Previous human studies with an oral formulation of NaNO2 have shown that administration twice daily improves vascular function. In the peripheral arterial disease study, subjects who received the lower dose of NaNO2 reported a significant reduction in pain. Although side effects were minimal, headaches and dizziness were reported by a large number of subjects, likely due to the rapid release of NaNO2 leading to vasodilation. An oral sustained-release formulation of NaNO2 (SR-nitrite) was developed in an attempt to overcome these problems and was tested in a porcine model of metabolic syndrome with critical limb ischemia. SR-nitrite-treated animals showed increased myocardial NO </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bioavailability, diminished oxidative stress, and cytoprotection in ischemic tissue. Importantly, 24-telometry recordings of blood pressure showed no evidence of vasodilation. In the present study, we hypothesized that the SRnitrite would reduce or eliminate headaches reported in patients following administration of the immediate release formulation. Given the promising results on reducing pain in diabetic patients with peripheral arterial disease reported in the previous study, patients with diabetic neuropathy were utilized in this study to determine whether any trends in reducing pain could be observed. The study design was a randomized, placebo controlled, double-blind phase II study was carried out to investigate the safety and potential biological activity of multiple doses of an oral, sustained-release formulation of sodium nitrite (SR-nitrite; Theravasc Inc., Cleveland, OH, USA), BID in doses of 40 mg and 80 mg over a 12-week treatment period, in human subjects with diabetes and neuropathic pain in the lower extremities and feet. The trial was approved by the Copernicus IRB and listed on ClinicalTrials.gov: www.clinicaltrials.gov/ct2/show/NCT02412852. The study was funded by Theravasc Inc.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">JAN101&#8212;Regulatory Strategy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sodium Nitrite has been previously approved as one of the active components of cyanide poisoning antidote. This means the approval path for JAN101 is through a 505(b)(2) NDA, which we intend to pursue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">JAN101&#8212;Commercial Strategy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to use third party providers and manufacturers in the United States to effectively support the commercialization JAN101, if we are successful in obtaining FDA approval.&nbsp;&nbsp;We believe that we can cost effectively promote JAN101 to the patients suffering from PAD. We anticipate our commercial operation to include outside sales management, outside sales support, distribution support and an internal marketing group. Additional requisite capabilities will include focused management of key accounts, such as managed care organizations, group purchasing organizations, and government accounts.&nbsp;&nbsp;We intend to selectively partner with third parties with vast experience in the space as we have been partnering for every aspect of development. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by extensive research and development efforts, rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We are currently focused on the development and commercialization of our asset pipeline of novel,&#160;non-opioid&#160;and&#160;non-addictive&#160;therapies for PAD. The number of patients suffering from chronic PAD is large and growing. While we believe that our product candidate and our Chief Scientific Officers development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical, biotechnology, and specialty pharmaceutical companies either marketing or developing therapeutics to treat&#160;chronic pain. Academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies.&nbsp;&nbsp;Our competitors may have significantly greater financial resources, robust drug pipelines, established presence in the market and expertise in research and development, manufacturing,&#160;pre-clinical&#160;and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or&#160;early-stage&#160;companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.&nbsp;&nbsp;The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, durability, safety, price and the availability of reimbursement from government and other third-party payors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant competition exists in the PAD pain field. Although we believe our approach to developing novel treatments for pain is unique from most other existing or investigational therapies, such as non-steroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;), corticosteroids and opioids, we will need to compete with all currently available and future therapies within the indications where our development is focused.&nbsp;&nbsp;With respect to JAN101, the main classes of marketed products that are available for the treatment of PAD pain include NSAIDs and opioids. Furthermore, numerous monoclonal antibodies targeting nerve growth factor, or NGF inhibitors, are in clinical development, including two product candidates in Phase&#160;3.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a number of companies developing or marketing therapies for the treatment and management of pain that may compete with our current product candidate, including many major pharmaceutical and biotechnology companies. Among the companies that currently market or are developing therapies that, if approved, our product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates would potentially compete with include: Acorda Therapeutics, Assertio Therapeutics, Biogen, Cara Therapeutics, Eli Lilly and Company, Endo Pharmaceuticals, Flexion Therapeutics, Grunenthal, Horizon Pharma, Janssen Research&#160;&amp; Development, Merck &amp; Co., Novartis, Pacira Pharmaceuticals, Pain Therapeutics, Pfizer, Purdue Pharma, Sanofi, Trevena and Vertex Pharmaceuticals.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies, and to operate without infringing or otherwise violating the proprietary rights of others. We endeavor to protect our products using a combination of intellectual property protections and available government regulatory and marketing exclusivities afforded to new medicines. For example, we endeavor to protect our products by, among other methods, filing U.S., and potentially in the future, foreign, patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also use other forms of protection, such as confidential information, trade secrets and&#160;know-how,&#160;and trademarks to protect our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proprietary nature of, and protection for, our product candidates, processes and&#160;know-how&#160;are important to our business. Our policy is to pursue, maintain and defend intellectual property rights, and to protect the technology, inventions, and improvements that are commercially important to our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Trade Secrets and Other Proprietary Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patents, we rely on trade secrets and&#160;know-how&#160;to develop and maintain our competitive position. For example, we have developed methods for the more efficient manufacture of sustained released sodium nitrite tablets. We seek to protect our proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LSU License Agreement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 19, 2019, we entered into a Patent and Know How License Agreement (the &#8220;License Agreement&#8221;) with UAB Research Foundation (&#8220;UABRF&#8221;), TheraVasc, Inc. (&#8220;TheraVasc&#8221;), and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting on behalf of LSU Health Sciences Center at Shreveport (&#8220;LSU Health Shreveport&#8221;, together with UABRF and TheraVasc, the &#8220;Licensors&#8221;). Under the License Agreement, the Licensors have agreed to grant to JanOne an exclusive, worldwide license, including the right to sublicense, to the Licensors&#8217; patent rights and know-how related to the Licensors&#8217; sustained release formulation of sodium nitrite<font style="Background-color:#FFFFFF;">.&nbsp;&nbsp;</font>Under the License Agreement, have agreed to pay a non-refundable upfront license fee and certain milestone payments upon the achievement of certain milestones of up to approximately $6.5 million and certain royalty payments and annual license maintenance fees.&nbsp;&nbsp;<font style="color:#000000;">The License Agreement requires us to use commercially reasonable efforts to develop and commercialize JAN101. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Commercial Operations</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no marketing and sales organization. We have retained global rights to our product candidate, and, if one of our product candidates is approved by the FDA, expect to access the market in the United States we expect that our sales force will be supported by sales management, internal sales support, an outside marketing group and distribution support. We intend to invest in our commercial capabilities prudently by focusing our marketing efforts on the physician subspecialties that treat patients with PAD. These physicians include, but are not limited to, pain management specialists, rheumatologist, surgeons and sports medicine physicians. We will also evaluate licensing and partnering with third parties to help us reach other sales channels and geographic markets inside and outside of the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies, and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">U.S. Government Regulation of Drug Products</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the FDCA and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">completion of&#160;pre-clinical&#160;laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an IND which must become effective before human clinical trials may begin;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">approval by an IRB at each clinical site before each trial may be initiated;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials in accordance with GCP requirements to establish the safety and efficacy of the proposed drug product for each indication;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an NDA;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of an FDA advisory committee review, if applicable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">payment of user fees and securing FDA and approval of the NDA; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">compliance with any post-approval requirements, including the potential requirement to implement a REMS and the potential requirement to conduct post-approval studies.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Pre-clinical&#160;Studies</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-clinical&#160;studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the&#160;pre-clinical&#160;tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some&#160;pre-clinical&#160;testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. Clinical holds also may be imposed by the FDA at any time before or during clinical trials, due to safety concerns about&#160;on-going&#160;or proposed clinical trials, or&#160;non-compliance&#160;with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Clinical Trials</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their www.clinicaltrials.gov website. The information contained in, or accessible through, this website does not constitute a part of this prospectus. We have included this website address in this prospectus solely as an inactive textual reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval trials, sometimes referred to as Phase 4 trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase&#160;2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and non-clinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">United States Review and Approval Process</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of product development,&#160;pre-clinical&#160;and other&#160;non-clinical&#160;studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after it the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications.<font style="font-weight:bold;"> </font>A Complete </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, non-clinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA or, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials designed to further assess a drug&#8217;s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for&#160;non-compliance&#160;with regulatory requirements or if problems occur following initial marketing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDASIA, made permanent the Pediatric Research Equity Act, or PREA, which requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a&#160;non-compliance&#160;letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Special FDA Expedited Review and Approval Programs</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the new PDUFA agreement, these six and ten month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, under the provisions of the FDASIA, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Post-Approval Requirements</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user program fee requirements for any marketed products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fines, warning letters or holds on post-approval clinical trials;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product seizure or detention, or refusal to permit the import or export of products; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses, and a company that is found to have improperly promoted&#160;off-label&#160;uses may be subject to significant liability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">The Hatch-Waxman Amendments</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, added two pathways for FDA drug approval. First, the Hatch-Waxman amendments authorized the FDA to approve an alternative type of NDA under Section&#160;505(b)(2) of the FDCA. Section&#160;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference from the data owner. The applicant may rely upon the FDA&#8217;s findings of safety and efficacy for an approved product that acts as the &#8220;listed drug.&#8221; The FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support the change from the listed drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second, the Hatch-Waxman amendments to the FDCA also established a statutory procedure for submission and FDA review and approval of abbreviated new drug applications, or ANDAs, for generic versions of branded drugs previously approved by the FDA (such previously approved drugs are referred to as &#8220;listed drugs&#8221;). An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. Premarket applications for generic drugs are termed abbreviated because they generally do not include&#160;pre-clinical&#160;and clinical data to demonstrate safety and effectiveness. However, a generic manufacturer is typically required to conduct bioequivalence studies of its test product against the listed drug. The bioequivalence studies for orally administered, systemically available drug products assess the rate and extent to which the API is absorbed into the bloodstream from the drug product and becomes available at the site of action. Bioequivalence is established when there is an absence of a significant difference in the rate and extent for absorption of the generic product and the listed drug. For some drugs, other means of demonstrating bioequivalence may be required by the FDA, especially where rate and/or extent of absorption are difficult or impossible to measure. The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not bioequivalent to the referenced innovator drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the Orange Book. Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1)&#160;no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA or 505(b)(2) application refers. The applicant may also elect to submit a &#8220;section viii&#8221; statement certifying that its proposed label does not contain (or carves out) any language regarding the patented&#160;method-of-use&#160;rather than certify to a listed&#160;method-of-use&#160;patent.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the reference NDA holder and patent owners assert a patent challenge directed to one of the Orange Book listed patents within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable&#160;non-patent&#160;exclusivity listed in the Orange Book for the branded reference drug has expired.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Marketing Exclusivity</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of&#160;non-patent&#160;marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or a NDA submitted under Section&#160;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or&#160;non-infringement&#160;to one of the patents listed with the FDA by the innovator NDA holder.&nbsp;&nbsp;The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the&#160;pre-clinical&#160;studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.&nbsp;&nbsp;Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">U.S. Coverage and Reimbursement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any therapeutic product candidate for which we may seek regulatory approval. Sales in the United States will depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our therapeutic product candidates can be subject to challenge, reduction or denial by payors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Healthcare Reform</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug product candidates, restrict or regulate post-approval activities, and affect the profitable sale of drug product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things: (i)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (ii)&#160;established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; (iii)&#160;expanded the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; (iv)&#160;increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; (v)&#160;expanded the eligibility criteria for Medicaid programs; (vi)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (vii)&#160;established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&#160;1, 2019, the&#160;tax-based&#160;shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on January&#160;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain&#160;ACA-mandated&#160;fees, including the&#160;so-called&#160;&#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on&#160;non-exempt&#160;medical devices.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state healthcare laws and regulations restrict business practices in the pharmaceutical industry. The U.S. laws that may affect our ability to operate include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, as amended by the federal Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal Physician Payments Sunshine Act, which among other things requires certain manufacturers of drugs, devices, and biologics, that are reimbursable by a federal healthcare program to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">similar federal laws and state law equivalents of each of the above federal laws.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Regulation Outside the United States</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable&#160;post-marketing&#160;requirements, including safety surveillance,&#160;anti-fraud&#160;and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market our future products in the EEA and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes,&#160;auto-immune&#160;and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the&#160;risk-benefit&#160;balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Data and Marketing Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the&#160;pre-clinical&#160;and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10&#160;years have elapsed from the initial authorization of the reference product in the EU. The&#160;10-year&#160;market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10&#160;years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. In Japan, medicinal products approved for administration to a patient via a new route of administration qualify for six years of market exclusivity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCPs. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8220;no fault&#8221; compensation to any study subject injured in the clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion from an IEC. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements also apply.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recycling</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We started our business in 1976 as a used appliance retailer that reconditioned old appliances to sell in our stores.&#160; Under contracts with national and regional retailers of new appliances, such as Sears Roebuck and Co. and Montgomery Ward Inc., we collected the replaced appliance from the retailer&#8217;s customer&#8217;s residence when one of their stores delivered a new appliance in the Minneapolis/St. Paul, Miami, or Atlanta market. Any old appliances that we could not sell in our stores were sold to scrap metal processors. In the late 1980s, stricter environmental regulations began to affect the disposal of unwanted appliances and we were no longer able to take appliances that contained hazardous components to a scrap metal processor. At that time, we began to develop systems and equipment to remove the harmful materials so that metal processors would accept the appliance shells for processing. We then offered our services for disposing of appliances in an environmentally sound manner to appliance manufacturers and retailers, waste hauling companies, rental property managers, local governments, and the public.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 1989, we began contracting with electric utility companies to provide turnkey appliance recycling services to support their energy conservation efforts. Since that time, we have provided our services to approximately 400 utilities and other providers of energy efficiency programs throughout North America.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk50381069"></a>We currently have contracts to recycle, or to replace and recycle, appliances for approximately 180 utilities across North America.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have seen continued interest from sponsors of energy efficiency initiatives that recognize the effectiveness of recycling and replacing energy inefficient appliances.&#160; We are aggressively pursuing electric, water, and gas utilities, public housing authorities, and energy efficiency management companies going forward and expect that we will continue to submit proposals for various new appliance recycling and replacement programs accordingly. However, for a variety of reasons, we still have a limited ability to project revenues from utility programs.&#160; We cannot predict recycling volumes or if we will be successful in obtaining new contracts in the next fiscal year.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate 13 recycling centers in the U.S. and Canada to process and recycle old appliances according to all federal, state, provincial, and local rules and regulations. ARCA uses U.S. EPA RAD-compliant methods to remove and properly manage hazardous components and materials, including CFC refrigerants, mercury, polyurethane foam insulation and recyclable materials, such as ferrous and nonferrous metals, plastics, and glass. All of our facilities comply with licensing and permitting requirements, and employees who process appliances receive extensive safety and hazardous materials training.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major household appliances in the United States include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refrigerators</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clothes washers</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Freezers</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clothes dryers</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ranges/ovens</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Room air conditioners</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dishwashers</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dehumidifiers</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Microwave ovens</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humidifiers</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Improper disposal of old appliances threatens air, ground, and water resources because many types of major appliances contain substances that can damage the environment. These harmful materials include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Mercury, which easily enters the body through absorption, inhalation, or ingestion, potentially causing neurological damage. Mercury-containing components may be found in freezers, washers, and ranges.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Chlorofluorocarbon (&#8220;CFC&#8221;), hydrochlorofluorocarbon, and hydrofluorocarbon refrigerants (collectively, &#8220;Refrigerants&#8221;), which cause long-term damage to the earth&#8217;s ozone layer and may contribute to global climate change.&#160; Refrigerators, freezers, room air conditioners, and dehumidifiers commonly contain Refrigerants.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">CFCs, having a very high ozone-depletion potential that may also be used as blowing agents in the polyurethane foam insulation of refrigerators and freezers.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Other materials, such as oil, that are harmful when released into the environment.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal government requires the recovery of Refrigerants upon appliance disposal and also regulates the management of hazardous materials found in appliances. Most state and local governments have also enacted laws affecting how their residents dispose of unwanted appliances. For example, many areas restrict landfills and scrap metal processors from accepting appliances unless the units have been processed to remove environmentally harmful materials.&#160; As a result, old appliances usually cannot be discarded directly through ordinary solid waste systems.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to these solid waste management and environmental issues, energy conservation is another compelling reason for proper disposal of old appliances. The U.S. Department of Energy&#8217;s updated appliance energy efficiency standards that took effect in September 2014 require new refrigerators to be 25-to-30% more efficient than those manufactured only one year earlier. Refrigerators manufactured today use about one-fifth as much electricity as units made in the mid-1970s.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While new refrigerators can save a significant amount of energy in the home, more than 30</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of all U.S. households have a second refrigerator in the basement or garage. These units are typically 15-</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to-</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 years old and consume about 750 to 1500 kilowatt-hours per year, driving electric bills up by more than $150 annually per household.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilities have become important participants in dealing with energy inefficient appliances as a way of reducing peak demand on their systems and avoiding the capital and environmental costs of adding new generating capacity. To encourage the permanent removal of energy inefficient appliances from use, many electric utility companies sponsor programs through which their residential customers can retire working refrigerators, freezers, and room air conditioners.&#160; Utility companies often provide assistance and incentives for consumers to discontinue use of a surplus appliance or to replace their old, inefficient appliances with newer, more efficient models. To help accomplish this, some utilities offer appliance replacement programs for some segments of their customers, through which older model kitchen and laundry appliances are recycled and new highly efficient ENERGY STAR<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;units are installed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Environmental Protection Agency (the &#8220;EPA&#8221;) has been supportive of efforts by electric utilities and other entities that sponsor appliance recycling programs to ensure that the collected units are managed in an environmentally sound manner. In October 2006, the EPA launched the Responsible Appliance Disposal (&#8220;RAD&#8221;) Program, a voluntary partnership program designed to help protect the ozone layer and reduce emissions of greenhouse gases. Through the program, RAD partners use best practices to recover ozone-depleting chemicals and other harmful materials from old refrigerators, freezers, room air conditioners, and dehumidifiers. Because of our appliance recycling expertise, we were active participants in helping to design the RAD program and currently submit annual reports to the EPA to document the environmental benefits our utility customers that are RAD partners have achieved through their recycling programs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2009, we entered into a Joint Venture Agreement (the &#8220;Joint Venture Agreement&#8221;) with 4301 Operations, LLC (&#8220;4301&#8221;) to establish and operate a regional processing center (&#8220;RPC&#8221;). At the time of the formation of this joint venture, we believed that 4301 had significant experience in the recycling of major household appliances and, in connection therewith, 4301 contributed its then-existing business and equipment to the joint venture. Under the Joint Venture Agreement, the parties formed a new entity known as ARCA Advanced Processing, LLC (&#8220;AAP&#8221;), in which each party had a 50% interest. In connection with the formation of the joint venture, we contributed $2.0 million to the joint venture. The joint venture commenced operations on February 8, 2010. On August 15, 2017, ARCA entered into an Equity Purchase Agreement with 4301 and sold its 50% joint venture interest in AAP to 4301 in consideration of $800,000 in cash. The gain recorded by ARCA was $81,000.&nbsp;&nbsp;On the same date and in a separate, related transaction, ARCA entered into an Asset Purchase Agreement with Recleim PA, LLC (&#8220;Recleim&#8221;), and the other parties thereto. Under the agreement, ARCA agreed to license certain intellectual property under patent No. 8,931,289 to Recleim for use at 4301 North Delaware Avenue, Philadelphia, Pennsylvania or any successor facility within 15 miles of where Recleim conducts business. On August 15, 2017, Recleim (i) paid in full all AAP indebtedness owed to BB&amp;T Bank in the amount of $3,454,000, (ii) terminated and released all security interests in AAP and ARCA&#8217;s equipment as part of Recleim&#8217;s purchase of certain equipment and assets from AAP on the same date, and (iii) assumed approximately $768,000 in AAP liabilities and all of ARCA&#8217;s liabilities to Haier US Appliance Solutions, Inc., dba GE Appliances.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our wholly-owned subsidiaries in our Recycling segment include, ARCA Canada Inc., a Canadian corporation formed in September 2006, ARCA Recycling, Inc., a California corporation formed in November 1991, and Customer Connexx, LLC, a Nevada limited liability company formed in October 2016 that provides call center services for recycling business.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Technology</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 18, 2017, in a move to diversify our offering beyond our then-current appliance recycling capabilities, the Company acquired GeoTraq by way of merger. As a result of this transaction, GeoTraq became a wholly-owned subsidiary of the Company. In connection with this transaction, the Company tendered to the three owners of GeoTraq $200,000, issued to them an aggregate of 288,588 shares of the Company&#8217;s Series A Convertible Preferred Stock then valued at $14,963,288 inclusive of the beneficial conversion feature, and issued three separate one-year unsecured promissory notes for an aggregate original principal amount of $800,000. These unsecured promissory notes have been repaid in full. In addition, there was $10,133,366 deferred tax liability associated with the purchase of the intangible assets of GeoTraq. The total value of the intangible assets purchased was $26,096,654, including the deferred tax liability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GeoTraq is a Mobile Internet of Things (&#8220;IoT&#8221;) technology company that designs innovative wireless modules that provide Location Based Services (&#8220;LBS&#8221;) and connect external sensors to the IoT. GeoTraq is planning to manufacture and sell wireless transceiver modules and subscription services that will allow connectivity using publicly available global Mobile IoT networks. GeoTraq addresses the large LBS market segment that is currently under served with existing solutions due to high deployment costs (hardware, service, logistics), limited battery life and large form factor</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We believe that there is a large under-served portion of the LBS market that is not addressed by existing solutions. RFID and Wi-Fi require close proximity for asset tracking, while GPS is too bulky and power hungry for many needs. GeoTraq addresses the white space in-between by designing wireless transceiver modules with technology that provides LBS directly from global Mobile IoT networks. GeoTraq&#8217;s technology allows for a substantially lower cost solution, extended service life, a small form factor</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and even disposable devices, which we believe can significantly reduce return logistics costs.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GeoTraq applied for and was granted Patent <font style="Background-color:#FFFFFF;">No. 10,182,402, which covers various aspects of operation of its Mobile IoT wireless modules. A description of the patent features includes:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">An apparatus comprising: an interval timer; a power control; a Short Message Service (SMS) packetizer; a geo-locator; a radio frequency (RF) communicator; and a controller and a memory, the memory comprising instructions for the controller to operate the interval timer cooperatively with the power control to cause a transition of the geo-locator from a sleep state to a wake state after a preset defined time interval, and to operate the geo-locator to receive signal strength levels and corresponding cell IDs from a plurality of cellular base stations, and to operate the SMS packetizer to package the signal strength levels and the corresponding cell IDs into a first outgoing SMS message, and to communicate the first outgoing SMS message to a preset address using the RF communicator.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The apparatus of claim 1, further comprising: a subscriber identity module (SIM); and the memory further comprising instructions to block visibility to the SIM by the geo-locator for a limited duration after the transition of the geo-locator from the sleep state to the wake state after the defined time interval.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The apparatus of claim 2, further comprising: the memory further comprising instructions to override a preset floor on the signal strength levels during the limited duration after the transition of the geo-locator from the sleep state to the wake state after the defined time interval.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The apparatus of claim 1, further comprising: the memory further comprising instructions to operate the SMS packetizer to package the signal strength levels with the corresponding cell IDs.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The apparatus of claim 1, further comprising: the memory further comprising instructions to receive a command SMS message via the RF communicator; a parser to extract a time interval command from the received command SMS message; and the memory further comprising instructions to apply the time interval command to the interval timer to set the defined time interval.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The apparatus of claim 1, further comprising: the memory further comprising instructions to receive a response SMS message via the RF communicator, the response SMS message being a response to the first outgoing SMS message; a parser to extract geo-locations for cell IDs from the response SMS message; and the memory further comprising instructions to associate the geo-locations for each of the cell IDs from the response message with corresponding cell IDs in the memory.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">A method comprising: applying an interval timer to a power control to control power for a subscriber identify module (SIM), a SMS packetizer, a geo-locator, and a radio frequency (RF) communicator after a preset defined time interval; operating the interval timer cooperatively with the power control to cause a transition of the geo-locator from a sleep state to a wake state after the defined time interval; operating the geo-locator to receive signal strength levels and corresponding cell ids from a plurality of cellular base stations; operating the SMS packetizer to package the signal strength levels and the corresponding cell IDs into an outgoing SMS message; and communicating the outgoing SMS message to a preset address using the RF communicator.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The method of claim 7, further comprising: blocking visibility to the SIM by the geo-locator for a limited duration after the transition.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The method of claim 8, further comprising: overriding a preset floor on the signal strength levels during the limited duration after the transition.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The method of claim 7, further comprising: receiving a command SMS message via the RF communicator; extracting a time interval command from the command SMS message; and applying the time interval command to the interval timer to set the defined time interval.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">11.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="Background-color:#FFFFFF;font-size:10pt;">The method of claim 7, further comprising: receiving a response SMS message via the RF communicator in response to the outgoing SMS message; extracting geo-locations for cell IDs from the response SMS message; and associating the geo-locations for each of the cell ids from the response SMS message with corresponding cell IDs in a memory.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the GeoTraq acquisition, we expect to have the ability to deploy IoT devices to locate, monitor and track the movement of inventory and other assets and monitor connected sensors.&nbsp;&nbsp;Our GeoTraq subsidiary has not generated any revenue to date, including in the fiscal year ended December 28, 2019.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ApplianceSmart, Inc.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to December 30, 2017, we sold new and out-of-the-box major household appliances in the United States though a chain of Company-owned retail stores operating under the name ApplianceSmart<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>.&nbsp;&nbsp;On December 30, 2017, we, together with our then-subsidiary, ApplianceSmart, Inc. (&#8220;ApplianceSmart&#8221;), entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with ApplianceSmart Holdings LLC (the &#8220;Purchaser&#8221;), a wholly-owned subsidiary of Live Ventures Incorporated (Nasdaq: Live), pursuant to which we sold to the Purchaser all of the issued and outstanding shares of capital stock of ApplianceSmart (the &#8220;ApplianceSmart Stock&#8221;) in exchange for $6.5 million. Effective April 1, 2018, the Purchaser issued the Company a promissory note (the &#8220;ApplianceSmart Note&#8221;) with a three-year term in the original principal amount of $3.9 million for the balance of the purchase price. ApplianceSmart is guaranteeing the repayment of the ApplianceSmart Note. On December 26, 2018, the ApplianceSmart Note was amended and restated to grant ARCA a security interest in the assets of the Purchaser, ApplianceSmart, and ApplianceSmart Contracting Inc. in exchange for modifying the repayment terms to provide for the payment in full of all accrued interest and principal on April 1, 2021, the maturity date of the ApplianceSmart Note. On March 15, 2019, JanOne entered into subordination agreements with third parties, pursuant to which it agreed to subordinate the payment of indebtedness under the ApplianceSmart Note and its security interest in the assets of ApplianceSmart and other related parties in exchange for receipt of a payment of up to $1.2 million within 15 days of the subordination agreement.&nbsp;&nbsp;<font style="color:#000000;">On December 9, 2019, ApplianceSmart filed a voluntary petition (the &#8220;Chapter 11 Case&#8221;) in the United States Bankruptcy Court for the Southern District of New York (the &#8220;Bankruptcy Court&#8221;), seeking relief under Chapter 11 of Title 11 of the United States Code (the &#8220;Bankruptcy Code&#8221;).&nbsp;&nbsp;As of December 28, 2019, indebtedness owed by ApplianceSmart to JanOne is approximately $2.9 million.&#160;&#160;However, JanOne has recorded a full valuation allowance for the entire amount of the indebtedness due to the uncertainty of repayment. </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Customers and Source of Supply for Recycling and Technology</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recycling</font>:<font style="font-style:normal;"> We contract with utility companies or their program administrators and other sponsors of energy efficiency programs to provide a full range of appliance recycling and replacement services to help them achieve their energy savings goals. The contracts usually have terms of one-to-three years, with provisions for renewal at the option of the utility. Under some contracts, we manage all aspects, including advertising of the appliance recycling or replacement program. Under other contracts, we provide only specified services, such as collection and recycling.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contracts with utility customers prohibit us from repairing and selling appliances or appliance parts we receive through their programs. We have instituted tracking and auditing procedures to assure our customers that those appliances do not return to use.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our pricing for energy efficiency program contracts is generally on a per-appliance basis and depends upon several factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Total number of appliances expected to be processed and/or replaced.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Length of the contract term.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Specific services the utility requires us to provide.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Market factors, including labor rates and transportation costs.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Anticipated revenue associated with the sale of recycled appliance byproducts.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Competitive bidding scenarios.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk36586069"></a><font style="text-decoration:underline;">GeoTraq</font><font style="font-style:normal;">: GeoTraq currently has no customers. GeoTraq sources its raw materials, including electronic chips, computers,<a name="_Hlk36586069"></a> and software from various third parties. GeoTraq is dependent on a single supplier for its modules.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Principal Products and Services for Recycling and Technology</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 28, 2019, we generated revenues from two sources: recycling and byproducts. Recycling revenues were generated by charging fees for collecting and recycling appliances for utilities and other sponsors of energy efficiency programs and through the sale of new ENERGY STAR<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup>appliances to utility companies for installation in the homes of a specific segment of their customers. Byproduct revenues were generated by selling scrap materials, such as metal and plastics, from appliances we collected and recycled. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal year 2019, we operated three reportable segments: biotechnology, recycling, and technology. During fiscal year 2018, we operated two reportable segments: recycling and technology (commencing on August 18, 2017).&nbsp;&nbsp;Our recycling segment includes all fees charged for collecting, recycling, and installing appliances for utilities and other customers and includes byproduct revenue, which is generated primarily through the recycling of appliances. Our technology segment is engaged in the development, design, and ultimately, we expect, the sale of cellular transceiver modules, also known as Mobile IoT modules. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Seasonality for Recycling and Technology</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promotional activities for programs in which the utility sponsor conducts all advertising are generally strong during the second and third calendar quarters, leading to higher customer demand for services during that time period.&#160; As a result, we experience a surge in business during the second and third calendar quarters, which generally declines through the fourth and first calendar quarters until advertising activities resume.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our technology segment did not have any customers at December 28, 2019.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Competition for Recycling and Technology</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recycling</font>:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many factors, including obtaining adequate resources to create and support the infrastructure required to operate large-scale appliance recycling and replacement programs, affect competition in the industry. We generally compete for contracts with several other appliance recycling businesses, energy services management companies, and new-appliance retailers. We also compete with small hauling or recycling companies that are based in the program&#8217;s service territory. Many of these companies, including used-appliance dealers that call themselves &#8220;appliance recyclers,&#8221; resell in the secondary market a percentage of the used appliances they accept for recycling. The unsalable units may not be properly processed to remove environmentally harmful materials because these companies do not have the capability to offer the full range of services we provide.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our primary competition for appliance recycling and replacement contracts with existing and new customers to come from a variety of sources, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Existing recycling companies.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Entrepreneurs entering the appliance recycling business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Management consultants.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Major waste hauling companies.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Scrap metal processors.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">National and regional new appliance retailers.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, utility companies and other customers may choose to provide all or some of the services required to operate their appliance recycling and replacement programs internally rather than contracting with outside vendors. We have no assurance that we will be able to compete profitably in any of our chosen markets.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Technology</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GeoTraq plans on operating in an industry segment that is made of numerous competing technologies designed to connect devices to the IoT. The business&#8217;s wireless solution uses IoT based on LTE CAT-M and the newly released NB-IoT protocols that were defined in the GSMA&#8217;s (Groupe Speciale Mobile Association) 3GPP Release 13 standard. The Mobile IoT industry utilizes radio spectrum that is licensed to wireless carries by various governmental regulatory agencies around the world. Mobile IoT is extremely competitive and constantly changing as carriers, manufacturers, and solution providers offer innovation to the IoT marketplace. GeoTraq believes there is a large under-served opportunity for <font style="font-style:italic;">&#8220;Simple IoT&#8221;</font> solutions that significantly reduce the complexity, cycle time and cost of deploying LBS and sensor monitoring solutions. The company&#8217;s transceiver modules and associated wireless connectivity subscription service is specifically targeted at accomplishing these objectives.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government Regulation for Recycling and Technology</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recycling</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal, state, and local governments regulate appliance collection, recycling, and sales activities. While some requirements apply nationwide, others vary by market. The many laws and regulations that affect appliance recycling include landfill disposal restrictions, hazardous waste management requirements, and air quality standards. For example, the 1990 Amendments to the Clean Air Act prohibit the venting of all Refrigerants while servicing or disposing of appliances.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of our recycling facilities maintains the appropriate registrations, permits, and licenses for operating at its location. We register our recycling centers as hazardous waste generators with the EPA and obtain all appropriate regional and local licenses for managing hazardous wastes. Licensed hazardous waste companies transport and recycle or dispose of the hazardous materials we generate. Our collection vehicles and our transportation employees are required to comply with all U.S. Department of Transportation (&#8220;DOT&#8221;) licensing requirements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 30 of ARCA Recycling&#8217;s clients participate in the EPA&#8217;s voluntary RAD program by committing to employ best environmental practices to reduce emissions of ozone-depleting substances and greenhouse gases through the proper disposal of refrigeration appliances at end of life. We prepare annual RAD reports that quantify the materials collected to submit to EPA on behalf of our clients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we believe that further governmental regulation of the appliance recycling industry could have a positive effect on us, we cannot predict the direction of future legislation. Under some circumstances, for example, further regulation could materially increase our operational costs or reduce environmental requirements for disposing of appliances at end of life. In addition, under some circumstances we may be subject to contingent liabilities because we handle hazardous materials. We believe we are in compliance with all government regulations regarding the handling of hazardous materials, and we have environmental insurance to mitigate the impact of any potential contingent liability.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Technology</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GeoTraq&#8217;s Mobile IoT modules utilize low-power wireless transmitters that emit RF energy waves, which are subject to regulation by the Federal Communications Commission (&#8220;FCC&#8221;) and may be subject to regulation by other domestic and international agencies. GeoTraq believes that FCC rules Part 15, Part 20, Part 22, Part 24, and Part 27 may apply to the company&#8217;s products. GeoTraq believes that its products are safe and will utilize FCC accredited testing laboratories to verify and certify that its modules comply with all required regulatory requirements. In addition, GeoTraq intends to seek and obtain necessary licenses and permits from the FCC and other regulatory agencies as required by law.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SELECTED_CONSOLIDATED_FINANCIAL_DATA"></a><a name="SELECTED_CONSOLIDATED_FINANCIAL_DATA"></a>SELECTED CONSOLIDATED FINANCIAL DATA</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth selected consolidated financial data for the periods ended or as of the dates indicated. Such historical consolidated financial data should be read in conjunction with the information set forth in our Annual Report on Form 10-K for the year ended December 28, 2019, filed with the SEC on April 6, 2020 and incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The statement of operations data presented below for each of the years ended December 28, 2019 and December 29, 2018, and the balance sheet data as of December 28, 2019 and December 29, 2018, are derived from the audited &#8220;Consolidated Financial Statements&#8221; contained in our Annual Report on Form 10-K for the year ended December 28, 2019. Our historical results are not necessarily indicative of the results to be expected for any future periods.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except for loss per share)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the 52-Week Period Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Data</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 28, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 29, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,097</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,311</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,741</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,786</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,217</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,150</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,431</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,097</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,480</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(668</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment charges</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,992</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on litigation settlement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,730</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations before benefit from income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,335</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,197</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,964</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,608</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.78</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,763,670</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,494,941</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 28, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 29, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,034</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,573</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,684</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,745</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,341</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,611</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073252"></a><a name="DESCRIPTION_SECURITIES_WE_MAY_FER"></a><a name="DESCRIPTION_SECURITIES_WE_MAY_FER"></a>DESCRIPTION OF SECURITIES WE MAY OFFER</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue from time to time, in one or more offerings the following securities:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">shares of Common Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">shares of Preferred Stock, which may be convertible into shares of Common Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">debt securities, which may be senior or subordinated and may be convertible into or exchangeable for shares of Common Stock or shares of Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">warrants exercisable for debt securities, shares of Common Stock, or shares of Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">rights to purchase any of such securities; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">units composed of our debt securities, shares of Common Stock, shares of Preferred Stock, and warrants, in any combination.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus contains a summary of the material general terms of the various securities that we may offer. The specific terms of the securities will be described in a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, which may be in addition to or different from the general terms summarized in this prospectus. Where applicable, the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials will also describe any material United States federal income tax considerations relating to the securities offered and indicate whether the securities offered are or will be listed on any securities exchange. The summaries contained in this prospectus and in any prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, may not contain all of the information that you would find useful. Accordingly, you should read the actual documents relating to any securities sold pursuant to this prospectus. See &#8220;Available Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; for information about how to obtain copies of those documents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of any particular offering, the initial offering price, and the net proceeds to us will be contained in the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, relating to such offering.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073253"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_CAPITAL_STOCK"></a><a name="DESCRIPTION_CAPITAL_STOCK"></a>DESCRIPTION OF CAPITAL STOCK</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:7.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following summary of terms of our Common Stock and our Preferred Stock is based upon our Articles of Incorporation (our &#8220;Charter&#8221;) and Bylaws (our &#8220;Bylaws&#8221;), currently in effect, and under Chapter 78 of the Nevada Revised Statutes (the &#8220;NRS&#8221;). This summary is not complete and is subject to, and qualified in its entirety by reference to, our Charter and our Bylaws. For a complete description of the terms and provisions of our Common Stock, please refer to our Charter and Bylaws, which are filed as exhibits to Registration Statement of which this prospectus forms a part. Throughout this section, references to &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer to JanOne Inc. and its subsidiaries.&nbsp;&nbsp;We encourage you to carefully read these documents and the applicable provisions of the NRS.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 10,000,000 shares of Common Stock and 2,000,000 shares of Preferred Stock, of which 259,729 shares are designated as Series A-1 Convertible Preferred Stock, par value $0.001 per share.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk28336321"></a><a name="_Hlk28332678"></a>As of December 15, 2020, we had <font style="Background-color:#FFFFFF;">1,829,982</font> shares of our Common Stock issued and outstanding and 259,729 shares of our Series A-1 Preferred Stock issued and outstanding.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The authorized and unissued shares of Common Stock and Preferred Stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may then be listed. Unless approval of our stockholders is so required, our Board of Directors (our &#8220;Board&#8221;) does not currently intend to seek stockholder approval for the issuance and sale of our Common Stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our issued and outstanding shares of our capital stock are fully paid and non-assessable.&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting, Dividend, and Liquidation Rights</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each holder of our Common Stock is entitled to one vote for each share issued and outstanding held on all matters to be voted upon by the stockholders. Our Charter does not provide for cumulative voting in the election of directors.&nbsp;&nbsp;Subject to the rights of the holders of the Series A-1 Preferred Stock to their preferential dividend in accordance with the provisions of our Charter, the holders of shares of our Common Stock and Series A-1 Preferred Stock (on an as-if-converted to Common Stock basis in accordance with the terms of our Charter) will be entitled to such cash dividends as may be declared from time to time by our Board from funds available therefor. Upon liquidation, dissolution, or winding up of the Company, and after all liquidation preferences payable to any series of Preferred Stock entitled thereto have been satisfied, our remaining assets shall be distributed to all holders of Common Stock and any similarly situated stockholders who are not entitled to any liquidation preference or, if there be an insufficient amount to pay all such stockholders, then ratably among such holders.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preemptive or Other Rights</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our shares of Common Stock do not have any preemptive, conversion, or redemption rights.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder Action; Special Meetings</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; actions can only be taken at an annual or special meeting of our stockholders. Our Bylaws provide that special meetings of the stockholders may be called at any time only by (i) our Chief Executive Officer, (ii) two of the members of the Board, or (iii) upon a written request of stockholders holding 10% or more of the capital stock entitled to vote.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Board of Directors; Removal; Vacancies&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Bylaws specify that the number of directors is to be determined by a majority vote of the Board. Our Board is currently composed of five directors. We do not have a classified Board. Pursuant to our Bylaws and the NRS, a director serves until&#160;the regular meeting next following or closely coinciding with the expiration of his or her term of office and&#160;until his or her successor has been elected and qualified, or until his or her earlier death, removal, or resignation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitation of Liability and Indemnification</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Charter provides that none of our directors and officers shall be personally liable to us or our stockholders for damages for breach of fiduciary duty as a director or officer, except for liability for (i) acts or omissions that involve intentional misconduct, fraud, or knowing violation of law or (ii) for authorizing any distribution in violation of Section 78.300 of the NRS. Our Bylaws provide that any officer or director who is made a party or witness to an action, suit, or proceeding, whether civil, criminal, administrative, or investigative, by reason of the fact that he or she is or was one of our directors or officers or serving at our request as a director, officer, employee, or agent, shall be indemnified and held harmless by us to the fullest extent authorized by the NRS. The right to indemnification shall include the right of advancement of expenses to the extent permitted under the NRS.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Listing and Transfer Agent</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;JAN.&#8221; The transfer agent and registrar for our Common Stock is EQ Shareowner Services.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 Convertible Preferred Stock</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In connection with the Company&#8217;s acquisition of GeoTraq, the Company </font>issued to the then stockholders of GeoTraq, among other consideration, an aggregate of 288,588 shares of the Company&#8217;s Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;).&nbsp;&nbsp;To accomplish the designation and issuance of the Series&#160;A Preferred Stock, we filed&#160;a Certificate of Designation with the Secretary of State of the State of Minnesota. On November 9, 2017, we filed a Certificate of Correction with the Minnesota Secretary of State. In connection with our reincorporation from the State of Minnesota to the State of Nevada in March 2018, we filed Articles of Incorporation with the Secretary of State of the State of Nevada on March 12, 2018, and a Certificate of Correction with the Secretary of State of the State of Nevada on August 7, 2018 (collectively, the &#8220;Nevada Articles of Incorporation&#8221;).&#160;&#160;<font style="Background-color:#FFFFFF;">On June 21, 2019, we filed a Certificate of Designation (the &#8220;Series A-1 Certificate of Designation&#8221;) of Powers, Preferences, and Rights of Series A-1 Convertible Preferred Stock (the &#8220;Series A-1 Preferred Stock&#8221;) with the Nevada Secretary of State.&#160;On October 1, 2020, we filed an Amended and Restated Certificate of Designation (the &#8220;Amended and Restated Series A-1 Certificate of Designation&#8221;) of Powers, Preferences, and Rights of Series A-1 Convertible Preferred Stock</font> with the Nevada Secretary of State.&nbsp;&nbsp;The following summary of the Nevada Articles of Incorporation and Amended and Restated Series A-1 Certificate of Designation does not purport to be complete and is qualified in its entirety by reference to the provisions of applicable law and to the Nevada Articles of Incorporation and the Amended and Restated Series A-1 Certificate of Designation, which were initially filed as Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 13, 2018, and as Exhibit 3.8(a) to the Company&#8217;s&#160;<font style="Background-color:#FFFFFF;">Current Report on Form 8-K, filed with the SEC on October 2, 2020, respectively</font>.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Series A-1 Preferred Stock was designated pursuant to guidance received from Nasdaq and has virtually all of the same rights, characteristics, and attributes as the Company&#8217;s Series A Preferred Stock, except as required by the Listing Qualifications staff of The Nasdaq Stock Market LLC (</font><font style="font-style:italic;Background-color:#FFFFFF;">i.e.</font><font style="Background-color:#FFFFFF;">, Section 3.2.5 in respect of voting rights of the Series A-1 Preferred Stock and Section 3.2.1(f) in respect of a Triggering Event, as such term is defined therein, and the formula to be applied in connection therewith), with respect to each of which requirements the Company has already been in compliance. The filing of the Series A-1 Certificate of Designation was unanimously approved by the Board of Directors on June 18, 2019. The affirmative approval of a majority of the holders of the Series A Preferred Stock for the exchange of such shares into shares of Series A-1 Preferred Stock occurred on or about June 19, 2019. The three holders of our Series A Preferred Stock were deemed to have exchanged their outstanding shares of Series A Preferred Stock for an equivalent number of shares of Series A-1 Preferred Stock, or an aggregate of 259,729 shares.&nbsp;&nbsp;The filing of the Amended and Restated Series A-1 Certificate of Designation was unanimously approved by the Board of Directors and by a majority of the holders of the Series A-1 Preferred Stock on October 1, 2020.&#160;</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot declare, pay, or set aside any dividends on shares of any other class or series of our capital stock unless (in addition to the obtaining of any consents required by our Articles of Incorporation) the holders of the Series A-1 Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend in the aggregate amount of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.00, regardless of the number of then-issued and outstanding shares of Series A</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Preferred Stock. Any remaining dividends allocated by the Board of Directors shall be distributed in an equal amount per share to the holders of outstanding </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Series A</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Preferred Stock (on an as-if-converted to </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> basis pursuant to the Conversion Ratio as defined below).</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of Series A-1 Preferred Stock have conversion rights into an aggregate of 85.0% of GeoTraq, Inc., currently a wholly-owned subsidiary of the Company.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a>&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Redemption</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock </font>have no redemption rights.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preemptive Rights</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of shares of <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock </font>are not entitled to any preemptive rights in respect to any securities of the Company, except as set forth in the Series A-1 Certificate of Designation or any other document agreed to by us.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each holder of a share of <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock </font>has that number of votes as is determined by multiplying (i) the number of shares of Series A Preferred Stock held by such holder and (ii) 17. The holders of <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock </font>vote together with all other classes and series of Common Stock and Preferred Stock of the Company as a single class on all actions to be taken by the holders of Common Stock of the Company, except to the extent that voting as a separate class or series is required by law.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Protective Provisions</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Without first obtaining the affirmative approval of a majority of the holders of the shares of <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock</font>, we may not directly or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock</font>; (ii) effect an exchange, reclassification, or cancellation of all or a part of the <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock</font>, but excluding a stock split or reverse stock split or combination of the Common Stock or preferred stock; (iii) effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock</font>; or (iv)&#160;alter or change the rights, preferences, or privileges of the shares of <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock </font>so as to affect adversely the shares of such series, including the rights set forth in the Series A-1 Certificate of Designation; <font style="font-style:italic;">provided</font>, <font style="font-style:italic;">however</font>, that we may, without any vote of the holders of shares of the <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock</font>, make technical, corrective, administrative, or similar changes to the Series A-1 Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of shares of the <font style="Background-color:#FFFFFF;">Series A-1 Preferred Stock</font>.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Certain Provisions of our Charter, our Bylaws, and the NRS</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain provisions of the NRS and our Charter and Bylaws could make more difficult the acquisition of us by means of a tender offer or otherwise, and the removal of incumbent officers and directors. These provisions are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Business Combinations<font style="font-style:normal;">&#160;</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The &#8220;business combination&#8221; provisions of Sections 78.411 to 78.444, inclusive, of the NRS prohibit a Nevada corporation with at least 200 stockholders (at least 100 of whom are stockholders of record and residents of the State of Nevada) from engaging in various &#8220;combination&#8221; transactions with any interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transaction is approved by the entity&#8217;s board of directors prior to the date the interested stockholder obtained such status; or after the expiration of the three-year period, unless:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">the transaction is approved by the entity&#8217;s board of directors or a majority of the voting power held by disinterested stockholders of the entity, or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.57%;text-indent:-4.52%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a)&#160;the highest price per share paid by the interested stockholder within the three years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher, or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.</font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A &#8220;combination&#8221; is defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction or a series of transactions, with an &#8220;interested stockholder&#8221; having: (a) an aggregate market value equal to 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal to 5% or more of the aggregate market value of all outstanding shares of the corporation, or (c) 10% or more of the earning power or net income of the corporation.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or within three years, did own) 10% or more of an entity&#8217;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions of Controlling Interest</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nevada&#8217;s &#8220;acquisition of controlling interest&#8221; statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These &#8220;control share&#8221; laws provide generally that any person who acquires a &#8220;controlling interest&#8221; in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. These laws would apply to us as of a particular date if we were to have 200 or more stockholders of record (at least 100 of whom have addresses in Nevada appearing on our stock ledger at all times during the 90 days immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation, unless our Charter or Bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws provide that a person acquires a &#8220;controlling interest&#8221; whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority, or (3) a majority or more of all of the voting power of that corporation in the election of its directors. Once an acquirer crosses one of these thresholds, shares that it acquired in the transaction that took it over the threshold and shares that it acquired within the 90 days immediately preceding the date when it acquired or offered to acquire a controlling interest become &#8220;control shares&#8221; to which the voting restrictions described above apply.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073254"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_PREFERRED_STOCK"></a><a name="DESCRIPTION_PREFERRED_STOCK"></a>DESCRIPTION OF PREFERRED STOCK</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares of our Preferred Stock may be issued in one or more series, and our Board is authorized to determine the designation and to fix the number of shares of each series. Our Board is further authorized to fix and determine the dividend rate, premium or redemption rates, conversion rights, voting rights, preferences, privileges, restrictions, and other variations granted to or imposed upon any wholly unissued series of our Preferred Stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the issuance of shares of a series of Preferred Stock, our Board will adopt resolutions and file a certificate of designation with the Secretary of State of the State of Nevada. The certificate of designation will fix for each series the designation and number of shares and the rights, preferences, privileges, and restrictions of the shares including, but not limited to, the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the voting rights, if any, of the Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any rights and terms of redemption;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the dividend rate(s), period(s), and/or payment date(s) or method(s) of calculation applicable to the Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether dividends are cumulative or non-cumulative and, if cumulative, the date from which dividends on the Preferred Stock will accumulate;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution, or winding up of our affairs;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the terms and conditions, if applicable, upon which the Preferred Stock will be convertible into Common Stock, another series of Preferred Stock, or any other class of securities, including the conversion price (or manner of calculation) and conversion period;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the provision for redemption, if applicable, of the Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the provisions for a sinking fund, if any, for the Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the liquidation preferences, if any, for the Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any limitations on the issuance of any class or series of Preferred Stock ranking senior to or on a parity with the class or series of Preferred Stock as to dividend rights and rights upon liquidation, dissolution, or winding up of our affairs; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any other specific terms, preferences, rights, limitations, or restrictions of the Preferred Stock.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the terms listed above, we will set forth in a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, the following terms relating to the series of Preferred Stock being offered:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number of shares of the preferred stock offered, the liquidation preference per share, the conversion rights, and the offering price of the Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the procedures for any auction and remarketing, if any, for the Preferred Stock;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any listing of the Preferred Stock on any securities exchange; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a discussion of any material and/or special United States federal income tax considerations applicable to the Preferred Stock.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073255"></a><a name="DESCRIPTION_DEBT_SECURITIES"></a><a name="DESCRIPTION_DEBT_SECURITIES"></a>DESCRIPTION OF DEBT SECURITIES</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description, together with the additional information we include in any applicable prospectus supplements or any related free writing prospectus or other offering materials, as applicable, summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may offer pursuant to this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any debt securities offered under such prospectus supplement may differ from the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from the terms described below, the terms set forth in the prospectus supplement or any related free writing prospectus or other offering materials, as applicable, shall control.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may sell from time to time, in one or more offerings under this prospectus, debt securities, in one or more series. These debt securities that we may issue include senior debt securities, senior subordinated debt securities, subordinated debt securities, convertible debt securities, and exchangeable debt securities. We will issue any such senior debt securities under a senior indenture that we will enter into with a trustee to be named in the senior indenture. We will issue any such subordinated debt securities under a subordinated indenture, which we will enter into with a trustee to be named in the subordinated indenture. We use the term &#8220;indentures&#8221; to refer to either the senior indenture or the subordinated indenture, as applicable. The indentures will be qualified under the Trust Indenture Act of 1939, as amended&#160;(the &#8220;Trust Indenture Act&#8221;), as in effect on the date of the indenture. We use the term &#8220;debenture trustee&#8221; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summary description, together with the additional information we may include in any applicable prospectus supplement, information <font style="color:#000000;">or document</font> incorporated by reference, related free writing prospectus, or other offering materials, as applicable, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the form of indenture filed as an exhibit to the Registration Statement of which the prospectus is a part, as it may be supplemented, amended, or modified from time to time, as well as the notes and supplemental agreement relating to each series of debt securities that will be incorporated by reference as exhibits to the Registration Statement that includes the prospectus or as exhibits to a Current Report on Form 8-K if we offer debt securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indenture does not limit the amount of debt securities that may be issued thereunder, and each indenture provides that the specific terms of any series of debt securities shall be set forth in, or determined pursuant to, an authorizing resolution and/or a supplemental indenture, if any, relating to such series.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue the debt securities issued under the indentures as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue discount,&#8221; or &#8220;OID,&#8221; for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will describe in the applicable prospectus supplement, the related free writing prospectus, or other offering materials, as applicable, the terms of the series of debt securities being offered, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the title or designation;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the aggregate principal amount and any limit on the aggregate principal amount that may be issued;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the maturity date or dates on which principal will be payable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the form of the debt securities of the series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the applicability of any guarantees;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt, or any combination thereof, and the terms of any subordination;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or, if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable, and the regular record dates for interest payment dates or the method for determining such dates;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the place or places where payments will be payable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether the debt securities of that series shall be issued in whole or in part in the form of a global security or securities, the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether the indenture will restrict our ability to pay dividends or will require us to maintain any asset ratios or reserves;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if, other than the full principal amount thereof, the portion of the principal amount of debt securities of the series that shall be payable upon declaration of acceleration of the maturity thereof;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether we will be restricted from incurring any additional indebtedness;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any restrictions on transfer, sale, or assignment of the debt securities of the series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a discussion on any material or special U.S. federal income tax considerations applicable to a series of debt securities; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any other specific terms, preferences, rights, or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special consideration applicable to any of these debt securities in the applicable prospectus supplement, related free writing prospectus, or other offering materials, as applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion or Exchange Rights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will set forth in the applicable prospectus supplement, related free writing prospectus, or other offering materials, as applicable, the terms on which a series of debt securities may be convertible into or exchangeable for shares of our Common Stock, shares of our Preferred Stock, or other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder, or at our option. We may include provisions pursuant to which the number of shares of our Common Stock, shares of our Preferred Stock, or our other securities that the holders of the series of debt securities receive would be subject to adjustment.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidation, Merger, or Sale; No Protection in Event of a Change of Control or Highly Leveraged Transaction</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we provide otherwise in the prospectus supplement, information <font style="color:#000000;">or document</font> incorporated by reference, related free writing prospectus, or other offering materials, as applicable, applicable to a particular series of debt securities, the indenture will contain covenant that restricts our ability to merge or consolidate, or sell, convey, transfer, or otherwise dispose of our assets as an entirety or substantially as an entirety, unless we are the surviving corporation or the successor to or acquirer of such assets (other than a subsidiary of ours) expressly assumes all of our obligations under the indenture or the debt securities, as appropriate. In addition, we cannot complete such a transaction unless immediately after completing the transaction, no event of default under the indenture, and no event that, after notice or lapse of time or both, would become an event of default under the indenture, has occurred and is continuing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we provide otherwise in the prospectus supplement<font style="color:#000000;">, information or document incorporated by reference, related free writing prospectus, or other offering materials, as </font>applicable to a particular series of debt securities, the debt securities will not contain any provisions that may afford holders of the debt securities protection in the event we have a change of control or in the event of a highly leveraged transaction (whether or not such transaction results in a change of control), which could adversely affect holders of debt securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Events of Default Under the Indentures</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we provide otherwise in the prospectus supplement<font style="color:#000000;">, information or document incorporated by reference, related free writing prospectus, or other offering materials, as</font> applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if we fail to pay interest when due and our failure continues for a period of 90 days; </font><font style="font-style:italic;font-size:10pt;color:#000000;">provided</font><font style="font-size:10pt;color:#000000;">, </font><font style="font-style:italic;font-size:10pt;color:#000000;">however</font><font style="font-size:10pt;color:#000000;">, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplement thereto shall not constitute a default in the payment of interest for this purpose;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; </font><font style="font-style:italic;font-size:10pt;color:#000000;">provided</font><font style="font-size:10pt;color:#000000;">, </font><font style="font-style:italic;font-size:10pt;color:#000000;">however</font><font style="font-size:10pt;color:#000000;">, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplement thereto shall not constitute a default in the payment of principal or premium, if any;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if specified events of bankruptcy, insolvency, or reorganization occur as to us.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency, or reorganization) necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default may constitute an event of default under any bank credit agreements we may have in existence from time to time. In addition, the occurrence of certain events of default or acceleration under the indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of at least 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the debenture trustee if given by the holders), declare to be due and payable immediately the principal (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) of and premium and accrued and unpaid interest, if any, on all debt securities of that series. Before a judgment or decree for payment of the money due has been obtained with respect to debt securities of any series, the holders of a majority in principal amount of the outstanding debt securities of that series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) may rescind and annul the acceleration if all events of default, other than the non-payment of accelerated principal, premium, if any, and interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the applicable indenture (including payments or deposits in respect of principal, premium or interest that had become due other than as a result of such acceleration). We refer you to the prospectus supplement<font style="color:#000000;">, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable,</font> relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an event of default.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method, and place of conducting any proceeding for any remedy available to the debenture trustee, or exercising any trust or power conferred on the debenture trustee, with respect to the debt securities of that series, provided, that:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">subject to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A holder of the debt securities of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies if:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the holder previously has given written notice to the debenture trustee of a continuing event of default with respect to that series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the debenture trustee to institute the proceeding as trustee; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series (or at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) other conflicting directions within 60 days after the notice, request, and offer.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will periodically file statements with the applicable debenture trustee regarding our compliance with specified covenants in the applicable indenture.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Modification of Indentures; Waiver</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and the debenture trustee may change the applicable indenture without the consent of any holders with respect to specific matters, including:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to evidence the succession of another corporation to us and the assumption by any such successor of our covenants in such indenture and in the debt securities issued thereunder;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to add to our covenants or to surrender any right or power conferred on us pursuant to the indenture;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to establish the form and terms of debt securities issued thereunder;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to evidence and provide for a successor trustee under such indenture with respect to one or more series of debt securities issued thereunder or to provide for or facilitate the administration of the trusts under such indenture by more than one trustee;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to cure any ambiguity, to correct or supplement any provision in the indenture that may be defective or inconsistent with any other provision of the indenture or to make any other provisions with respect to matters or questions arising under such indenture; provided that no such action adversely affects the interests of the holders of any series of debt securities issued thereunder in any material respect;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to add to, delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication, and delivery of securities under the indenture;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to add any additional events of default with respect to all or any series of debt securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to supplement any of the provisions of the indenture as may be necessary to permit or facilitate the defeasance and discharge of any series of debt securities, provided that such action does not adversely affect the interests of any holder of an outstanding debt security of such series or any other security in any material respect;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to make provisions with respect to the conversion or exchange rights of holders of debt securities of any series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to pledge to the trustee as security for the debt securities of any series any property or assets;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to add guarantees in respect of the debt securities of one or more series;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to change or eliminate any of the provisions of the indenture, provided that any such change or elimination becomes effective only when there is no security of any series outstanding created prior to the execution of such supplemental indenture that is entitled to the benefit of such provision;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to provide for certificated securities in addition to or in place of global securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to qualify such indenture under the Trust Indenture Act;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">with respect to the debt securities of any series, to conform the text of the indenture or the debt securities of such series to any provision of the description thereof in our offering memorandum or prospectus relating to the initial offering of such debt securities, to the extent that such provision, in our good faith judgment, was intended to be a verbatim recitation of a provision of the indenture or such securities; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">to make any other change that does not adversely affect the rights of holders of any series of debt securities issued thereunder in any material respect.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the debenture trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) that is affected. However, the debenture trustee and we may make the following changes only with the consent of each holder of any outstanding debt security affected:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">extending the fixed maturity of the series of debt securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reducing the principal amount, reducing the rate of, or extending the time of payment of interest, or any premium payable upon the redemption of any debt securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reducing the principal amount of discount securities payable upon acceleration of maturity;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">making the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">impair the right to institute suit for the enforcement of any payment on any debt security when due;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if applicable, adversely affect the right of a holder to confer or exchange a debt security; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment or waiver.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may, on behalf of the holders of all the debt securities of such series, waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium, or any interest on any debt security of that series or in respect of a covenant or provision, which cannot be modified or amended without the consent of the holder of each outstanding debt security of the series affected;&#160;<font style="font-style:italic;">provided</font>,&#160;<font style="font-style:italic;">however</font>, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discharge, Defeasance, and Covenant Defeasance</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We can discharge or decrease our obligations under the indenture as stated below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may discharge obligations to holders of any series of debt securities that have not already been delivered to the trustee for cancellation and that have either become due and payable or are by their terms to become due and payable, or are scheduled for redemption, within one year. We may effect a discharge by irrevocably depositing with the trustee cash or government obligations, as trust funds, in an amount certified to be enough to pay, when due, whether at maturity, upon redemption or otherwise, the principal of, and any premium and interest on, the debt securities and any mandatory sinking fund payments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise provided in the applicable prospectus supplement, <font style="color:#000000;">information or document incorporated by reference, related free writing prospectus, or other offering materials, </font>we may also discharge any and all of our obligations to holders of any series of debt securities at any time, which we refer to as defeasance. We may also be released from the obligations imposed by any covenants of any outstanding series of debt securities and provisions of the indenture, and we may omit to comply with those covenants without creating an event of default under the trust declaration, which we refer to as covenant defeasance. We may effect defeasance and covenant defeasance only if, among other things:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we irrevocably deposit with the trustee cash or government obligations denominated in the currency of the debt securities, as trust funds, in an amount certified to be enough to pay at maturity, or upon redemption, the principal (including any mandatory sinking fund payments) of, and any premium and interest on, all outstanding debt securities of the series; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we deliver to the trustee an opinion of counsel from a nationally recognized law firm to the effect that the holders of the series of debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the defeasance or covenant defeasance and that defeasance or covenant defeasance will not otherwise alter the holders&#8217; U.S. federal income tax treatment of principal, and any premium and interest payments on, the series of debt securities.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the case of a defeasance by us, the opinion we deliver must be based on a ruling of the Internal Revenue Service issued, or a change in U.S. federal income tax law occurring, after the date of the indenture, since such a result would not occur under the U.S. federal income tax laws in effect on that date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we may discharge or decrease our obligations under the indenture as described in the two preceding paragraphs, we may not avoid, among other things, our duty to register the transfer or exchange of any series of debt securities, to replace any temporary, mutilated, destroyed, lost, or stolen series of debt securities or to maintain an office or agency in respect of any series of debt securities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registered Global Securities and Book Entry System</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The debt securities of a series may be issued in whole or in part in book-entry form and will be represented by one or more fully registered global securities. We will deposit any registered global securities with a depositary or with a nominee for a depositary identified in the applicable prospectus supplement<font style="color:#000000;">, information or document incorporated by reference, related free writing prospectus, or other offering materials</font> and registered in the name of such depositary or nominee. In such case, we will issue one or more registered global securities denominated in an amount equal to the aggregate principal amount of all of the debt securities of the series to be issued and represented by such registered global security or securities. This means that we will not issue certificates to each holder.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless and until it is exchanged in whole or in part for debt securities in definitive registered form, a registered global security may not be transferred except as a whole:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">by the depositary for the registered global security to its nominee;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">by a nominee of the depositary to the depositary or another nominee of the depositary; or</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">by the depositary or its nominee to a successor of the depositary or a nominee of the successor.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The prospectus supplement<font style="color:#000000;">, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable,</font> relating to a series of debt securities will describe the specific terms of the depositary arrangement involving any portion of the series represented by a registered global security. We anticipate that the following provisions will apply to all depositary arrangements for debt securities:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">ownership of beneficial interests in a registered global security will be limited to persons that have accounts with the depositary for such registered global security, these persons being referred to as &#8220;participants,&#8221; or persons that may hold interests through participants;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">upon the issuance of a registered global security, the depositary for the registered global security will credit, on its book-entry registration and transfer system, the participants&#8217; accounts with the respective principal amounts of the debt securities represented by the registered global security beneficially owned by the participants;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any dealers, underwriters, or agents participating in the distribution of the debt securities will designate the accounts to be credited; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">ownership of beneficial interest in the registered global security will be shown on, and the transfer of the ownership interest will be effected only through, records maintained by the depositary for the registered global security for interests of participants, and on the records of participants for interests of persons holding through participants.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some states may require that specified purchasers of securities take physical delivery of the securities in definitive form. These laws may limit the ability of those persons to own, transfer, or pledge beneficial interests in registered global securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So long as the depositary for a registered global security, or its nominee, is the registered owner of the registered global security, the depositary or such nominee, as the case may be, will be considered the sole owner or holder of the debt securities represented by the registered global security for all purposes under the indenture. Except as stated below, owners of beneficial interests in a registered global security:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">will not be entitled to have the debt securities represented by a registered global security registered in their names;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">will not receive or be entitled to receive physical delivery of the debt securities in the definitive form; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">will not be considered the owners or holders of the debt securities under the relevant indenture.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for the registered global security and, if the person is not a participant, on the procedures of a participant through which the person owns its interest, to exercise any rights of a holder under the indenture.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We understand that, under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a registered global security desires to give or take any action that a holder is entitled to give or take under the indenture, the depositary for the registered global security would authorize the participants holding the relevant beneficial interests to give or take the action, and the participants would authorize beneficial owners owning through the participants to give or take the action or would otherwise act upon the instructions of beneficial owners holding through them.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will make payments of principal and premium, if any, and interest, if any, on debt securities represented by a registered global security registered in the name of a depositary or its nominee to the depositary or its nominee, as the case may be, as the registered owners of the registered global security. Neither we nor the trustee, or any other agent of ours or the trustee will be responsible or liable for any aspect of the records relating to, or payments made on account of, beneficial ownership interests in the registered global security or for maintaining, supervising, or reviewing any records relating to the beneficial ownership interests.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the depositary for any debt securities represented by a registered global security, upon receipt of any payments of principal and premium, if any, and interest, if any, in respect of the registered global security, will immediately credit participants' accounts with payments in amounts proportionate to their respective beneficial interests in the registered global security as shown on the records of the depositary. We also expect that standing customer instructions and customary practices will govern payments by participants to owners of beneficial interests in the registered global security held through the participants, as is now the case with the securities held for the accounts of customers in bearer form or registered in &#8220;street name.&#8221; We also expect that any of these payments will be the responsibility of the participants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the depositary for any debt securities represented by a registered global security is at any time unwilling or unable to continue as depositary or stops being a clearing agency registered under the Exchange Act, we will appoint an eligible successor depositary. If we fail to appoint an eligible successor depositary within 90 days, we will issue the debt securities in definitive form in exchange for the registered global security. In addition, we may at any time and in our sole discretion decide not to have any of the debt securities of a series represented by one or more registered global securities. In that event, we will issue debt securities of the series in a definitive form in exchange for all of the registered global securities representing the debt securities. The trustee will register any debt securities issued in definitive form in exchange for a registered global security in the name or names as the depositary, based upon instructions from its participants, shall instruct the trustee.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Information Concerning the Debenture Trustee</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses, and liabilities that it might incur.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment and Paying Agents</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless we other indicate in the applicable prospectus supplement<font style="color:#000000;">, information or document incorporated by reference, related free writing prospectus, or other offering materials</font>, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement<font style="color:#000000;">, information or document incorporated by reference, related free writing prospectus, or other offering materials</font>, we will make interest payments by check which we will mail to the holder. Unless we otherwise indicate in a prospectus </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplement</font><font style="color:#000000;">, information </font><font style="color:#000000;">or document </font><font style="color:#000000;">incorporated by reference, related free writing prospectus</font><font style="color:#000000;">,</font><font style="color:#000000;"> or other offering material</font><font style="color:#000000;">s</font><font style="color:#000000;">, as applicable</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we will designate the corporate trust office of the debenture trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement</font><font style="color:#000000;">, information </font><font style="color:#000000;">or document </font><font style="color:#000000;">incorporated by reference, related free writing prospectus</font><font style="color:#000000;">,</font><font style="color:#000000;"> or other offering material</font><font style="color:#000000;">s</font><font style="color:#000000;">,</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities which remains unclaimed at the end of two years after such principal, premium, or interest has become due and payable will be repaid to us, and the holder of the security thereafter may look only to us for payment thereof.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Governing Law</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0.07%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subordination of Subordinated Debt Securities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement<font style="color:#000000;">, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Debt Securities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 15, 2020, we had the following debt securities outstanding:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Secured Revolving Line of Credit Promissory Note, dated August 28, 2019, issued to Isaac Capital Group LLC in the original principal amount of $2,500,000.&nbsp;&nbsp;The promissory note matures on December 31, 2020 and bears interest at 8.75% per annum.</font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_WARRANTS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_WARRANTS"></a>DESCRIPTION </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF WARRANTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue warrants to purchase debt securities, shares of our Common Stock, shares of our Preferred Stock, or any combination of these securities. We may issue the warrants independently or together with any underlying securities, and the warrants may be attached or separate from the underlying securities. We may also issue a series of warrants under a separate warrant agreement to be entered into between a warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants of such series and will not assume any obligation or relationship of agency for or with holders or beneficial owners of warrants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description is a summary of selected provisions relating to the warrants that we may issue. The summary is not complete. When warrants are offered in the future, a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general provisions may apply. The specific terms of the warrants as described in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials will supplement and, if applicable, may modify or replace the general terms described in this section.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This summary and any description of warrants in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to all the provisions of any specific warrant document or agreement, which we will file with the SEC for incorporation by reference into this prospectus. See &#8220;Available Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; for information on how to obtain a copy of a warrant document when it is filed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When we refer to a series of warrants, we mean all warrants issued as part of the same series under the applicable warrant agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Terms</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials may describe the terms of any warrants that we may offer, including but not limited to the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the title of the warrants;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the total number of warrants;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the price or prices at which the warrants will be issued;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the currency or currencies that investors may use to pay for the warrants;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the date on which the right to exercise the warrants will commence and the date on which the right will expire;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether the warrants will be issued in registered form or bearer form;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">information with respect to book-entry procedures, if any;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if applicable, the minimum or maximum amount of warrants that may be exercised at any one time;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if applicable, the designation and terms of the underlying securities with which the warrants are issued and the number of warrants issued with each underlying security;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if applicable, the date on and after which the warrants and the related underlying securities will be separately transferable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if applicable, a discussion of material United States federal income tax considerations;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if applicable, the terms of redemption of the warrants;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the identity of the warrant agent, if any;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the procedures and conditions relating to the exercise of the warrants; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any other terms of the warrants, including terms, procedures, and limitations relating to the exchange and exercise of the warrants.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrant Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue the warrants in one or more series under one or more warrant agreements, each to be entered into between a bank, trust company, or other financial institution as warrant agent, and us. We may add, replace, or terminate warrant agents from time to time. We may also choose to act as our own warrant agent or may choose one of our subsidiaries to do so.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The warrant agent under a warrant agreement will act solely as our agent in connection with the warrants issued under that agreement. The warrant agent will not assume any obligation or relationship of agency or trust for or with any holders of those warrants. Any holder of warrants may, without the consent of any other person, enforce by appropriate legal action, on its own behalf, its right to exercise those warrants in accordance with their terms. Until the warrant is properly exercised, no holder of any warrant will be entitled to any rights of a holder of the warrant property purchasable upon exercise of the warrant.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form, Exchange, and Transfer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue the warrants in registered form or bearer form. Warrants issued in registered form, <font style="font-style:italic;">i.e.</font>, book-entry form, will be represented by a global security registered in the name of a depository, which will be the holder of all the warrants represented by the global security. Those investors who own beneficial interests in a global warrant will do so through participants in the depository&#8217;s system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depository and its participants. In addition, we may issue warrants in non-global form, <font style="font-style:italic;">i.e.</font>, bearer form. If any warrants are issued in non-global form, warrant certificates may be exchanged for new warrant certificates of different denominations, and holders may exchange, transfer, or exercise their warrants at the warrant agent&#8217;s office or any other office indicated in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the exercise of their warrants, holders of warrants exercisable for debt securities will not have any of the rights of holders of the debt securities purchasable upon such exercise and will not be entitled to payments of principal (or premium, if any) or interest, if any, on the debt securities purchasable upon such exercise. Prior to the exercise of their warrants, holders of warrants exercisable for shares of Common Stock or shares of Preferred Stock will not have any rights of holders of the shares of Common Stock or the shares of Preferred Stock purchasable upon such exercise and will not be entitled to dividend payments, if any, or voting rights of the shares of Common Stock or the shares of Preferred Stock purchasable upon such exercise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise of Warrants</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A warrant will entitle the holder to purchase for cash an amount of securities at an exercise price that will be stated in, or that will be determinable as described in, the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials. Warrants may be exercised at any time from the initial exercise date and time through and including the close of business on the expiration date set forth in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials. After the close of business on the expiration date, unexercised warrants will become void. Warrants may be redeemed as set forth in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants may be exercised as set forth in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials. Upon receipt of payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, we will forward, as soon as practicable, the securities purchasable upon such exercise. If less than all of the warrants represented by such warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants.</p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073257"></a><a name="DESCRIPTION_RIGHTS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_RIGHTS"></a>DESCRIPTIO</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N OF RIGHTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue rights to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock. These rights may be issued independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the rights in such offering. In connection with any offering of such rights, we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each series of rights will be issued under a separate rights agreement that we will enter with a bank or trust company, as rights agent, all of which will be set forth in the relevant offering material. The rights agent will act solely as our agent in connection with the certificates relating to the rights and will not assume any obligation or relationship of agency or trust with any holders of rights certificates or beneficial owners of rights.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description is a summary of selected provisions relating to rights that we may offer. The summary is not complete. When rights are offered in the future, a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general provisions may apply. The specific terms of the rights as described in a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, will supplement and, if applicable, may modify or replace the general terms described in this section.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This summary and any description of rights in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to the rights agreement and the rights certificates. We will file each of these documents, as applicable, with the SEC and incorporate them by reference as an exhibit to the Registration Statement of which this prospectus is a part on or before the time we issue a series of rights. See &#8220;Available Information&#8221; and &#8220;Incorporation of Certain Documents by Reference&#8221; above for information on how to obtain a copy of a document when it is filed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials may describe:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">in the case of a distribution of rights to our stockholders, the date of determining the stockholders entitled to the rights distribution;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">in the case of a distribution of rights to our stockholders, the number of rights issued or to be issued to each stockholder;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the exercise price payable for the underlying debt securities, shares of our Common Stock or shares of our Preferred Stock upon the exercise of the rights;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number and terms of the underlying debt securities, shares of our Common Stock or shares of our Preferred Stock that may be purchased per each right;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent to which the rights are transferable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the date on which the holder&#8217;s ability to exercise the rights shall commence, and the date on which the rights shall expire;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent to which the rights may include an over-subscription privilege with respect to unsubscribed securities;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">if applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering of such rights; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any other terms of the rights, including, but not limited to, the terms, procedures, conditions, and limitations relating to the exchange and exercise of the rights.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions described in this section, as well as those described under &#8220;&#8212;Description of Debt Securities&#8221; and &#8220;&#8212;Description of Capital Stock&#8221; above, will apply, as applicable, to any rights we offer.</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073258"></a><a name="DESCRIPTION_UNITS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_UNITS"></a>DESCRIPTIO</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N OF UNITS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue units composed of (i) our debt securities, (ii) shares of our Common Stock, (iii) shares of our Preferred Stock, (iv) warrants to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock or any combination of these securities, and (v) rights to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock in any combination. We will issue each unit so that the holder of the unit is also the holder of each security included in the unit. As a result, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description is a summary of selected provisions relating to units that we may offer. The summary is not complete. When units are offered in the future, a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general provisions may apply. The specific terms of the units as described in a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, will supplement and, if applicable, may modify or replace the general terms described in this section.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This summary and any description of units in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to the unit agreement, collateral arrangements and depositary arrangements, if applicable. We will file these documents with the SEC for incorporation by reference into this prospectus, as applicable. See &#8220;Available Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; for information on how to obtain a copy of a document when it is filed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials may describe:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities composing the units;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether the units will be issued in fully registered or global form; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any other terms of the units.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The applicable provisions described in this section, as well as those described under &#8220;Description of Debt Securities,&#8221; &#8220;Description of Capital Stock&#8221; and &#8220;Description of Warrants,&#8221; will apply to each unit and to each security included in each unit, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073259"></a><a name="USE_PROCEEDS"></a><a name="USE_PROCEEDS"></a>USE OF PROCEEDS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, we intend to use the net proceeds from the sale of securities for general corporate purposes.</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073260"></a><a name="PLAN_DISTRIBUTION"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PLAN_DISTRIBUTION"></a>PLAN OF DI</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STRIBUTION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may sell the securities through underwriters or dealers, through agents, directly to one or more purchasers, through a rights offering, or otherwise. We will describe the terms of the offering of the securities in a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the name or names of any underwriters, if any;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the purchase price of the securities and the proceeds we will receive from the sale;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any underwriting discounts and other items constituting underwriters&#8217; compensation;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any initial public offering price;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any discounts or concessions allowed or reallowed or paid to dealers; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any securities exchange or market on which the securities may be listed.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only underwriters we name in the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, are underwriters of the securities offered thereby.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of securities may be effected, from time to time, in one or more transactions, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">block transactions (which may involve crosses) and transactions on The Nasdaq Capital Market or any other organized market on which the securities may be traded;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">purchases by a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">ordinary brokerage transactions and transactions in which a broker-dealer solicits purchasers;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">sales &#8220;at the market&#8221; to or through a market maker or into an existing trading market, on an exchange or otherwise; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">sales in other ways not involving market makers or established trading markets, including direct sales to purchasers.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities may be sold at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to the prevailing market prices, or at negotiated prices. The consideration may be cash or another form negotiated by the parties. Agents, underwriters, or broker-dealers may be paid compensation for offering and selling the securities. That compensation may be in the form of discounts, concessions, or commissions to be received from us or from the purchasers of the securities. Dealers and agents participating in the distribution of the securities may be deemed to be underwriters and compensation received by them on resale of the securities may be deemed to be underwriting discounts and commissions under the Securities Act. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also make direct sales through subscription rights distributed to our existing stockholders on a pro rata basis, which may or may not be transferable. In any distribution of subscription rights to our stockholders, if all of the underlying securities are not subscribed for, we may then sell the unsubscribed securities directly to third parties or may engage the services of one or more underwriters, dealers, or agents, including standby underwriters, to sell the unsubscribed securities to third parties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some or all of the securities that we offer though this prospectus may be new issues of securities with no established trading market. Any underwriters to whom we sell our securities for public offering and sale may make a market in those securities, but they will not be obligated to do so and they may discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity of, or continued trading markets for, any securities that we offer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agents may, from time to time, solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus or other offering materials, as applicable, any agent involved in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated, any agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the securities covered by this prospectus may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If underwriters are used in an offering, securities will be acquired by the underwriters for their own account and may be resold, from time to time, in one or more transactions, including negotiated transactions, at a fixed public offering price, or at varying prices determined at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed with the underwriter or underwriters at the time an agreement for the sale is reached. The applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials will set forth the managing underwriter or underwriters, as well as any other underwriter or underwriters, with respect to a particular underwritten offering of securities, and will set forth the terms of the transactions, including compensation of the underwriters and dealers and the public offering price, if applicable. The prospectus, and the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials will be used by the underwriters to resell the securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a dealer is used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, the name of the dealer and the terms of the transactions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may directly solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others. These persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities. To the extent required, the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, will describe the terms of any such sales, including the terms of any bidding or auction process, if used.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agents, underwriters, and dealers may be entitled under agreements that may be entered into with us to indemnification against specified liabilities, including liabilities incurred under the Securities Act, or to contribution to payments they may be required to make in respect of such liabilities. If required, the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, will describe the terms and conditions of such indemnification or contribution. Some of the agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us, our subsidiaries or affiliates in the ordinary course of business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the securities laws of some states, the securities offered by this prospectus may be sold in those states only through registered or licensed brokers or dealers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any person participating in the distribution of Common Stock registered under the Registration Statement that includes this prospectus will be subject to applicable provisions of the Exchange Act, and the applicable SEC rules and regulations, including, among others, Regulation M, which may limit the timing of purchases and sales of any of our Common Stock by any such person. Furthermore, Regulation M may restrict the ability of any person engaged in the distribution of our Common Stock to engage in market-making activities with respect to our Common Stock. These restrictions may affect the marketability of our Common Stock and the ability of any person or entity to engage in market-making activities with respect to our Common Stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, and penalty bids in accordance with Regulation M under the Exchange Act that stabilize, maintain, or otherwise affect the price of the offered securities. If any such activities will occur, they will be described in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All securities we offer other than shares of Common Stock will be new issues of securities with no established trading market. Any underwriters may make a market in these securities but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073261"></a><a name="LEGAL_MATTERS"></a><a name="LEGAL_MATTERS"></a>LEGAL MATTERS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated in the applicable prospectus supplement, Clark Hill PLC, Los Angeles, California, will provide opinions regarding the validity of any securities offered by this prospectus. Clark Hill PLC may also provide opinions regarding certain other matters. The legality of the securities for any underwriters, dealers, or agents will be passed upon by counsel as may be specified in the applicable prospectus supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc514073262"></a><a name="EXPERTS"></a><a name="EXPERTS"></a>EXPERTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements incorporated in this Prospectus by reference to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 28, 2019, have been audited by WSRP, LLC, an independent registered public accounting firm, as stated in their reports incorporated by reference herein, and have been so incorporated in reliance upon such reports and upon the authority of such firm as experts in accounting and auditing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Company at December 29, 2018 incorporated in this Prospectus by reference to the Registrant&#8217;s Annual Report on Form 10-K, as amended, for the year ended December 29, 2018, have been audited by SingerLewak LLP, an independent registered public accounting firm, as stated in their report incorporated by reference herein, and have been so incorporated in reliance upon such report and upon the authority of such firm as experts in accounting and auditing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>


















</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ 48# 2(  A$! Q$!_\0
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M3YZC4Z<_==OZ^9YRY87C..H^BBBN@R"BBB@ JO?_ /(.NO\ KD_\C5BJ]_\
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M@0:W#N.%E!C_ !/3]17=UTY%)/"V71LQS--5K^04445[1YXUU#QLIZ$$&O,
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M5G@SP64'!;'ID\>M:7A'_D<]&_Z^E_D:PYG*I=GO1H0H8%TH.ZC&2O\ ??\
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>WC!?G^9K+%UY*SD(    , =!2T45W',%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>grk3fpqjsz23000001.jpg
<TEXT>
begin 644 grk3fpqjsz23000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ 48# 2(  A$! Q$!_\0
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M3YZC4Z<_==OZ^9YRY87C..H^BBBN@R"BBB@ JO?_ /(.NO\ KD_\C5BJ]_\
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M@0:W#N.%E!C_ !/3]17=UTY%)/"V71LQS--5K^04445[1YXUU#QLIZ$$&O,
M,#'IQ7HVIW2V>FW$['[J';[D\#]:\Y P *^6XADG.G'JD_T_R/:RJ+Y9/T.A
M\(D_VA<CL8@?UK2\6_\ ((3_ *[+_(U3\'PG?=S]L*@_F?Z5<\6_\@A/^NR_
MR-;4$UE$K]G^9G5:>/7R_(XWH*Z[3/#%ND*RWP\V1AGRP?E7_$UR!Z5Z>G^K
M7Z"N3(\-2K3G*HKVM;YW-\RK3IQBH.U[F9<>'=,FB*+;+$V.'CX(KB)X6M[B
M6!\;XW*G'M7IE>>:O_R&;W_KJ:Z,]PU*G"$X12=[:&66UIRE*,G<UO"#'[7=
MKG@HIQ^)K?U>].GZ9-.N/, VIG^\>!7/^$/^/VZ_ZYK_ #-7?%[$6%NO9IN?
MP!K;!UI4LJ<X[J_YD5Z:GCE%^7Y'($GEF))/))[^]=?HF@6Z6T=S>1"69QN"
MN,J@[<>M<A5T:SJ0&!?2X'T_PKPL!7H4*CG6CS=OZ9Z.)I5:D>6F['=2Z=93
M1E)+2$J?]@5QNN:4-+NE\HDV\N2F3DJ1U%5_[9U/_G^E_3_"HKB_NKM56XN'
ME53D!L<&NW'YAA<33M&#4NCT,,-A:]&=W*Z[:FEX8O3;ZG]G)_=W QC_ &AT
M/\Q7;5YM8OY>HVK@\B9/YUZ37I9!5<J$H/H_S./-()5%)=4%%%%>\>8%4=0U
M6UTUX5N&(\UL<#.T>I]JO5Y]K4UQ-JDLEU$\7.U%<8PHZ?XUYN:8V6$I*4%J
MW\CLP6'5>=I;([Z.2.:,21.KH>C*<@U2U:^M[:SGBDD =H9&"]P I))]N*X*
M!I2^RV:7<W\,1.3^ K)\4:LFDZ=<Z>LP?5+Q/*F56W&WB/WMQ_OMTQV&2:X\
M/F]3$-1C3MW=]/RZ]#T*.4<U914K_+\?1'GL7^J3_=%>M?!ZU9;#5;LCY99D
MC4^NU<G_ -"KS'3=-O-8U".PT^$RW$G0=E']YCV KZ%\/:+#X?T.VTV$[O*7
M+OCEW/+-^)KOPT&Y<W8][B/%PAA_87]Z7Y+4X_XO632Z%8WJC(MKG:WL'&,_
MF!^=>0<CE3A@<J?0CI7TMJ^F0:SI-UIUR,PW$90D=1Z$>X.#^%?/&LZ->Z!J
M<FGWZ%94Y5P/EE7LR^H/Z=*>)@U+F[D<-XN,Z#P[?O1_)_\ !/>?"WB&W\2:
M)#=Q.OGJH6XBSS&_<'V/4>U;=?,=G?7>G7(N+&ZFMI@,;XG*DCT/J/K6C=^+
M?$-[ 8;G6KIHB,,JL$R/<J!51Q6FJU.6OPQ*55NE-*+[WNO\_P #HOBIJ5I?
M^(K6&UF65K2%DF*'(5B0=N?7CGTKGO"/_(YZ-_U]+_(UFS6%Q:6EI<30F**Z
M5G@SP64'!;'ID\>M:7A'_D<]&_Z^E_D:PYG*I=GO1H0H8%TH.ZC&2O\ ??\
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>WC!?G^9K+%UY*SD(    , =!2T45W',%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>grk3fpqjsz23000002.jpg
<TEXT>
begin 644 grk3fpqjsz23000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "N 8<# 2(  A$! Q$!_\0
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MGSW.R_OH8?,>!,<8&" "?XB#BNQK*OM?L]/OS:W.] L(E:7&5 +;0/4DGT%
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MG1?).GW"QFZM<S[H]@_?)VW;O;I774 8^I?\C!HO^_-_Z+-;%9&I?\C!HO\
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MZ$:UJ8#7^XWTKS71O^0+9\_\LEKTI_N-]*\UT;_D"V?_ %R7^5 %[ZU!>_\
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M!F@"3^QM-^3-C;ML^Z6C!(YSW]^:S_$?%QH?_823_P!%O5V_UNRTURMRTJ@
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M8_\ 7I-_Z$E &Q1110!Q7B+_ )&N'_KR/_H8JO5CQ%_R-D/_ %YG_P!#%5J
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M([RYQR3P.@Z]?852\06=M'?:),EO"LK:DN75 &/R/WKH'GBB9%DD1&D.U S
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MX;O=.N;B>'5@7G"!]UL,?+G&.?<UI):ZH'4OJ<;*#RHM@,CZ[JT:* "BBB@
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E9KB#5WWS*JMN@4C SC^==%10!FBSU/\ Z"W_ )+K16E10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>grk3fpqjsz23000003.jpg
<TEXT>
begin 644 grk3fpqjsz23000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #! ) # 2(  A$! Q$!_\0
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M%5YS.+BW\K/E[CYF,=,<58H ***8TJ+(L98!WSM'KB@!]%%% !1110 4444
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MOFR;]GE\;,=??-24 1B>,SM"&_>*-Q7VJ2BB@#D/!VPZIJ[@EW:3+2& IO\
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M=10!F1?\C-=_]></_H<M:=9D7_(SW?\ UYP_^ARUIT %%%% !43B3SXRJH4
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MMQIUYYJ(KL/W? )('\?^R:E2]F:15.G72@D LQCP/<X>@"Y147VJW_Y[Q?\
M?8H^U6__ #WB_P"^Q0!+147VJW_Y[Q?]]BC[5;_\]XO^^Q0!5O);U+^T2WA#
MP,3YK%<XZ=\\<9/?IBK]1?:K?_GO%_WV*/M5O_SWB_[[% $M5I3<B^@"*IMR
MK^8=O(/&WG/U[4_[5;_\]XO^^Q7,#7-:M[F59K>.>+,AB9".1N?8#@]>%!/3
M!!]: .MHKDSKVM*(&:UM_F(+*F3_  9VDYX^8A<]!C)JQ::YJ<T%Q)-:01M'
M&[)'OY=P!A>OKD9[XR* -62:\&M0PI%_HIB+/(4[\\ YZ].WY]K]<L-8U<V5
MW,(X3+YFV!.!\@0G=@G.2W8],^U/L-<U.?5&BN;:**UP5$F[HPSCJ<D'CGV]
M\T =-5#S;S^VQ$(A]C\DDOMZ-D8YSSW_ "KG+7Q#KAA6*:SB$HC3,I7@N0=P
MP#ZX.<X&<=:F_P"$AUCRV(LH,JFXDYY.X# &<GCYOTZ@F@#K**K0WL,D$;O)
M&CLH+(7&5..G6I/M5O\ \]XO^^Q0!7CEO3J\\;VX6S$2^7*",LV3G//].W7F
MKM1?:K?_ )[Q?]]B@7,#$ 31DDX #CF@"6BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>grk3fpqjsz23000004.jpg
<TEXT>
begin 644 grk3fpqjsz23000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ 5L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH ***\A\<?%2T?1[RSTB^NM-U:VO%C_ 'L6W>@?#%20
M1C'/K1UL'F>O45R?AKQ_H_B?59M-TPW,S00AVN&B*QOSC )[UUE 7"BBB@ H
MHHH **** "BBB@ HKR;XF>+M5L])UW2KWP_=1:?*GEVNHQ."I;C&X=N:T/A_
MXNU758=(L+;P]=)H\5HL;ZC,P^9E4#('H2*%J#T/2:*\5^*'B_5?[!U/2=4T
M"[L87N%%G?1N"L@# \^A(!KLO!GBS5?$%U%%_P ([<V>C+; Q7L[#,C#&./0
MCZT+5 ]&=Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 4-9UK3O#^FOJ&JW26UJA ,C GDG &!R:\8\4
M^(_"?C'Q7&-5\1VP\/6]NQBCBAE$C3$$98[.W7TXKN?BZ ?!]L",@ZE;?^AU
MVWV.U_Y]H?\ OV* /*/ GQ'\/Z)H']G:UXCLYF@D9+>2*"7<T0^[N^3K7H>D
M^+M"US2[K4M-U!)[2TSY\@1ALP-QX(ST]JU/L=K_ ,^T/_?L5PVD1HGQC\31
M(BK&=-M\J!@?E3;N)*Q:_P"%N>!?^@]'_P!^)?\ XFC_ (6YX%_Z#T?_ 'XE
M_P#B:J?!ZV@D^&&E,\$;,6GR60$_ZUZ[K[':_P#/M#_W[%(9R'_"W/ O_0>C
M_P"_$O\ \31_PMSP+_T'H_\ OQ+_ /$UU_V.U_Y]H?\ OV*/L=K_ ,^T/_?L
M4 <A_P +<\"_]!Z/_OQ+_P#$T?\ "W/ O_0>C_[\2_\ Q-=?]CM?^?:'_OV*
M/L=K_P ^T/\ W[% '(?\+<\"_P#0>C_[\2__ !-'_"W/ O\ T'H_^_$O_P 3
M77_8[7_GVA_[]BN/LKF23XM:GI3[#8Q:9%,D/EKA7+X)Z9H Y?Q#XJ\!>)/$
M&E7U[XKW6%@2YL#;2;)'[,?E_G_C3O"GBWP)X4N=3%KXM+Z?=3>;!9FWDVV^
M>N#MS_D5ZM]CM?\ GVA_[]BC[':_\^T/_?L4+0'J>2:MXE^'VN^+K76-2\4B
MYL[:%DBT][:3RU<\;ON\\9Z^U6/!WC+P/X1L+FQ3Q>;FT>=I+>*2WDQ A_A!
MVY->I_8[7_GVA_[]BC[':_\ /M#_ -^Q0M >IR'_  MSP+_T'H_^_$O_ ,31
M_P +<\"_]!Z/_OQ+_P#$UU_V.U_Y]H?^_8H^QVO_ #[0_P#?L4 <A_PMSP+_
M -!Z/_OQ+_\ $T?\+<\"_P#0>C_[\2__ !-=?]CM?^?:'_OV*X^:YD7XOVVD
M#8+!M%:X:#RUP9/-*[NF<XXH 7_A;G@7_H/1_P#?B7_XFC_A;G@7_H/1_P#?
MB7_XFNO^QVO_ #[0_P#?L4?8[7_GVA_[]B@#D/\ A;G@7_H/1_\ ?B7_ .)H
M_P"%N>!?^@]'_P!^)?\ XFNO^QVO_/M#_P!^Q1]CM?\ GVA_[]B@#D/^%N>!
M?^@]'_WXE_\ B:/^%N>!?^@]'_WXE_\ B:Z_[':_\^T/_?L4?8[7_GVA_P"_
M8H Y%?BUX'=U1=>C+,< >1+_ /$UVM<1\3;F31?!4U[INRWN5N(5$B1KD R
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ML7,$EJ\#NPCMPF&"@[<X'()P1ZU[70 4444 %%%% !7!:?\ \EPUC_L#P_\
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MA+6[NRAN4"7'V8"%Y 05*L6&>?SKKO#NN/K]A)=2:3J&F%)3'Y-_%Y;MP#N
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M551P%48 IU '@M__ ,DP\6_]C2__ *-CKWJO!;__ ))AXM_[&E__ $;'7O5
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M2.1N'OS0!;^!,\ESHFN32Q"*1]0RT87 7Y%XQ7K%<$/@SX&'32I1_P!O<O\
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M0!T7C'_D=OA__P!?4W_HL4_Q7_R57P']+[_T4M'_  IKP/\ ] J7CI_IDO\
M\51_PIKP/G/]E2Y'_3Y+_P#%4 :DG_("O?\ L+#_ -*5K+T__DN.L?\ 8&A_
M]#KG+_X2Z$OCS2+2UTBY.C26TTEXPGD*AQC9EMW!R>@-='_PIKP/G/\ 94N?
M7[9+_P#%4 =[17!CX-^" <C3)@1T/VR;_P"*KN8HUAA2)-VU%"C<23@>I/6@
M!]%%% !1110 4444 %%%% !1110 4444 %%%96L:[::3#(N^.:^\LO#9+*HF
MFQ_=4D$T-@7IKVTMIHHI[F&*24XC1W +GV!ZU/7DTNE:KXP%EK]JMAJ,=U B
M7$+-Y9MID)(P6!( )^9>"2OI7J-A#-;Z?;0W,WGSQQ*LDN,;V Y./<T[ 6*R
MK'Q'IFH:Q>:3;SDWUF?WT+(05''.<8P<U6\4:U+IVFRQZ<T<NJ-M\NW5E,NT
MD LJ$C<0,G'M7$Z+:7/BG5991OTS4K2-2=4M9(WDD#$@QS!1LW8 ..=O%):L
M'L>J44U%*(JEBQ QN/4TZ@ HHKBM>\6VLVK6VA6M[ EO>"2">^2176)RI CR
MI^5\X(SZ4 ==;7MI>&06US#,8VVOY;AMI]#CI4]>?>"_"NM:-JWG7L-G;K'&
M8I9;8C%T ,1X4 ;0.2<G))KT!F5%+,0J@9))P!38(@O[V'3=/N+VXW>3;QM(
M^U=QP!DX'>HM)U:QUS3H]0TZ<3VLF=D@! .#@]?<5R'BSQ)>B>#^RQ#=:45_
M?3I+%Y#-G!CE=B0JXZX!)SBI?!.BN((-9MY9]-M+I6D?28R# 'R1O0D9"D#.
M..M):@SMZ*** "H;F[M[*$S74\4$0."\KA1^9I+R^M-/MS<7MU!;0*<&2:0(
MH_$\5YGKEQJ/C/5[FUL1;+)ILF8;&YVYNX77#2JQRIZ_*<''>@#U)'61%=&#
M*PR&!R"*6L3PIIEWI.AQVMV$0AB8X(VW+!'_  H&P-V!W[FM.[OK2Q16N[J"
M ,=JF60(&/H,TV"*6J>(],T:_LK._G,,MZVR#Y"0[9 VY Z\_P ZU:\DO-0U
M#7=4CTO7='$OVFX"1H\B)+; DXD@"Y8@  ER0.*]*T33KG2].6VN]2GU"4,3
MYTP ;'8<4EM<'N:-%%% !4#7MHEVEH]S"MRXRL1<!R/4#K6+XG\4P:)IMX;0
MQ7>I0Q;Q9QR*TBC^^4SNVCJ<=JXV7PWJVLZNNLZ?+87MK>[+F&]# -:R[ I.
M""648.U<\$\T+5@SU.BD4$* 3D@<GUKE_%^NW-E9_9](<37Q<":.W:-YHH\$
ME@C''H,G@9S0P1J:-XCTS7I+J/3YS)):.8YT9"IC;)&#D>U:M>:>&-.E\0:A
M-JUNQT>YAD6.XFL)4ECOE(#$,0-I<'JP]2*]+IV$%%%%(84444 %%%% !111
M0 4444 %%%% !1110 5Y3XNT:[L;^\6\BBN[35IT$&J3<2:=)T4949VYZ'CG
MKUKU:D(### $>AHZ@4]/TJSTTS/;0(DMPP>=U&/,?&-Q]^*S-=\22:=?V^EZ
M;:)?:M.AE6V:81?NQU;<0?H!705A^)O#5MXCL1&TDEM>0G=:W<)VR0MZ@CL>
MX[T,$<!;:5J'BG[=<1:5 ?ME\)5OYI L]@Z$!HR.IV[2!@X.:]6M[:&TB\N"
M*.-<Y(10H)]>*S_#FG2Z5H5M:3QP).@)E\@DJSDY+<\Y/7FM6GY"\PHHHI#*
M6K64NHZ3=6<%W):2S1E4GCQN0^O->;Z'X?BO_$L>DZSI-G:36%H8ITC!VZBF
M1LD' & 1GKD$UZK28&[=@9QC-"T8/80E(8LG"HB_D!7FWB/Q/=>(=%EM[*R5
M=*OIQ:VVH^=E7D#CY70#*HY!7.>_2O2ZX^;P3'#XLMM5L/+%F\IEN[*5F\OS
M,<2HHXWYQUX[]:.NH;+09X;\.3#5+V_O]&M-.@N(8XS8QL)$9T)/F$ 8'4 =
M^*[,  8 P!110 4444 <AXUTO4)GM-6LX5U&.QW-+I4H&R<$$;EX^^ >*B\"
M:-ISZ-::FL4+N)9I+3:#_HJ.>8@3@\<\'O7:4@ 484 #T%"T!ZF?KFM6F@:3
M-J%X^V-!A1G&]CT4>Y/%>=WLVL:UXQ,=_P"%[:XD_L\I]BGN59-C-_K4?&/0
M,,9Z8KTZ\L[?4+.6TNX4FMYE*21N,A@:YWPMX5D\.ZA?%IA=6[!5M)I79IHX
M^3Y9)XVCMC\:%OJ'30T/#>B?V/HMC;W/ERWL$ B>?&6(';<><#I^%;-%%-NX
M!2$9!&<>]+12 \GO=$O+#Q!::5?I$[7.H"ZM-><8E)SDQ-@?>*@@9(!%>G6&
MFV6EP-!8VT=O$SM(408&XG)-62 <9 .#D9I:.E@ZW.8UGQ7-::G)IND:>-2O
M+>+S[J(3B-HX^V,CYF/8?K7(Z#H%YK*:==+I]KY'VTWRZN7Q-+$Q),;KC.[G
M:03C KL/%GA-/$$*W-K,;358 1!<(Q7<.\;XY*'O6UIEJ+'2[6U$,4/E1*IC
MASL4@<@9[4+N#[%B&&*WB6*")(XU^ZB* !^ I]%% !1110 4444 %%%% !11
M10 4444 %%%% &/XKU&XTCPEJVHVA47%K:R2QEAD;@,C(KP:/XO>/I;5;F,V
M30N2JN+0X9E 9E'N%.3[5[WXGTR;6O"VJ:9;LBS7=L\*-(2%!88&<=J\23X)
M^,$@$7V[2#\NPL9YLE1C"\+C *@],^N1Q0!4_P"%M^/2KR1RV$D$:[WF6S;:
M(]P42<C.TL<=,Y'2HKCXQ^.;:-FEFT\%#M=3:,"CYP4.?XNI],=\\5JR?!SQ
MM-*TTNI:3).SF3S3-+D2$@E^%QDX Z8XZ9YJ*X^"OC2YA\E]2TGRQ'Y2J)I?
MECW;P@RO3=SSS[T >DZAXEO$NM"ADUBUTN.]TXW,LTT2L&?Y.!DC'WC65-XS
MU-)(H#K=DEHU^8%U;[,/+D3RB_"YQD-QD''-==:^&V2]TBYN)(G^Q:<;-XMN
M0Q.WD$]OE].]4K?P9)::Q;2PWB?V9:W;W4%JT>3'O0JR Y^[DY QQS0OZ^__
M "!_U]W^9K>'+E[RP:=M9@U5"Y"S0PB-1CJ."<UL4@4*,* !["EH *\?\6?%
MG7-'\5ZKI&FZ?ILJV)C5$F9S-.6"\(JD9(W=/05[!7@7B_PCXKC^).J:_I.C
M74\WF136%S$\916 4$LK=> 1CCF@"9_C-XO6VBD31M*FF??YEK$)6F@"G&9$
MSE0>U32?&'Q0EU!$EMX=FBD53)<PRR-#!N. )'SA3]:PXM(^(UG>S:Q8Z%?Q
MZW?+(FH7#^2T<JL00%3'R]!GG\J@C\'>*+.WDTRP\+ZO%H]\(O[1@DGA:25D
M8D;'V_(.?0T >D>#/B-JGB%O$4=Y!II;2H!)')9,S1R'#=R>1QVK7B\1^(;/
M2M/UG5(=,DTVY\KS1;"19(1(0%/S$A@"PSTKD/ACX*U;2CXI6;2Y].MKZ!8;
M5+N57;HW4KUZCG%==%X?\17VD:?HFIC38-/M_)\Y[>5Y))1&00 "H R5&3S0
MM_N_X(,70/'$M_H6LWNH6T<,^GNY6./.)(^=A&3U)!'UK;\):O=:[X8L]2O8
M8X+F8-YD<>=JD,5P,_2N=M_ U[%/I9-Q (8V;[<@)/FJLIDCQQV)YS73>&M,
MFT;08+&X9&EC:0DH21\SLPZ^QI] ZB^)=4ET3PQJ>J0(DDMI;/,B/G:2H) .
M.U<=I^N?$O4M-M;^#2_#?DW,*31[IY0=K $9&>N#75>,K.XU'P5K5G:1&6XG
MLY8XHUZLQ4@"O+=-G\6Z?I=I9-\*["<V\*1&5Q'N?: -QXZG&:0'8?;_ (H_
M] OPS_X$2U1UGQ)\2-"T>ZU2\TOPX;>V3S)/+FE+8]AFL?\ M/Q9_P!$DTW\
MH_\ "L_6_P#A+M9T6[TY/A?96C7$>P3Q",-'[B@#T:?7]:N;S1;335T^.2^L
M#=RM<J[!2-G VD?WN]-B\7W47A[5[F[@MVOM/N#:J(&)BGD.W9MSSR6 ([<T
M-X-CU&ZT*35+:WGM['3C;R0R')$A"<CMCY3WJSJGA&&].EV%LD5GI%K,;B6*
MW8QNS@?)C;[DDG/84+;7^M?\@Z_UV*<OB[4&\)VU[#!:IJC7R6$\4FXQQ2F3
M8W0YQW'/0BM"SU?6+37[?2M;BLF^V1NUO/9[@-R8)5E8DYQSG/:L/4/!&I07
M-U_8\\+VTUS;WOEWEPY;SHV^;+8)PR@?B*V[32]8O=?M=5UK[%"+*-UMX+5V
M?+. "S,P';@#'>FOZ^[_ #!E3XI2R0?#36Y(9'CD6)<,C8(^=>]<WIWPTT:Y
MNY(Y+[6-JV-O.,7[_><R;O\ T$5WGB?0H_$WAN]T:6=H$NE"F15R5PP/3\*Y
M.+X<ZY"Y>/Q[JRL8UB)$*?=7.T?AN/YT@,NU^&^D367AZ5[[5]U^%,V+Y^\#
M/QZ<@5C>+_!MEX?\'Z[K%AJ&K+>:?=QQP,UZY !:(<CN?G-=8GPWUJ..V1/'
MFJA;7'D@0I\GRE>/P)%07OPJU'4K&XLKWQMJ<]K<N'FB>%,.P(()_P"^1^5
M&S>6LNK>-ELI-2U&WMTTQ9@EK=/$"Y<C)VGGBN7UG5==M'&G6FIW4LFFZHP6
M0O\ /<1+!YWEN1][TY]J[S4/"Z7VIIJ,6J:A97"VXMR;5T 90<\[E/>EMO"6
MG6OV,JT[R6T[W!DD?<TTCJ58N2.>#[=J%HOZ[CZ_UV.=OM?NKWQMH;V-U*-+
M7Y98XB<3.\+2 $#KA57C_:JW%XPEO[G7+(6-_ ((_P!S(UJZ;/W1;+D_=.>E
M:>G>#=,TN*SCMFGQ:73W4>YP2692N#QT"G 'L*UI--M76\Q$$>\7;,Z]6^7;
M_*A[60EO=GFV@7LUS:^'YM+U'Q!=:E(T+7BW)G:WV$#S"3(-OK@@]<8JS+XP
MV>.S<_VJ@TY+P:6;/S1@DCF7;[/A<^E>@6&GQ:=I-OIT#OY5O"L*,Q&[ & ?
MK6</">F?\(TVA%'-NR%6D)'F$DY+[L?>SSGUIMJXK:&%8Z9-KFL>(WEUG5H&
MMK[RH!;WCHD8\M#]WIU)[5O>$M1N-5\+V5W=L&N&5DD<# <JQ7=CWQG\:I?\
M(5$L]U)#K>KP+=N'GCBF10YVA<YV9&0!T-=!8V5OIUC#9VD8CMX4"1H.P%'0
M;U=RQ1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>grk3fpqjsz23000005.jpg
<TEXT>
begin 644 grk3fpqjsz23000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $; 8,# 2(  A$! Q$!_\0
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M@ HHJ":\M;=9&GN88ECQO+N %STSGIF@">BH([VTEE6*.ZA>1D$@19 25/\
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MYOS9QY<+R?\ H(.*J_V_I_F>7NN=^-VW[)+G'K]VJ7_"<>%_^@Y9?]_*H_\
M"9^&O[=\[^V;3R_LVW=OXSNSBIYX]R>>/<Z>UO(;Q6:'S<*<'S(F3_T("IZY
M_P#X3CPO_P!!RR_[^5IZ9K&G:S"\NFWD5U'&VQVB;(!QG'Y&FI)[,%*+V9=H
MHHIE!1110 4444 %%%% !1110 4444 %%%% !7+^-H=4FTV$Z?I\-_&CDW$$
MUTT(9<>Q ;Z$@5U%<E\0M,L+[PU)<WUN]Q]C821H)GC7)(7+;.6 SG&#TXH8
M%/X?-8WL=S=6<%O:-#)Y,D%DT@BSC/S*WREO=<_6NYKDO H1=.N$BU"*[19
M!Y4LSA!CI^\)(_#BK%UK6H)JD]BOD1_Z1#%')M+;%=78EN1D_*!^/>A@=&_*
M, VTX^]Z>]9_A_/_  CFF9.?]%CY]?E%<]IWBB_OFMW>T66.:1;=K:-!N;-N
M)2X+,!C)Q@]N]=!X>P/#6F?+M'V6+Y?3Y1Q0!IUG:S_QYP_]?=O_ .CDK0W+
MZBL[66'V.'D?\?=O_P"CDH TJ*3</4?G1D>M "T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%%  >E<-XLB2XUFWDN;2*2*&)XQ'>V,MQ$Y8J0R>7D!
MN".>:[FN5\5^);K0;RQCC6".WG.))YT9AG<!M&TC!P=W/4#CV %O["^UWPG'
M9V'E:>-H1HI[5MDJ!<;0FY652<<'G P1@US[>#=;DLA92069;8)6N@^-S?91
M#Y6WDXW#.<D8KOM+N9KS2K2ZN8#!/-"DDD1ZHQ )7\*MT <;:V5Q9WMK->,M
MG)>:D9DT^.1&4#RBO7;DGY<G''-97QA_Y >F?]??_M-J[+5O,^V:5M1#&;OY
MF+8(^1\8&.?S%<;\8?\ D!Z9_P!?G_M-JPQ7\&7H<V,_W>?HSR&BBBOF3X\*
M]=^#W_(%U3_K['_HM:\BKUWX/?\ (%U3_K['_HM:[\N_C?(]/*?]X^3/2***
M*]X^F"BDS6)IV@:?_9\'VS2[1KG;F1GA5F+=R3CF@#2U*XDM-+N[F)0TD,+R
M*"."0I(K*L[K7[S3K680VT<C2'S/-1DW1\8(7)(/7@FKW]@:-_T";'_P'3_"
MC^P-&_Z!-C_X#I_A0!S&H?\ "5+J5PD;7'V&2=V22- QB4;!M(!!*D9((^8?
M-[5U6D&Z;2;8WBNMQL&\.P+9]R /Y4S^P-&_Z!-C_P" Z?X4?V!HW_0)L?\
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M@E:*74;2.13AD>=00?<$U<9E7&X@9.!DU1T^$6\4J2-&6DN)77!SU<G'UQ0
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MFELH6B"-*"=K'.6&,Y]Z@NKN\TZPT_4K>*"2:_N;=;J:5B65)'4!4'H V!R
M,9Y)IMZ^I2Z])"T]I)Y4<D\?DQ$/:8_U>Y\\[^05P,C/I0!UU%16TPN+6*<
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M)FOG82[OO 1AR@R.,GH.@]/EA_$6L22-))J-P[L<LS/DD^I-,77=450JWTP
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M&-<.HNVFW ,#Q;!<2+U*G.?+/]VM.QO/$<2.D[71BCD5'D:U+. SR;F Q\V
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M1BHQ21X]>O.O4E5J.[>X44451D%%%% !1110 4444 %%%% !28I:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOS77Z5=/?:19W<@ DG@21@ 0 2 >AY% %RBBB@ HHHH **** "BBB@ HHHH
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MLT53MQJ/F_Z4]J8\?\LE8'/XFKE !1110 4444 %%%% !1110 4444 %%%%
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MFTFM6N()8ROER;<$AARO&<J<C'0YX\[^.VN6'V#2_#L,J3WEN_FS$')C 7:
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MT3?3HCZDHHHKU#X,**** "N?\4S36L6GW6;D6$%T)+W[,&+B,(V"0O)4/M)
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3MEF/ICC';OS71T4 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>grk3fpqjsz23000006.jpg
<TEXT>
begin 644 grk3fpqjsz23000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (7 70# 2(  A$! Q$!_\0
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M57BM'6C0#VK_ (:2\0_] 32_SD_^*H_X:2\0_P#0$TO\Y/\ XJO%:* /:O\
MAI+Q#_T!-+_.3_XJC_AI+Q#_ - 33/SD_P#BJ\9DB\M4.Y3N&< ]*CJIP<'R
MRW ]J_X:2\0_] 32_P Y/_BJ/^&DO$/_ $!-,_.3_P"*KQ6E&<\4EN![A!^T
M-XHN<^5H&FL!WS)_\543?M'>(T<JVAZ8&';,G_Q5>1"273T !.YQGKP*A22)
MV3<"C;LM)U_2O5JX/#PC&FY-5/M)[>BTWZZNRZLS4I;]#VP?M!>)2JD:+I?S
M#(SY@S^M5#^TCXA!Q_8FE_G)_P#%5Y7JA<Q1E5D6+H-XQD^N*RR>F!C'I1FM
M'#4:OLJ":MU[W[+_ ((4W)J[/:/^&D?$/_0$TS\Y/_BJ/^&DO$/_ $!-+_.3
M_P"*KQAI7< ,Q./6F5YDU%/W'=>>GZLT/N/P=K<WB3PAIFLW$4<4UW")'2/.
MU3D],U=UR_?2O#^I:C$BO):VLLZJW0E5+ 'VXKGOA7_R2[P]_P!>@_F:UO&'
M_(DZ]_V#KC_T6U0!X)_PTEXA_P"@)I?YR?\ Q5'_  TEXA_Z FF?G)_\57F_
M@72;+7/&FF:;J".]I.["14;:2 C'@]NE=G9VG@779+[2M+TF]LIXK26Y6^^T
M"9%**6(<,O"\8R.Y%-*[L:1A>+D]E]_W7-7_ (:2\0_] 72_SD_^*IQ_:1UW
M:,:+IN[ODO\ _%5XQ'#)/+LA1I&/0*,FK=N+ PNMT)(Y4'RE<G<?<=JUITY/
M336^KVT\S/1]3UM?VDM?W#=HFF8[X,G_ ,54]W^TAJRNHM-'L&7')D+]?SKQ
M-_*\[YEPN/X#4-3S<L'%I?JA-:GM7_#27B'_ * FE_G)_P#%4?\ #27B'_H"
M:7^<G_Q5>*T5F,]VN_VA=?MC ?[%L/+D0$NPD&3WQ\W2J[_M(ZWM79HVG%N=
MV2^/;^*O%'210I=6 894D=130 >M:59PD[P5D$4XZ,]\M_V@M6GTQKC^S--6
M9&VLA+XYZ'K6<_[1WB*.0HVB:9E3@\R?_%5XZ0;5L"0D,H(V-@,/?_"EN;F2
M^N=^S+L<#')/H*SBF]#JK.GR)6M):>OG^1[3;_M'ZH87^T:/9++_  [-Y!^O
MS57?]H[Q$H#?V)I94]#F3_XJO&IMT:B%H@CH>21\Q]C40RQK>HTE[-QU7W_,
MY$NJ9[1_PTEXA_Z FF?G)_\ %4?\-)>(?^@)I?YR?_%5XN[;FS@#Z"FU@-GM
M7_#27B'_ * FE_G)_P#%4?\ #27B'_H":7^<G_Q5>*T4 >U#]I'Q#_T!-,_.
M3_XJI[S]HO7K>X,<>DZ7(N 0P,G<9_O5X=2DYHMU*37*U;7N>T_\-)>(?^@)
MI?YR?_%4?\-)>(?^@)I?YR?_ !5>+ $]!24$GWW!(9;>*0@ N@8@>XHIEE_Q
MXV__ %R7^5% 'R9XFT=-?^.NIZ9-<1V\$VHMYLTC!51!RQR?8'\:Z"P^(?A[
M6O&5U;R>'$LUUE3ILU]_:$A"Q,-BG8?D &%/;&*XSXE0//\ %/Q!&F-QO'ZD
M"N3G@$#[#(CD==AR/SK54:CA[2WN]Q75[#]0LWT[4KJRD9&>WE:)F1MRDJ<9
M!'4>]5@">@HJQ:W36CLZI&V1@AUS2I*#FE4=EWW!WMH1&*0*6*, .IQ4N)%M
MA&8AASN5MO/']*+B[:X)+(BY_N@C%-^U2[8U+96/[O%=;^J0FU"4K6WLN^MU
MZ>I/O-:D-/CB>5MJ*6(&<"D(/4C -2PM%MVMN5B>'!Z#Z5A1I1E449NR^[]'
M^.A3>FA!THP?2M*[M+;9";*1I6;AL^M:,.CPVUJLTUR%=A\R<?E7I4,DQ%6K
MR:<NGO+5:]GU,W6BE=G.5L:#IUKJ$TBW,I78-P4'&[UK.NI$EG9HXU1>@ %1
MQRO%('C8JPZ$5X^(IJ,I0A*_F=F$K0I58U*L.9+=&]K%P7O?LZ1QM%$%6-'
MS^'J*R+ZV^RW!C)&X=5':JY=F.2<FIK6UEO)&6,K\J[B6.!54*;F_94X7;VM
M?\-?S+Q>+]O)U)=_+;MMZ$MEIEQ?JY@V%D(^0M@G/I55U:*4H0-R'!J>WN9K
M.Y\Y<-(G&6Y IES(9YFF,:IO.<*,"LTJD9OR)G[!T8\M^>^O9KHR)Y&?&YB<
M=,FFT454I2D^:3NSG'%W88+$@= 33UMYFC\P1MM]<<5%2Y-5&46[U+OY_P#
M8O02BBBLQGV?\*_^27>'O^O0?S-:WC#_ )$G7O\ L'7'_HMJR?A7_P DN\/?
M]>@_F:UO&'_(E:\/73KC_P!%M0!\C_#&9+?XC:-+)*D2K(_SNP4#]VV.3TKN
MM"F\7VM]._B_7+63PZ89/ML-W?Q3B5-IPJJ&)W9QC&*\8Y!Q2@$G &33LV[
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M,>U<_3E&>^/K712Q]6C"U+1ZZ];,3AS:/8FGEFFF\^X+,S\[CWIL2PGYI68
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MY05Q_$I_I454Y.F_<E]UQ;GV?\*_^27^'O\ KT'\S6MXO)'@K72."-/N,?\
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MW-%(#AO^%/> ?^A=A_[^R?\ Q5'_  I[P#_T+L/_ ']D_P#BJ[FB@#B!\(?
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M&H(TC+]@5I#N<B)@6. ,GGG@ ?A4']F3G.;;2N9/-/\ HY^_G.[KUSWK8HH
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MFXD RL4=G*&?V&Y0/S(H [NX_P"0E9?]M/Y5<KR!_P!H'P?)<1N=/UWS(LX
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M2O/?"D,,/Q8F6%(%4Z'DB'3Y+09\\?PR$D_4<?E7;>,?^1)U[_L'S_\ HMJ
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ML,@TZL3Q9J]QH>@R7MLL?F"6./?*"4C#.%+-R.!GU% &LUK;NZNT$3,IRK%
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MTUO:F*>_BC$WV7S '9"<9 ]\$ GC-</9:'=>+M7N+_5T<6NXQ^5+%M#1YXC
M/52#\V0&5T!4XQ0!W.DSVMSI-K-8Q"*U>,&.,)LV#TV]L>E7*9%%'!$L42*D
M:#"JHP *?0 44'@9-<)KMU/XE2XMM&U11*B2PFTCG0QWT3 !BC\[77/O@]1@
MYH Z.+5-.NO$$UJ;<?:[5O(6=U7EF02%%.=WW<$\ ?6MBL'PYX7M] M_FD^U
MW62!<RH-ZK@?(I[+QG:..3@"MZ@ HHK+UG7]-T2U$M]<&,/)Y2B-"[%B,XP
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M%QN&#C/*L",KD9KNH+>&U@2"WACAB086.-0JJ/8#I0!)112,ZHA9V"J.22<
M4 +6'_;6CS>)&L9$07]JZP1RR(N=[QF38AZ_<&3VK*\27CZZ+S1M"U-H=3MD
M;S(&4JDZE2I3?CY3SD$=".A&:N^%O"T6AV_F3R-=7;8*R3_,T*[0"BDDX&<G
M PN3P!0!TE%%% !1110 4444 %8OB;6SH>EF98I6DE/EQ.L1=$D(^7?CD G
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M4C0!551@ #H *=0 4444 %5AIUB-0-^+.W%XR;#<",>85]-W7%6:* "BBB@
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M@ISC/7BN^U_1=:NM<M=4T6ZL898[.:T<7<;N,2-&VX;2.1Y??UKIZ* //_\
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M9J>O,?BCI]MJGB?PC:7=LEQ"[7A:-[9YP<1J1\B$,?P- '0ZYIVE:Y>)<_\
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MTQYY\0_":Z)X1T=I+R:62#6(!%&DCK#&CE<J$+'(&S(R3C<<8'%>B:[XSL=
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ML%/0###G*\[3D9;&:RML> =T6XA"P\QMP9CB4,.@91@R <1C!CP2:L>!@/\
MA<=K@CC2YP,'^$. I'JI&-K'EA@GDF@#W6BBB@"G<_\ (2LO^VG\JN53N?\
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M17,B?PXV':%! P>&SA^HP*R"2O0,V"0-B"7.WD$9^\&Z(YYN#\C8%6_"!/\
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MQC[,F=FW'V GG=GR]N>F/G\CJ#^]S@8H FWMY:C,V%6)0/,7: A)7:.H4?\
M+,'F-LF3 (J?P,3_ ,+CM?O<Z9<-R1U,@))]6_O,/E8Y*\$53P<L?*&"7.[[
M.?FW#@[OX]_0M_R\8VC&VK?@;_DL=GQC_B42#[N,88?+[8Z;/X,;><4 >ZT4
M44 4[G_D)67_ &T_E5RJ=S_R$K+_ +:?RJY0 5P'B0RCXJ:'Y/VK=_9=S_QZ
MK&S??C[/QBN_KS+QPD4GQ)T,36\$Z_V;<_+/:R7"_?CYVISGWH Z;??_ /4>
M_P"_%I_A1OO_ /J/?]^+3_"N9^RV'_0)TK_P0W?^%'V6P_Z!.E?^"&[_ ,*
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M5QR<F@#W*5BL3L.H4D5X!X7\8^,O%$_E:SXCMM.TB:V9_M=SIT)A=]VWRLL
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M''.*L>&]!?38;TW,5M&MW<"X2S@R8;?"J,)D#J5W'@<G\:Z"@ HHHH ****
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M[8C.S!\MAC+[\X*+@L-V#5[PMH$>FZ#I$=W:*+^R@,8=V$C1[OO*K?W?0>@
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MJ'1/#>C:64O+"RC65D(CE:,>8L;8.S=C=C@<$DCI6W0 4444 %%%% !1110
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MEF>\MU93;NJJBS!A\S9'S*QV[7484]<?,:[\ *H50  , #M0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#6-(M-=TR33[Y7:WD
M9&8(Y4_*P8<CD<@=*I:)X9M=(GDNVVSW\A8/=%=K.I(QN&<%L*H+8!;:":**
M -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M Q_$,.L2V4;:,\'FQOND@F'RW";2#'G^$G(^;MBLKP[X)L],?[5<JUQ(666!
M+I59[9OF/W@2"PW;=P[*.O6BB@#K:*** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>grk3fpqjsz23000007.jpg
<TEXT>
begin 644 grk3fpqjsz23000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $H G # 2(  A$! Q$!_\0
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M[MPA\V.211@#+#$+Y(]N#G@ [6BL;P]XJT3Q5:R7.B:A'=QQ-MDV@J4/;(8
MC\JV: "BBB@ HHHH **** "BBB@ HHHH **** "BJ>IZK8Z/9M=ZA<Q6\(.
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M*** "BBB@ HHHH **** "BBB@ HKG/&VK:OHWAR2ZT2Q6\OF<11QG.<MPI
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M/Y?A]H]G?1:>EZ;B?R2CRE-ORDYS@^E '<T5\[_\-+WG_0L0?^!A_P#B*/\
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M2600KE@AB+D8V\A_>M+QOK'B'0]2@DM=26&PND9(E73Q,PG &Q,[P<-\QSC
MQ0!W5N%%M$$1D0(-JL.5&.A]ZDJ&T:5K.!K@;9C&ID'HV.?UKGO&VOWWA^PM
M9[$6YW2L9O-VEA&J,S;%+IN;@< T :WB#_D6]4_Z\Y?_ $ UR_P=_P"23Z!_
MURD_]&O6-<>.]6OM*\01?V5]M"6TFV&V79)"/-FB._<><+&'Z _-TK9^#O\
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MTK.N]7NM6^-_@MKG2YK-4M9S'(Y!6;="6)7O@$XYH ]BHHHH **** "BBB@
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M:WI?P2M_%-CXPUBW5(\I8Q/B-<S%"!@_C]:^@O$'_(MZI_UYR_\ H!KQP_\
M)J<./^>0[X_Y>: ,1(?$K,O_ !6OB/!;&T;C+C&<>7G/F_\ 3+[P7Y\XXI!%
MXFV9_P"$WUHG86RMSN3.>I?.!%_>E^ZK?*1D5IQ)+O2,++Y_F; HN]K^;MR1
MY_9]O/VGN/W>.,TU2IB+J08A"SEA'L7R@<,?*[IGK;?\M#\^>: ,_P CQ+D_
M\5MX@^\HY<YP>H(SPY_@CZR<$8S70^!/"OB+Q=X1M=:G\?Z_;R3/(IC63(&U
MV7N?:J)#[F&'R)$4YGR?,;'E@M_$QXVS?\L.!@[:[SX*Y_X5;IN<Y\VXZG/_
M "V?OWH R=2^#-YK$"0:EXZUJ[A202+'. ZAAT.">O)J!_@:\J1QR^--8DCC
M_P!6DBJRQ^FT$X7\,5Z[10!Y(WP0F>=9W\<:V\Z#"3/@R*/9B<C\#WIC? QG
M:5F\::QOF4I+)@;Y%/4,V<L/8FO7J* /+[7X2ZK96L5K:_$+7X;>%0D<:$!5
M4= !GI3+GX/ZA>3VT]SX^UV66U<R0.Y!,;8QE>>#BO4Z* /-?^%7ZY_T4CQ%
M_P!]_P#UZ/\ A5^N?]%(\1?]]_\ UZ]*HH \MOOA#J.IV<EG?>/]=N+:48>*
M4AE;G/(SZBIU^%NMHH5?B/XA"@8 ##C]:]+HH \HN?@Q=WMVEU<^.M;FN$0Q
MK(^"P4G)&<],@5(OP?U!)6E7Q_KH=IO/+ C)DV[=W7KMXSZ5ZG10!Y/_ ,*6
MNOLAM/\ A.M:^SF%X#'@;?+;[RXST/<47'P7NKL@W'CK6I2)4F&\ X=!A6Z]
M1VKUBB@#D/"_@W4O#VIR7=YXMU75XVB,8@NVRBDD'<.>O&/QKKZ** (KJ".Z
MM98)8XY(Y%*LDB!E.?4'J/:O/?A?9QVIN56.,.L*)(T/V0IN!(./)^;&0?OD
M]/7->B3*&@D5D+@J05!Y;VKSCX:6MG;ZA<&S2\VFSC\Q+AF(LWW'=!S&N2 %
MYR3Q^) )(H/ FF^-5L(-&:/489T"SC.P2G! &6SD>8.V/F^M>C5YC>PWMI\2
M8)KYDF#W<:P72V-KO1&'$>\R>:!U!(7O[UZ=0!R7COPS>^)+*UBL6@WQ&56$
M[$ "2)DW# /*E@<>W45Y[XU\/:Q-\8?#,%KXENK::[AG-O+Y2M]D"Q_,%'<-
M@]?6O;Z\U\4_\ER\#?\ 7O>?^BS0!P.K77C?3/%VIZ&?'=XRV,,<K7!@4 !Q
MDLP&3M' XR>1@=<)]K\<^84_X3:_,@<(8O)3>KD9$9YV[V'((.W Y8'BM'Q/
MO_X7#K>SS/,"6AA\L OYOEG;Y6>#+C=M#?+C?GD"JY$?V1 ?*^S?9I F2?(^
MS[AYFT_>-ONQYC'YPV O&: *@OO&Q0./'MTR%682B ;2J_>;D9PG\7&3_"'H
MT^]\;WWB[2M"_P"$\NU-^KMO$ +*JIN#XQ@JPY'.0.H!XK1<S?:F,GVG[1YL
M);S%43^8!^YR!\OFXSY('RL,^9BC0#+_ ,+1\+@^?Y7FWI.0OE^;L/F9/7S<
M_P"L'W0WW>* .P_X0#QO_P!%,OO_  #3_&N7OOV>I]2NYKN]\6O-<32&621K
M%=S,>I)W?I7N5% 'A3_LZE[A)V\3)O3IC34"_BH.#^(H7]G4I<-./$R;VZYT
MU"O_ 'SG _*O=:* /%-&^ VH>'M0-_I/C.:TNBI3S([,9VGJ/O>U=#_P@'C?
M_HIE]_X!I_C7I5% 'E.F?"OQ3HUD+/3OB'>6]N&9Q&EFN,L<D_>[DFKG_" >
M-_\ HIE]_P" :?XUZ510!YK_ ,(!XW_Z*9??^ :?XU3B^%?BB#5;C5(OB'>+
M>W*+'-,+-<NJ_=!^;M7JU% 'F%Q\./&-W;2VT_Q)O9(9D,<B&S3#*1@CKZ51
MM?@]X@LK>V@MO'UU'%:R++"HLUPCJGE@CYNR\5Z[10!Y+_PJ3Q)Q_P 7 N^(
M)+<?Z&O^K<@NOWNA('Y4_P#X53XG\^6;_A85WYDKQN[?8U^9H_N'[W;%>KT4
M >3:=\)O$NDRWDMA\0;N![V8W%P5LU_>2'JQ^;K7INE6MS9:5:VUW>->7$48
M22Y9=IE8=6([9JY10 4444 %8GBK36U;0GM(YXH9&EC*&5R@8AP=NY?F4G&,
MCGGBMNN7^(:;_!-\=MNVS8X^T2^6HPX.=VY<$=1\PYH UM!L;C3=$MK2[G\Z
M:,'<^YFZDD#+<G (&3R<5H&-&=7**67[I(Y&?2L3P:2WA+3V/EX9"5\N;S1M
M+''S;FR<8S\QYS6N;JW%T+4SQ?:"NX1;QN(]<=<4 >=_#?\ Y'KXA_\ 833^
M35Z57FOPW_Y'KXA_]A-/Y-78^+=9F\/>$]4U>"))9;.W:54DSM8CL<4 ;-%?
M-7_#26O_ /0#TS_OJ3_&C_AI+7_^@'IG_?4G^- 'TK5'2_\ 4W'_ %\R_P#H
M9KYX_P"&DM?_ .@)IG_?4G^-16_[16O6ZNJZ+IIWR-(<L_5CGUH ^FJ*^:O^
M&DM?_P"@'IG_ 'U)_C1_PTEK_P#T ],_[ZD_QH ^E:*\L^%/Q1U+X@:EJ-M?
M6%K;+:PK(I@+9))QSDUZG0 5XK^TE_R*6C_]?Q_] :O:J\5_:2_Y%+1_^OX_
M^@-0!\U4444 %%%% !1110!]2?L[?\DZN?\ L(R?^@1UZW7DG[.W_).KG_L(
MR?\ H$=>MT >90:I<6_Q;NK&.?4889IU)M=RF.3]U\TFWR\A?E7D-Z_2M/XC
M#RX+>XN+:PGLE@FCS<F!6BF;;L<&4$8&#D#GIP:@\$:1XOT.\=-5@AN(+E(S
M<3-JCRLLPW>9(JLG ?*_*" -M7_$/@"#6-:_MNUOGMM2!B(,T:SQ?NV#+\K<
MKRHSL9<]Z .IT]F?3K5G9&9HD)*# )P.@]*PO$7C.ST3Y(%2]FCE"721R'_1
M5*EM\FU6*C [CO71Q"00H)2IDVC>5& 3WQ[52U+1-.U956]M5DVDG@E2<C!!
M(QD$'!!X- '&:E\1M+FT/7%O5^Q0+;2+#,S;Q+EY81P!P2\1QUX(YKCF_P"3
M4X<X_P!2.H_Z>:]0U+P_I6G:+KMS:64<<MQ:RF0\G/#MP#P!N9C@8Y)->7MQ
M^RG">>(0>.O_ !\T 44\C[,H,EJ+;RP#(UN3!Y/9S%U,&_@0_>#Y?.*E.[?\
MX<3;P0KL&E\_'RH'' G*X*3?=1<*1D5@+XX\/IMF.I7HPWG;U0_:>FW<&QM^
MT]BWW/+P,[J:/&?AY4\K^T(AE#!MB@D$/S'.T@KG[,>KK]\OD@8H W_W>!AH
M=NUMI$1"F/\ Y:L!VB4Y\V/K*<E<9KOO@IC_ (59IN,$>;<8VC _US]J\D_X
M3?P\26_M&<[F63)C;=\G=N/]<,?N2/E4;=V.:];^"C;OA9IC#<09;@@MU_US
M]: /0:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DQ A<E"XVG*@
M<GVKSCX6:I<W3W=E+<ZA)';Q*%AN65Q;\D!"1&I#8 XR>A],GL?%5EJ&H^&K
MRTTI]MW+L"_OC%E=Z[QO )7*[AD>M4/!EKKVG:;_ &?K-I"B0LY@F6^:X<H7
M8JC;D!^52J[B23B@#%U4M;_$*V$UOIRSSWD+6MT?(\SR@FUXR"#(6SD@C@<<
MC!KO;BX@M(&GN9HX8EQNDD8*HR<<DUR&G> $T/Q(FK:3?D([N9X;N(2LP<J6
MVR<.#\HQN+ <\5U]Q;07<#07,,<T+8W1R(&4X.1D&@#C;CXE6$#W:"RN'>"=
MX50,H:0*'8N 3]W$;8/>N9U+Q!INM_'3P:EA<"22WMKCSTVD&,O"64'/L>U=
MU<^!M!O/,\^VE<NV0QN9,H/FRJ'=\JG>V5&!S7)^(K>&U^-O@2*")8T6UNE
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MUNGM7$F.67&2,=N:5U>Q49QD[)FK1113+"BBB@ HHHH **** "BBB@ HHHH
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M *G%=+IUEJ6K!5TZSE6 X_?3M@#WQ43=UM_D8.JMD6HKJUTXB",F68C)51G
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M.E>H?"Z[DOM'UBYE&)'U:<L/?""J:L=&%NI,[JBBBI.T**** "BBB@ HHHH
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M_P#Y!MK_ -<4_D*LU6T__D&VO_7%/Y"K-<IWA4-U_P ><_\ US;^535#=?\
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M<HBL5(W=LFN6N;A_M0)_O<Y%4Z<79F$XN#LC:U(VPE,MO(>>H!XKVKX&-O\
M!%XP[ZG,?T6O &D=R4P"/6O?O@6,>!KL>FI3?R6N:J@25[H].HHHK 84444
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M_D&VO_7%/Y"K-5M/_P"0;:_]<4_D*LUTD!4-U_QYS_\ 7-OY5-4-U_QYS_\
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M:_\ 7%/Y"K-5M/\ ^0;:_P#7%/Y"K-=)U!4-U_QYS_\ 7-OY5-4-U_QYS_\
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M>MKJZ_\ <'N__C5*/$-A_P ^^L?^">[_ /C5%%!7L8CAXBT__GVUC_P3W?\
M\:HC\1V"K@V^KGG_ * ]W_\ &J**"O910'Q#IS?\NVL#Z:1=_P#QJJMQJUA*
MO$&K-[-H]W_\:HHI61+I19BSS6Q8F.UUA3G/&DW7_P ;JDU_<Q'Y-/U=QGK_
M &5=#_VG112E",MQQII=22/5KDJP?2]8&1@?\2JY_P#C=;7PTMKJWT?5&NK6
MYMS-JDTL:W$+1,R$+@[6 ./PHHI0IQAL:1BD=K1115E!1110 4444 %%%% !
..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>grk3fpqjsz23000008.jpg
<TEXT>
begin 644 grk3fpqjsz23000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &! 6T# 2(  A$! Q$!_\0
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MXVG-9[*,]*EMI/+N$8=5(-,RJ*Z/0%7C&,"G8H3!4$=",T_%6<@W%+2XI<4
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MS0D34FMI'8>#;]&=M/G4'G<F1V[@>]>@PQ! -CDKZ$YKQ=+F6UN(KNW.'!W
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M_M&Y3DXP,5>LX7M[2.&23>RKC.,5US:?9L5+6L)*G()0<&G_ &2W_P">$?\
MWR*:T!Q.3/I3,-CYB,]B*Z_[);_\\(_^^11]DMO^>$?_ 'R*=Q<AQQ%;/AL$
M&ZR3_#_6M?[';?\ /O%_WP*DCABASY<:IGKM&,T7!1L[CZ***184444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRXCNSHFM834(A^[D/W9U[$'UJDW%\K,IQ5:+J0W6Z_5>7Y'44445H<H4444
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M_IMW\0]?C\5ZY"T>CVS'^RK!^C<_ZUAW_K]!SZA3(XTAB2*-%1$ 5548  Z
M4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B+%;2
MZ#;^=<7$,RW2FU^SP"9WEPP "D@'@DYR,8S77UYK\0-><W=[IDNFV-WIVG6T
M5Y=">5TE;<Q \HKT8 $YH N?#>VTFV-[_9LEQN:WM/W4\(C*Q^62C<$AB27R
M?48[5WU<7\/=+;3[.[E&FVFG03E##!'.TTP4 X\UR3SC& .!S7:4 %%%% '-
M?$'_ ))[KW_7F_\ *E^'_P#R3[0?^O*/^5)\0?\ DGNO?]>;_P J7X?_ /)/
MM!_Z\H_Y4 =)1110 4444 %%%% !1110 4444 %%%% !1110 A (P1D&O+_&
M'A5_"2WGBGPTT,,(7=J&F3+NM[E,\_+T!_SQW]1K+\1VUI>>';ZWOH+BXM9(
MB)8K=29''HH'.: /G+1]0C\8>*!HD5G!IUKJU^9I6A12Z)M_U:M@8'!Z>M?3
M&GZ?:Z5I\%C90K#;0($C1>@%>/> /#&D6GC":X?0=<MY$NV;3I9X)%C2/;_&
M3QGKUKVJFQ!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<[K&B^%-1N[BYU6PL+JZMX=TOF('D5 "1QUQUKHJX?Q3H>N:MXAMFM[
M:T>Q3R\2DA9$Y^?YQ\XXZ;3]: +7@F]\,7#7D?A[35L6"QR3*(E7>IW;#\I(
M[-P>?:NNK(T71#HIFCCNVFMG(*+)$@=3WRZ@;OQ&?<UKT %%<;XJ\7:MX<-U
M=+HL3Z9:!-T\UUL:<L<;8E .2/?%4-9^)#V'B1M(MK6Q&R&)WDOKLP89QD+]
MT\@8ZD=: -SX@_\ )/=>_P"O-_Y4OP__ .2?:#_UY1_RK.^(NN:5#X,UG3Y]
M1M([Z2R;;;M,H=LCC ZG-1^!O$^@6O@;18+C6].AFCM(U>.2Z164XZ$$\4 =
MS16+_P )?X:_Z&#2_P#P,C_QH_X2_P -?]#!I?\ X&1_XT ;5%8O_"7^&O\
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MW)1+'4K2T,R2#(# ;2?WGM@8H H77B75/^$<U"34XM>O]+;9YM^42P,!R/\
M4K]Y^<<'TQ72:=X.U:^UG3M2UV_MIQIZ'[-=VJM%<W"G! F[8 SD#.<FMI/
MVB-?07]Y%-?7D03][=3NX=E& Y3.W=QUQ72T@&111P1+%%&L<:C"J@P!]!3Z
M**8!39(TEC:.1%=&&&5AD$>A%.HH X;_ (5K:+>O#%J-U'X?E?SI-(5OW32
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>grk3fpqjsz23000009.jpg
<TEXT>
begin 644 grk3fpqjsz23000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $R ?\# 2(  A$! Q$!_\0
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MC)Z^E?0-M:6UE"(;6WB@B'1(D"J/P%10Z9I]M<O<P6-M%</]Z5(55F^I R:
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M%<Q':LQ'\+X]>F?P.14_P\\?-XG2XTG6(/L/B33SLN[5AC=CC>H]/7TSZ$4
M=U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT6DZ=)=N/1FW#_XB@#U2.-(8DBC4*B*%4#L!TIU%% !7R_\ \S?XH_["4O\
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M_O"^?Y'FYO\ [I+Y?F7****^B/C1#T->F? W_DF\?_7W-_,5YF>AKTSX&_\
M)-X_^ON;^8KR,U^Q\_T/HLA_Y>?+]3TFBBBO'/H@KSKQ5X/\)Z9HFKW>MZE?
M6MG?7BW<[K+R)/FPJ *3CYCQS7HM<#\7;<S>$;>1-/N+^6WOX9H[>&(R!RN<
MAP/X2,@GW% 'EPM_@_D8U_7_ ,F_^(KZ-CQY2;>5VC&:\DC^(]ML4-\,]55L
M<A;$$#_QVO7$.44XQD9QZ4^@A:***0PHHHH \V^.?_)-9O\ KZB_F:Y_6/\
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M/@O_ ,E UC_L'K_Z&M<77:?!?_DH&L?]@]?_ $-:Y\3\!RXOX/F>\5XK=_\
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MURUDEGB5[!"7@E,;C$B'AAR.GY9KGQ/P'+B_@^9] UXK=_\ ):?$W_7M;_\
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MG_:Q7H/@OQA>Z]>ZAI.LZ0=*U;3PC20"3>K(PX(/_P"OJ*9)V-%%%(84444
M>;?'/_DFLW_7U%_,US^L?\FP0_\ 7O;_ /H]:Z#XY_\ )-9O^OJ+^9KG]8_Y
M-@A_Z][?_P!'K0!\_4444Q!6UX/_ .1UT/\ Z_X/_0Q6+6UX/_Y'70_^O^#_
M -#% 'VA117E?QELDU.X\(Z=*\B0W>J+!(T9PP5MH./?FD,]#US4;C2M*DN[
M73;C49D*@6UN1O;)P<9].M<"WB.6*!8&^%M^L+7/VA8S'%M\X_QX_O>]1?\
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M ,DUF_Z^HOYFN?UC_DV"'_KWM_\ T>M 'S]1113$%;7@_P#Y'70_^O\ @_\
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M%+T8UN;E%%%?C9Z85R5]_P EC\'_ /7.Y_\ 19KK:Y*^_P"2Q^#_ /KG<_\
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M-;FY1117XV>F%<E??\EC\'_]<[G_ -%FNMKDK[_DL?@__KG<_P#HLU[O#?\
MR,8?/\F95_@9ZW7AOQF_Y*#X=_Z]9/YM7N5>&_&;_DH/AW_KUD_FU?I-3X'Z
M&&#_ -XI_P")?F<W1117C'Z"%;_PF_Y*IJ'_ &"S_P"AQU@5O_";_DJFH?\
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M%!*(X-D4*J1N8OV7'X\_F(#V:BD4,$4,<L!R?6EH ***X'X@_$2\\"W=D?[
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MKRIOAN@A^5),]?Q[XS[UI_"M_K/B1;;[7K>I>)(+Q#-JTL1@M+2-2"WECOZ
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M<0B(/)(F/X<Y!QW&,GMZ'S2XO_%WQ"\))+/HFFZRD9S'=:?-Y-U:2CU#=_4
M8/Y&OH"N.'@1;#QQ'XBT.].GI/D:C:*F8[GT('9L]_Q]<@',>%;'4O'_ (7F
MT3QWH=Y#-8.HAOY$\J1CZ@GG<!U(R".O->JPQ+;P1PH6*QJ%7<Q8X QR3R3[
MFGT4[@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>grk3fpqjsz23000010.jpg
<TEXT>
begin 644 grk3fpqjsz23000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &8 B0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX+CQ%JY58D9-D:;_ )@6&>RE1UZFJ=IXZ\4^&?%&BV'B;4]%U>QU>00>;IY
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M5 )' P&;')QVYIV"Y+1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#QS3OB/X@N?CP_A&22W_LD3S1A1"-^%A9Q\WU KV.OG#1O^3KY/^ONY_\
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M]C_X'W'_ ,;H ^CZYN]\906NM7>E0:1JU]<6BQM,;2!75=XRO)8=@:Y+X6>
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M /'&>"1P>*TO[*L_M-E.(@/L4;);H.$C! &0/7 P/0$CO5VB@ HHHH ****
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MW!O;Z!()(V9?+"KC! QG/'<FN>_X5)X?_MC[7]IU+[%]K^W?V5]H_P!$\_\
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M.*N:?/<75A#/=V;V=PZY>W=U<QGT+*2#^!JS10 4444 %%%% !1110 4444
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M0EGNXUCQ<2-CY0K]ESU''X\8T? 7AN]\+>&TTR_ELYYHG94FMH?++Q _)O\
M5L=3_/J:OC37?%6A.UUI.FV<^EQ6XDFGG/S*VX@C <$C&WL>M5/#'B'QOK-Q
M8W-UH^GII%Q\S7$;88+@\@&0GK[5C[>*ER6=_0]*.6598?ZSS1Y?\2OZ6[^6
MYWM%%9VJZ]I6B1>9J5]#;C&0K-\S?11R?P%:MI*[."%.=27+!7;[&C2,RHI9
MV"J!DDG %>9W_P 59;VX-GX7TB:\G/ DD0G\0B\X]R159?!7C#Q8PE\3:L;6
MV)S]F4AC_P!\+A1]22:YWB4W:FN;\OO/7CDTZ:Y\9-4EYZR^45J<+?>-]9U'
M6;+5;AX3=67^I*QX ^H[U] Z'=RW_A_3;R<@S7%K%*Y P-S("?U->-:S\/K7
M2_%NCZ,E],\=_G=(RC*<]J]JTVR73=+L[!'+K;0)"&(Y8*H&?TK'!QJ*<N?^
MF>GQ'6P52A1^K*V[6EM+O];EJBBBN\^2"BBB@ HHHH **** "BBB@ HHHH *
M*** .<\7^&]1\26EM#IWB.]T1X7+/):9S(",8.".*\M\(>$_%'BW1[K4X?B9
MK,,(N98($W,S (Q&9/G&"<9V^A'->ZU\W>,+?P&_BS4_[,LO%<R),W]I-HI7
M[,K\[OO ]\YZ#TI=1]#U;X2WMS>>#YEO=3N-2N[:^GMYKB:0R!F0@?(QZIC!
M'UK9\9Z7X9UO1O[/\42VL=K(^Z-IIQ$5<#JC$CD9_6F> !X=_P"$,L#X5 &E
M%24SG?NS\V_/.[.<_P"&*K?$'PQH7B[1%TK5KB"WNGW&PE>4*RRXZJ,_,.F1
MZ'Z4Y"B<!_PJ[X=%\/XYO'@[PG5X-I'I]WI7JGA>PT+2]!@LO#IMSIT.54P2
MB0%NI)8$Y/K7&>&_A!X:'A^S77_#5A_:BIMN&@GD*.1QN'(ZC!QCJ37=:'H&
ME^&].^P:/9K:6N\OY:L2-QZGDGTI^0C2HHHI#"BBB@ HHHH ^<-&_P"3KY/^
MONY_])GKZ/KYPT;_ ).OD_Z^[G_TF>OH^@ HHHH \U^.>A_VO\-KF=$W3:?(
MMROKC[K?H<_A5OX,Z[_;OPRTPN^Z:R!LY.>FS[O_ (X4KM=3L8]4TJ[L)@#'
M<PO$V?1@1_6O"/@!?R:/XH\0^$[HE7!\Z-&[/&VQ_P 2"O\ WS4[,U>M-/MI
M^J_4^@:***HR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@M4^)4D6N
M:AI>A^&=3UM]-(6\EMMJI&V,[1GECUXKO:\6N].T?5_&/B"]\->,;WPKK4$^
MR_@N"HAG<?QA"PRIYYYZYQSRNH'<0?$SP]-X'7Q6SW$=EYGDM$8\RK+G&P@<
M9_''O78$@#).![U\W^)-6G\7_!E]0UE(9KS2]8^R1WEOE(YU.W+@# .0<9QV
M[5U_B?3?#MUXBT;PG8:.^JM::>T\-M<ZHT-G%&6(WLWS,[YSZ\?I7]?A</Z_
M&Q[%61K7B73M!GTV"]D?SM1NEM+9$3=N=CCGL ,\YKY]6>ZD^"7V=+QE\CQ0
M+>!XIF81)@8",>=H))%='\0?A]X7T/4O!UO;VCQP7FKK%=O)=2$R*VW=EBW!
M/J,&C^OR_P P[_/]3W:BHK:*&"TAAM_]3&BK'AL_*!@<]^*EI %%%% !1110
M 4444 >=_$WQ;!IMI<>'WM9'EO+0.LH8;5RQ'(_X#6/X:^*.EZ/X7@L+BSN6
MN+6-40)C$AYR<]@./SK(^+TT<_C*)(G#M#9HD@7G:=SM@_@0?QKH?A9X1$5K
M+JVI6=M,MPL;V;N Y0?-N.#T/W:\SGJRQ+4'Y'W'U7 T,FA4Q$6[VE:]FWM^
M7X:D/]O>/O&7RZ19?V78OTF/RY'^^>3_ ,!%:.E?"6S$WVK7K^;4;ACEE#%5
M)]S]YOS%>CT5UK#1;O4?,_/_ "/ GG56,?9X6*I1_N[_ #EO^15L--L=+MQ!
M86D-M$/X8D"Y^OJ:M445NDEHCR)2E)\TG=GG#_"2&25)7\0:@TB?==L$K]#G
MBNM\->'SX=L)+4ZA<WN^3>&N&R5X P/;C/XUM45G"A3@[Q1VXC-,7B8>SJSN
MO1?Y!1116IP!1110 4444 %%%% !1110 4444 %%%% !7BNC:SXG^&45[X=;
MP3J&KQF[EFM+VQ!*S*YR-Y"G!^OY<9/M5>):'X<U3XGQ7_B.^\8:GI\BWDL-
MK9V,NQ+0(<#<,]<<]C[\T=0Z'<_##0=1T'PFXU6%+>]OKR6]DMD^[!YA&$'T
M 'YUT&N>&]&\26R6^LZ;;WL:$E/-3)0GKM/4?A7._"S7-0USPBYU.Y6[N;*\
MELC=KTN%0C#^^0>O?%=M38(\%U#5OAWX<U">ST/QQKVC36[E&BM'EN+<,."-
MKJP;&.QKTWX=ZR^N^&6O'UT:VHN&1+O[']E)  X*>H.>1ZUYGX;\1WOA&"^T
MH?#+6KV%;R9X;H63;Y$9B1N^0Y(Z YY&.!7K7@_6)-<T+[9)H5UHK>:R?9+F
M/8_&/FQ@<'Z=J2V![F_1110 5X3_ ,+!\6^=_:7]MV?VS^UOL7_"*_95\[R]
MV,[O]9G'.>G\J]U;)4A3AL<'TKYR.@ZM_P (\^AMX3U0^.CJ7FC7A!\G^LSY
MGVC^[MXQT[]:%\0/8[WQ!XA\5:SXVUK0_#.J0:9%H5DMQ,SVJS&YE9=PC^;[
MJX.,CGKU[=/X-\8V_B'P1I>NW\UO:272%9 [A%\Q6*MC)Z9!/XUQ6KKJ_@WQ
M_P")-430]2U6VUW3XTADL(#+MN$0)M<#[H/7/O\ 6G6GP?\ [:^%WAW0-8O)
MK*YL3)<2")58AI"6VG/INQ^%-;?UY@]_Z\CBM!ECG_:J:6&1)(VNKDJZ,"#_
M *,_0BOI*OEOP#H<?AK]HRUT:&9YH[.:XC61P 6_T>3DXKZDI %%%% !7SCX
MJ/\ P@G[1-CJX_=VE]*DDA[;9/DD)^A)/X5]'5XE^T;H?VC0--UF-?FMI3#(
M0/X6Y'Z@_G4RTLS>C[RE#NORU_*Z^9[;17.> ==_X23P)HVJ%MTLMLJS'_IH
MORO_ ./*:Z.J, HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[6O OA?
MQ%>"[U;1+2ZN0 #*RX8@=,D8S^-=#10!E3>&=$GT'^PI-+M3I6 /L@C 08.>
M .ASSGUK'U+P;X&6VT^WU/2]+2*T4I:K<$+M7.2HR>1DYP<CGWKK:\ _::_Y
ME;_M[_\ :- 'L7_"%^&Q9260T>U6UDNOM;0JN%\[^_@=#5K6_#VD>)+);/6;
M"&\@5Q(J2C[K>H/4=36G10!'!!%:V\5O @2&) B(.BJ!@#\JDHHH **** "B
MBB@ K"\6^(X?#&@S7S[6G/R6\9_C<]/P'4_2MMW2*-I)&"HH+,Q.  .]>11+
M)\3O'9E<-_8.G'@'@.,]/JY'Y"L*]1Q7+'=['J97@X5INK7TIPUE^B]6<[$E
MU9Z;?W.HZ7>7>I:S;>9#<!<B-68Y)XZMMS],>M=UX$\7,MMI?AZ71M0C=4\O
M[08SLR,G)]!7HRJJ*%4!5 P !P!2UG3PSIRNI?@=F,SNGBZ3IU*.[NO>>CM9
M:>2Z!11176?/A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^)<W@7X+>%KV?33J37$DUNH-QY6U4=MO.UL\ #\*:6@&+HW_ "=?)_U]W/\
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M*X'X@?\ )<O 7_ OYFO7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQWI1V![G5T444 %><7'P@L)I[JVCUK48= N[K[7<:.A7RG?.<!L9"Y X]NO
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M+M!;W=O;QH%4H%4,G49^7UP<FOK.[MEO+*>U=W1)HVC9HVVL 1C(/8^]?/\
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M/B@>)UMX+CPP]@\\1)EM+U2%G4XX#@Y5ASCL<\UMQ11P0I##&D<2*%1$4!5
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M^T.RNM3L?L-]+$K36V[=Y;=QG_.*OD!E((!!&"#WJN-0LF&5O+<CRC-Q*O\
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M2^(M $R&W%Q:WMW"QACP><Y^3GJ&/=>O- '2O\2?B1X_9H?!F@'3[)CM^V.
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M &%X2?Q))HF[Q5%:1:EYK?+:'Y-G&.YYZUNT44 %%%% !1110 4444 %%%%
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M?3'/6>$O$4/BSPKI^N01F);J/<T9.=C E6&>^"#1TN!X5HW_ "=?)_U]W/\
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M([-+/6+&*\MTD$JQRC(# $ _D3^=7+2U@L;."SM8EBMX(UBBC7HBJ, #Z 4
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M5X;\^H]B*Y3X46FH6DVJ6>G:E'J7@J&9HK":?)E+ *6"'&#'EF&?53CK71^
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M9N'5)!P2,D@'@9/)->]VUQ#=VL-S;R+)#,@DC=>C*1D$?A1TN'D</\*M"O\
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MU/1YO^$MN,V!T@1DGSR.)%)Z*"-V<\8^A/IOA?1'TCPQHME?".:^L;..!IL
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!0_L73!K9UD6,']I&+R3=;!OV>F:OT44 %%%% !371)8VCD171P596&
M00>H(IU% %+2M(T_0]/2PTNSBM+5"2L42X ).2:NT44 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>grk3fpqjsz23000011.jpg
<TEXT>
begin 644 grk3fpqjsz23000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *  =(# 2(  A$! Q$!_\0
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M)S:V>,X'R/\ _%4 >D45Y=+\1];4[5L[#=C)RK__ !59\GQ5UY)"HLM-./\
M9?\ ^*H ]AHKQ"7XQ^(8B0;#2R?9)/\ XJJ;_&[Q*I(&FZ9ZC]U+_P#%_P"%
M 'O$I81.4&7"G:/>O _"T7A&>'3-8UK5[V+QI)JS+,8)R;KS-Y41M'SB/  /
MR^V:SKC]H'Q7 6']EZ,=OK'*,_\ C]8X^.6JC4_[2'ACPU]O/6Z%H_F^GW]^
M: .^L?B7K]QJ=G<M?:<\=YJ<M@VC+#B>V1<XE)R22,<Y&/Z9P\9^-;KPY8RW
M>L6Y76=)O9T\BU"20-""00P/)(&.V,\5R:_'+54OI-07POX;6]D!#7(M&$C
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MT;_OW+_\<H ^G**^8_\ AH_Q5_T"M&_[]R__ !RC_AH_Q5_T"M&_[]R__'*
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MOZ4_:<D'.>XIGX4 )2T=310 E%%%  :*** #VHHHH **** "O8?V</\ D?\
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M%,;1ZY _K5"6(*?ER<=>* (:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M:GHYE=@0WF=0P' 'YT <ASFCVJS>64MG)A^5/1@.M5: "BBB@ HHHH ****
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M'&.?2DK3N+1%=MAY[C(JH\  9@PP.G- %>BG8XIM !12@9I* "BBB@ HHHH
M**** "BBB@ HHHH ^C/$@@M_C'.LT>B79N+NU*R7IN2]J=B )N0;%)(RH)[C
M/6O<Z\1\3W.EQ?$:_5Y;E?\ B::>L^F"]""]<JN)A'MR=A\O@'#8)[5[=0!
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MF[UFZOI!_#8P;%/_  )S_2J,NJ^%;4D6_AB6X?CY[N\<Y_X"@%9;@J".,DY
M JOY+,&.-QQSQ0!?N/%-NN?(\)Z HSQOMVD)S[ENU59_%Q\M5_X1;PPXZC_B
M78)_'=G-4]OEC;C(+=QTJ-X&D<[1]#B@"*7QCIK@K=>"/#TJ $'R8I86&?\
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M3O#.A2>$/#MP+AI6!U;4DZ7#CI$A_P">:G\S7!4 %%%% !1110 4444 ??\
M1110!\,^+_\ D=-=_P"PA/\ ^C&K&K9\7_\ (Z:[_P!A"?\ ]&-6-0 4444
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M![4/^_:5Y)<_$;QQ;R%/^$GU'/\ UTJM_P +0\<?]#/J'_?R@#V3_AFS1?\
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M#VH?]^TH_P"&;-%_Z#VH?]^TKQO_ (6AXX_Z&?4/^_E'_"T/''_0SZA_W\H
M]D_X9LT7_H/:A_W[2C_AFS1?^@]J'_?M*\;_ .%H>./^AGU#_OY1_P +0\<?
M]#/J'_?R@#V3_AFS1?\ H/:A_P!^TKJO 7PCT_P#K<^J6FIW5U)-;&W*2HH
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MW%LR@=<#VH HT4XKZ9_&FT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI0!2EV3D!D0G'.1T%9.J:6DL+CRU97&#Q_*NBBL2\I)&6SQ[TEW9%@$Q].*
M/%M0T2ZLF=@F^$'AE.<#WK,KVB?1U^SG*]>AQ7'ZUX5C(>2 ;)1_='#4 </1
M3Y8I(9#'*A5AU!%,H **** "BBB@ HHHH **** "BBB@ KV']G#_ )'_ %#_
M +!;_P#HV*O'J]A_9P_Y'_4/^P6__HV*@#Z/UH*VB7H8$J86R!]*\VATY90=
M@)QZUZA?)YEA.GJA%<O]A*-G&#[4 <P-,"D$AJ4VJ1C<!@_[1KJ1;+CYUY[$
M=:KSZ:)"=L@+9^[Z4 <LS*<*%XSC<:CN+3[0I#,3&.I'!K2N].*!FRW X..
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M 460[L=!TIIQ&"2=V.0,5/,5!PF3GKSTJL<;"K+CMDGK0!%-<2.OS853T '
MK.E8DAE&3G]*NRH&SEB<>M4I0V<DDC/ SB@"/RM\1R1E?454?3?,!)*EOO
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MQE"I4YZ9!K*FW"0A1CGIGK0!Q\VF\,02&!Q^E8FJ:+*KY4;E(YXZ&NZF@!#
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M@U4=)MQQ&T;8&2 :]!NHX]I4*..E8EU&K9^49H XZ>^G@&TELXXXJ"6^FG!
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MG)W2R.K?WF/S50GT\YR!@@=&&1GTKL+K3VMR R';VS5 V1F!#$>^* .&D%[
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MP_Y'_4/^P6__ *-BKQZO8?V</^1_U#_L%O\ ^C8J /H_6KA;31;R=ND<3-7
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MH<-C@^E:WB__ )'37?\ L(3_ /HQJQJ %9F=BS$EB<DFDHHH **** "BBB@
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MX<T/1M#QTFM[423#_MI)N-<OJVN:IKMS]HU74+F]F[-/*7Q],]!]* .RBO\
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ME% 'W_1110!P=Y\&_ E_>SWESHK//<2-+(WVN8;F8Y)P'QU-0_\ "D/A[_T
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M8'B*[(#?],P?I]VJMQ\2?'D4SJOB.Z('3A/3_=H ]U_X4A\/?^@$W_@9/_\
M%T?\*0^'O_0";_P,G_\ BZ^?)OBEX]B/_(QW>.W$?^%)'\4_'\K;5\1W1/T3
M_"@#Z$_X4A\/?^@$W_@9/_\ %T?\*0^'O_0";_P,G_\ BZ^=V^+'CU3@^)+K
M\D_PI/\ A;7CS_H9+K_OE/\ "@#Z)_X4A\/?^@$W_@9/_P#%T?\ "D/A[_T
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MC_A2'P]_Z 3?^!D__P 77SM_PMKQY_T,EU_WRG^%'_"VO'G_ $,EU_WRG^%
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M ,#)_P#XNBOG;_A;7CS_ *&2[_[Y3_"B@#[+HHHH ^=-;C67Q!J'S1QJ+J7
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M@MM-2,8 ..G)Z4 <E:Z&N[RVCR3T..E,?1G%P 5R,\].:[Q+:.,[@N6Q6;/
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MW0_CZT >9WFGS6;_ # %3R"#FJ=>A2Z89BPVL<9;@XKF-2T.:%G=(S@<X H
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ME=W$K-N4J!]:R;F\\O\ Y: L>O- '0_VIY1QMSZ$U?M];W\*N&/H*\^?53G
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M'!!I*ZKQGHJ6-]]I@XCE/S ^OK7*T %%%% !1110 5[#^SA_R/\ J'_8+?\
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MW; !GL!S6?+9,[$<<^PH Y^?6M4^;S7CD7&-DD",/U%9TFH6\X/V[0=.F7@
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MT=3P0:ZO6]/6*1F:(L%Z=@!WS7$:@4B?R@ASZ#'S#M0!J>*]!T[5-(/B[PU
M8;/S/+U'3P<FQE/0C_IFW8]NGTX2NL\&:Y_PC7B)6O(O,TJ^4VNH0-]UX7X/
M'J.H^E9OBW07\,^*+_22Q>."3]U)_P ](SRC?BI% &+1110 4444 %%%% 'W
M_1110!\7_$LHWC?4&CW%?.D'/J)&S^N:Y"M_QG,9?%^LJY)*:A< >P\QJP*
M.QL]2>2V29I'2%%PD:D8].:Y[4]3>_G)'RQ@\ =ZJ>>XA\H-\G7%14 %%%%
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M53W#%8U4+V8UE/JD\C!G;)'8 "J-% #G<NQ8GDUUGP^UBTLM8N-*U1]NDZQ
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MVIRW5]E-(TY/M5Y*1QL'\&#W8C 'UKSWQ9X@F\2>(;[4YB,W$I=5Q]Q>BK^
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M;L?A7$ZCJWPRDTVY33_#>M17C1,())+P%4?'RDC)R :Z/]G#_D?]0_[!;_\
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M2N=0UV.1S_:^H[ >";E\_P Z /IG_A2W@'_H!#_P(D_^*H_X4MX!_P"@$/\
MP(D_^*KY6DUW74.#K&H9S_S\O_C2)KFNOQ_;.HY[?Z2_^- 'U5_PI;P#_P!
M(?\ @1)_\51_PI;P#_T A_X$2?\ Q5?*3>(-=0X;6-1!][E_\:;_ ,)%KG_0
M9U#_ ,"G_P : /J__A2W@'_H!#_P(D_^*H_X4MX!_P"@$/\ P(D_^*KY0_X2
M+7/^@SJ'_@4_^-'_  D6N?\ 09U#_P "G_QH ^K_ /A2W@'_ * 0_P# B3_X
MJC_A2W@'_H!#_P ")/\ XJOE#_A(M<_Z#.H?^!3_ .-'_"1:Y_T&=0_\"G_Q
MH ^K_P#A2W@'_H!#_P ")/\ XJC_ (4MX!_Z 0_\")/_ (JOE#_A(M<_Z#.H
M?^!3_P"-'_"1:Y_T&=0_\"G_ ,: /J__ (4MX!_Z 0_\")/_ (JC_A2W@'_H
M!#_P(D_^*KY0_P"$BUS_ *#.H?\ @4_^-'_"1:Y_T&=0_P# I_\ &@#ZO_X4
MMX!_Z 0_\")/_BJ/^%+> ?\ H!#_ ,")/_BJ^4/^$BUS_H,ZA_X%/_C1_P )
M%KG_ $&=0_\  I_\: /J_P#X4MX!_P"@$/\ P(D_^*H_X4MX!_Z 0_\  B3_
M .*KY0_X2+7/^@SJ'_@4_P#C1_PD6N?]!G4/_ I_\: /J_\ X4MX!_Z 0_\
M B3_ .*H_P"%+> ?^@$/_ B3_P"*KY0_X2+7/^@SJ'_@4_\ C1_PD6N?]!G4
M/_ I_P#&@#ZO_P"%+> ?^@$/_ B3_P"*K7\._#[PSX3OY+[1=-%K<21&%G$K
MME"02,$GNHKXY_X2+7/^@SJ'_@4_^->M?L]ZKJ-]X[OX[R_NKB,::[!9IF<
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M  (D_P#BJ^4QXAUS/_(8U _]O3_XT'Q#K><?VSJ/_@4_^- 'U9_PI;P#_P!
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MHH **** "BBB@ KV']G#_D?]0_[!;_\ HV*O'J]A_9P_Y'_4/^P6_P#Z-BH
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MVAC_  KFJKV#&?S.J9X! R.*O1J4"@EF X&U<&IHHF,.7&&![9XH SS;,"&
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M0^QD^]U'.*CFT5EN<[1@'@ &NW$*)T SCK5">U)8[AD'G/I0!REUH[2-@1$
M#C%4)O#0VL2@RP]*[J*U# ]<^OK4PM%7MGW- 'B?B+P-;ZK;LDRL) OR28Y4
M_P"%>.Z_X5U'P_+^_3S("?EF0?+^/H:^OKW3D=26CSSGBN0U?08;E)$>)'1A
M\RD<'ZT ?*E%>D>+_AS)9AKO287*C[\ Y_%?\*\X961BK A@<$$=* $HHHH
M**** "BBB@ HHHH *]A_9P_Y'_4/^P6__HV*O'J]A_9P_P"1_P!0_P"P6_\
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M)CH!Q[]:EW9W @9 ZBHF8[<;L_X4 ,R,=/UIO\..:<3WR.::3GG^M "444E
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M **** "BBB@ HHHH *<CM&X=&*L.A!P13:* .DTGQG?::561%N$'JQ#?G_\
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M:QU[#+^](.>5V\'\*V5U6%F!5MASD@]*\53Q Z@ @].3WI1XFN%;*KCMG/-
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M[:?121Y:Q;LC"K[UB_%NQ6,V6GQ@LVEVD<#$$??Y9_U;]* /(Z*** "BBB@
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* <@'@T4E% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>grk3fpqjsz23000012.jpg
<TEXT>
begin 644 grk3fpqjsz23000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %  EP# 2(  A$! Q$!_\0
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M$-EK<326M[:@INAP!(I_A88Z=?SK.$8\JT,J<(\BTZ$W_")^&_\ H7]*_P#
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M2].U?$4#-:_9'E&Z:%NPQUQM&*.2/8.2/8]0_P"$6\,@9.@Z1C_KSC_PI?\
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MI7_@%'_A1_PB?AO_ *%_2O\ P"C_ ,*V**.2/8.2/8Q_^$3\-_\ 0OZ5_P"
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M;-?^^_\ ZU<AHLFZ+;6C(M/E0KLWCXKD'_+FO_?S_P"M4;>+Y%_Y<E_[^?\
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M./M1_P#B:\ELD+%5"Y'6K6OP%/#DS8(PR_S%.P[*QW(_:1O/^A9@_P# L_\
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M7HM<_"095W'.WOZUJV>]9% 9C'D97.,U=[[D6-?3XW1U1EP1UXJUXD4-X;G
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MDS"URUFTC46NH5)A)RR^M=3I-[%?Z>LL3;AT/L:2ZA2\A*RMG=TR*Y:UO_\
MA'M2D5Q_HTK?,N/N^XIWLSDJPOJMSL)JSIVP:N^:D\2R1L&1AD$53G7GBJ9S
MHS+G.-W8USVH:C% 2">:Z:[MW-L[#J!P*\RUB8FX8>]8U)6-J<5(O2ZC'=1M
M$>C5S&IO]G/RC![FKMOOWJ:J:G SG,G0]*F,KK4TY;;&5-=(\9!ZU6F4*8RT
MZ2,Z9*J&S&<D;3D 9P >,C##G.0&W-K)#N#<@\@U65F,G.6)-,A[FYIJ^9)'
MM.&_G7>1X$**>6Q^=<9H%C<R7@*QL5'.2*]4T'0S).+B4;B.F>BUK2@V-Q;&
M:/HK%A<3J0.RFN[T^T<Q;RQ1%'!!K+,]MYPA4@#/S-FEU#Q!'$JP0N/+7CKU
MKILDK(TA3;5DC:G^T21!#)N0GO6G T(MEAC5=JC# ]:XNWUEI3MW9&>OI70Z
M7.KL&W\@8!'K6<E=&OL[+4WPK"VCB$@V$=.XJ)["$*1C.>]3<1KYG#$UG7VL
M-$/+2+GKD5FK]#+6^AF:U8KY#$!1QTKE#I"WUO)#-$'8CY'(SMK8O3,9Q++<
M>8#R$'3\:?;O+Y_FJ -Q&<=!6MKJS-DVD<I>^![=D5B&)!.6SC]*Z+0;+3]#
M@W6\):=E(+'DFM!O]+RF"4)Y-+Y4<*X1163BNAA5JJUNI!*Y/)[]:HS-DU8F
M;K5-SF@Y3KO GW[WZ)_6NSKC/ GWKWZ)_6NSK)[EK8*SM>02:%>(W0Q\UHUF
MZ^<:#>'TCH6XSRZYTEBN^'D>E48WNK23"AMPYK:AN"*?,GF'S$QN[@]ZT:)3
M(K/Q&D9'G@KZD"MR-[?4+?S5 9&'<5A0QV+3JTL0C<'\#72VBPR)]Y<8XP:<
M6S9/0YVY\,0O)YMF_DOUP.AJ72].,,C"\.[L/2N@DL4 #PN0>XJA*\L# M'N
M&>M4DBU)M6$DTO3[8^?%$JN.<^M7HM138J,.".M0,;>X3D[C_=%1F-;= =N$
M]*KW4*UUJ8VL:--/?-/:'9(#E6S6K:6U^+=1+L)QR,U?0K'B5L%<<U8BF0KN
M7H:FUG=#;TL<?XC\/_VK821W"KN RIKQ>^TB6PNC&RXP2,U]+O"MRC @]*X_
M7/"D=\""BECTXYJ9QOJ3N>#SRK%$H_BK/$RORW7L*[SQ+X"O[!#.(LQ=B#7$
M&S:&;;(AXK'8EIB0Q[FR3@U?M6D=P<XP:J*&$XP*M0@[OE]:5Q6.LT4FWG64
MD-[,,@UT/BW4H;SP;/"+...0LF'48_B%<WIBN@5B/I6KKI5_#[(W&67/_?0J
MKJP6.8TRS  =A6L5(-0PJ(XE4>E3Q*6-:)6,6[LT=*MFNKQ(EP,'))KO=S6T
M2X'S8P#6-X1T_:OG2IF1QP".E=9/;QG(XP*I*^IUTE969S,]I<W-PJ(&"L<N
MU;2&/385C5,D\5;A@(CSN!%*84WKN^<@\4)6-[*Y8M0&0,>,U.UK'<G) )''
M2FK:LS ,VU/05>55A3*]%ZDU3(D[&-=:; DH<X##BH)&A7@?,0. *KW=XVHW
MC+#D0QGDCO5ZRM(UC\V5OH*E/L/979DSPW%VV)?W5N#\V#R14KLC!4C^Z!@<
MT_5I5,;Q0MMW+C-4;&W%E:"(,6[Y8\TNIRU>Y.P"C J!VYI9)*KEB308@QR:
MN6EBTA#,/EI]C9-,P9AA16QL")M'&*+!<AV*B[5%1GK3W-19H8D;FAQF7X56
M,:]6TY0/^^:X2:,H!D\@X->@>&Y!%\,]-D89"V"$C_@-<%?2N]Q(K#&T\5E1
M^!"C\,?0@6KMF^UA5!35F!L,*V0SI$226($RY7TJC<V^1\K%''1A5RSE4V^,
MU5NIL$TV--K8ABOKBT7$X+J.Z#-13WUG=H0K@$]O2HVN3GFJS6MM(^_R@KG^
M)>*6IK&JUN6H=-655;=O..F:G-BUJ=T2'CL*R774+>0-"XFB[CHP_P :T;36
MV*[#D,/X7'6I21NJK9'-!*DGGI'\Q^\O3(HQ$S9 :-^_-)=W_GD' &>X'2JC
MQ2[3)&X)QR#18T3+<TLL,>6;<N>"*S+B./486)0\<;J!<RR(RLO(')]ZT;&+
MSHE).W/'-+5Z"DM#(TN\GTB4VUP&:U)^1C_#75)&)HU=6!5AD4@T/SX""$(Z
M9]:6RM)-*_<7!/E%OE;' I_#HSDG'JBM>H\<?R#YJ\ZU_0[C[7YZ1_NY.>!T
M/I7IE]'MDW8R.Q!JG/$MS:.FT;A\RU,HIK4B,W'8\H:SE1?F0@"JEU&)4*EN
M@]*[;4(E2)SC!'^-9\.FM='Y>_4YJ53TT.F#YE=G%_V3/>1HN-J]-QKH-&\%
MQH$>2,NV<\C[U=?!I=E8+]HNG+,.%7( IUMJ)DN\VID9\X7:.U5&*CN:QAS:
MDUAHZPA08U11_"!R:W&OHH8&C4;5"X^7BLXW,R))OSYA'0]35*7>P5I&(]5K
MH53LBO9I[B73/( (@<>HJ73K*-Y$^TIG)]>E.ANHMWR)D$4R;4[?<1YBJ1U
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MX%*,+:F<W*>B.E=DC4LS!5'<FL:7QYHVE7B#<UPX;&V)<_K7FVKZ]JVJ:B(
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MBK5FD<?RDJ%/>E;H)JR.4G^T6%TTJC=&Q^8>E6_M$4I4JXY[9K8OM.$F2OS
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M[:X,F 9&-27%CO R,,:$NILWI9%,*B/D_/(>@%:-I97,B&7.S!Z#TH@M[:Q
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M'!ZU+)=P71S.BEC_ !=ZJY<:C0Q]"M)HR]K*%;V.*LV*7,06(R'<O<GK6:\
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M.:W)K?*B1>&!YJG<Q-,I=< C@@47"Q50^:X^;FNS\,B2!P 23Z&N3M;<L0K
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MZI10!C>&'N)-&0W#:@QWML;4(U25ER<9 ]O4 ^M;-%% !1110 4444 %%%%
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M-YOF[WQN"H2!C;CC!KN]'\3PZIJ=QIDME=65]!&LK0W 7)1LX8%21V/?-;M
M%#17FDTF!IQ=>81_R]JJR8[;@. :OT44 %%%% !1110!@>!_^1&T3_KSC_E6
M_6!X'_Y$;1/^O./^5;]3#X413^!>@4445184444 %,EC6:)XG^ZZE3]#3Z*
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M7MQ=W2S^;.D:.4DV\)G;CT^\:N:3X>L='GFN(#-)<3 *\T\A=RHZ#/I6K10
M4444 %%%% !1110 4444 %%%% !1110 445G7NO:3IT_D7NHVUO+C.R20*:
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \#_ /(C:)_UYQ_RK?K
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M4 %%%>?>)O%VM:7XB^P6<VE"!MG%Q)B49/.T=.GKBB^J0=+GH-0WG_'E<?\
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M .IHHHH **** .5UK_DH?A;_ *XWO_H*5U5<KK7_ "4/PM_UQO?_ $%*ZJ@
MHHHH **** "BBB@# \#_ /(C:)_UYQ_RK?K \#_\B-HG_7G'_*M^IA\*(I_
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MG_Q-']J^(_\ H64_\&"?_$T ;]%<CI'BS6=<L/MEGX:!A\V2+Y[] =R,5/\
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M^1J +^N64NHZ/<6D!022 8+G Z@UQ8\#:M_SUM?^^V_PKI?MGB[_ * 6B_\
M@XE_^1J/MGB[_H!:+_X.)?\ Y&IIM":N<Z/!&JC_ ):6O_?9_P *>/!>J#_E
MI:_]]G_"M_[9XN_Z 6B_^#B7_P"1J/MGB[_H!:+_ .#B7_Y&I\[%RHQ%\'ZF
M/^6EM_WV?\*E7PIJ*_\ +2W_ .^S_A6M]L\7?] +1?\ P<2__(U'VSQ=_P!
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M_P"#B7_Y&H^V>+O^@%HO_@XE_P#D:CG8<J,=O".HGI);_P#?9_PJ,^#M3/\
MRTMO^^S_ (5N?;/%W_0"T7_P<2__ "-1]L\7?] +1?\ P<2__(U'.PY48/\
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MB[_H!:+_ .#B7_Y&H^V>+O\ H!:+_P"#B7_Y&H WZ*P/MGB[_H!:+_X.)?\
MY&H^V>+O^@%HO_@XE_\ D:@#?HK ^V>+O^@%HO\ X.)?_D:C[9XN_P"@%HO_
M (.)?_D:@#?HK ^V>+O^@%HO_@XE_P#D:C[9XN_Z 6B_^#B7_P"1J -^BL#[
M9XN_Z 6B_P#@XE_^1J/MGB[_ * 6B_\ @XE_^1J -^BL#[9XN_Z 6B_^#B7_
M .1J/MGB[_H!:+_X.)?_ )&H WZ*P/MGB[_H!:+_ .#B7_Y&H^V>+O\ H!:+
M_P"#B7_Y&H WZ*P/MGB[_H!:+_X.)?\ Y&H^V>+O^@%HO_@XE_\ D:@#?HK
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:?_!Q+_\ (U'VSQ=_T M%_P#!Q+_\C4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>grk3fpqjsz23000013.jpg
<TEXT>
begin 644 grk3fpqjsz23000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "5 G # 2(  A$! Q$!_\0
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MD;?/:9&\D9C+')V$'*GT.?SKI:*V^N5N_P""_P C-48+2QD:7HATN:3R[G?
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M?@R;^R;_ /Y]9/RH_LF__P"?63\J@_X66W_0OW?_ '^2D_X68?\ H7[O_O\
M)1_J]@/^?_\ Y-$/K]?^3\&6/[)O_P#GUD_*C^R;_P#Y]9/RJM_PL[_J 7?_
M '^2D_X6>/\ H 7?_?Y*?^KN _Y__P#DT0^OU_Y/P9:_LF__ .?63\J/[)O_
M /GUD_*JG_"T5_Z -W_W^2D_X6FG_0!N_P#O\E'^KN _Y_?^31%]?K?R?@RY
M_9-__P ^LGY4?V3?_P#/K)^54O\ A:D?_0"N_P#OZE)_PM:+_H!7?_?U*?\
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M)=&_Z"$/ZU2R[&?\^I?^ O\ R#ZQ1_F7WHTS3368?$FC_P#00B_6FGQ'H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^?J^\/85?Y6>C^1%_P \D_[Y%'D1?\\D_P"^17FQ\>^)1_RY:3_WU)33X_\
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M!J__ (!/_A6BRS&?\^V+ZU1_F*QJ-JM'3M8/_,!U?_P#?_"FG3-9/_,!U?\
M\ W_ ,*M99B_^?;)^M4?YBI'_P ?UG_U\Q?^ABOHBO [?1]9>_M/^)'JB 7$
M;%GM'  # DDXKWROH\NHU*.&Y:BL[O\ )'GXB<9U;Q=]%^H4445VF(4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445SOBCQ'=:'-I\%I8QW4UXSJ \OEA=JYZX-)M)-MV2U^X#HJ*X4^,O$ _
MY@%K_P"!O_V--/C77Q_S +7_ ,#?_L:Y?[0P?_/V/_@2-/8U?Y7]S.\HK@3X
MYUT?\P"U_P# W_[&F'QYK@ZZ!;?^!G_V-/Z]A/\ G['_ ,"0>QJ_RO[F>@T5
MYVWQ"UE>N@VW_@9_]C49^)&K+UT&W_\  P__ !-4L9AG_P O(_>A>RJ?RO[F
M>D45YF?B=J:]=!@_\"S_ /$U;T7XC7>IZ]9:;-I$4*W+E?,6X+;<*3TV^U:0
MK4JCY833?JA2C**NT_N/0:***T)"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "N-U_RKCQOIMCK&TZ/):R,D4W^IFG!'#@\-A<D _T
MKLJAN;6WO83#=6\4\1ZI*@93^!HZ@<1JT&GPZ_HUBNT>'YY9OM,>?W!F"+Y<
M9[;<;N.F1BJDGAVSUZ^\2:%:P0MHZ01-:C:&BM[K!R(^RC&TD#CGWKT%K*U>
MT^RO;0M;8QY)C!3'ICI3X+>"UA6&WACAB7[J1J%4?0"CH!Q%D-'\6::^JW>F
M6A:SLVM766%3Y,F")$Y'08Q_^NL+2](\.S+X'6?3],>-[2?S!)#&0WR@\Y'/
M))^M>I-9VSP20-;0M#*29(R@VOGKD=\U3;P]HC*JMH^GE4&%!MDP._'%.^O]
M>?\ F*VECEO#%Y)87NO1:59WFH:+%=(EFMNZ%4.P>8J&1U&P-V!X.0*N>6O_
M  L:^6*9HYIM)7.9"=K;R 0,X'X5UD44<$2Q0QK'&HPJ(N !["HOL%D;LW9M
M(/M)7:9O+&\CTW8SBE_7X6'_ %^)Q'A"WN;?Q,T$4-LD=M9E+^XMGW)<SE@4
M9C@?/M#$]2-PYZ5W]1P6\-K$(K>&.*,=$C4*!^ J2FV'4****0!1110 4444
M %%%% !1110 4444 %%%% !7%>-_^0[X;_ZZ7'_HNNUKC?'%M>O?Z)=VEA<7
MBVTDQD6!<L-R8'ZUCB82J8>I".K<9)>KBRH-*<6^C7YE!Z@:H6N-4/\ S+>K
M_P#?E?\ XJHS)JI_YES5_P#ORO\ \57Y['(\P_Y]/\/\SV_KE#^8>W6H'[T$
MZL?^9<U;_OTO_P 54;)JY_YEW5?^_2_XUM')<?\ \^W^'^8?7:'\Q!+5*6KK
MVVLMT\/:I_WZ'^-5WT_6VZ>']3_[]#_&NB&3XY;TW^'^9+QE#^8SV ).3^M6
MM'"V^O6-S WF743DQ0@9+G:1C YZ9IKZ/KK=- U'_OT/\:O>&=#UJ/Q?I=Q/
MI%Y!!%*S/)(F !M(KTL%E>+C63=X;ZZ=CFK8JDX-+7R.WL]<UF;6+>&:P=$<
M8:,QLO'][)]*ZRDP-V[ SC&:6OH</2G2BU.;EZG!4FI/16"BBBMR HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>grk3fpqjsz23000014.jpg
<TEXT>
begin 644 grk3fpqjsz23000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %& G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:+?\^-Y_W['^-']HM_SXWG_?L?XU=HH I?VBW_/C>?\ ?L?XT?VBW_/C>?\
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M14/VNV_Y^(O^^Q1]KMO^?B+_ +[% $U%0_:[;_GXB_[[%'VNV_Y^(O\ OL4
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MKWMU;FPN +B(DQMQO'I0!:@_X]X_]T?RJ2HX/^/>/_='\JDH **** "BBB@
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M?^ Z?X4?\(WH?_0'L/\ P'3_  K3HH S/^$;T/\ Z ]A_P" Z?X4?\(WH?\
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ML/\ P'3_  K3HH S/^$;T/\ Z ]A_P" Z?X5'-H7A^W@DFFTK3TCC4L[&W3
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MJ?\ 0QWG_?B'_P"(H_L?5/\ H8[S_OQ#_P#$4 ;5%8O]CZI_T,=Y_P!^(?\
MXBC^Q]4_Z&.\_P"_$/\ \10!M45B_P!CZI_T,=Y_WXA_^(H_L?5/^ACO/^_$
M/_Q% &U16+_8^J?]#'>?]^(?_B*/['U3_H8[S_OQ#_\ $4 ;5%8O]CZI_P!#
M'>?]^(?_ (BC^Q]4_P"ACO/^_$/_ ,10!M45B_V/JG_0QWG_ 'XA_P#B*/['
MU3_H8[S_ +\0_P#Q% &U16+_ &/JG_0QWG_?B'_XBC^Q]4_Z&.\_[\0__$4
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M)XH"@$D #/7 ZT <F;[4X_&=[Y6C-+BSC4?Z0@RN]\-SZ^E:?]IZU_T+S_\
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M#6HK)_X2C0?^@Q8_]_U_QH_X2C0?^@Q8_P#?]?\ &@#6HK)_X2C0?^@Q8_\
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M_K_C5&)K57OO^0?<?]<F_E5'_A*-!_Z#%C_W_7_&H;OQ)HDEG.B:M9,[1L%
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MN]12,NIS';J/DB]_]IO?\JT_(B_YY)_WR*>2%!). *YB_P!=NEU7R[8CRXR
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M(XO_ $%]6_\  H_X57O-*MK&(//K.KC)PJBZ)9SZ 8R30W8:3;LCHF8(I9B
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^1SN_\ KPA_]#DK9H QO/\ $G_0/TS_ ,#'_P#C='G^)/\ H'Z9_P"!C_\
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MV3^5/F3VU'[&=]5;UT+/VCQ)_P! _3/_  ,?_P"-TOG^)/\ H'Z9_P"!C_\
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M^9$ET-N?DB;=PW/7Y1S[].*WM'U6/5('<,GF*QW1C.4&3MS[\?GD=J ((?\
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M_;=HWWM6U'_@-@R_^TZ;)K.B1QF2YU'5-BCYF>.90/R44_9Q6R?WDNO7EO\
MU^9L);7?DY\FPMG_ -E"X'\JI2Q7"'_2M?BC']V-4C_Q-5QJ/AK^**YD_P"N
MEK._\UJQ%KOA^'_50R)_NV$@_P#9*%!K9B<JDM[$'DZ<Y^:>6\/^[+*/YXJ0
MQ&*"3[+ILD0VGYQ#''C^9_2K7_"4Z2/XKG_P#E_^)H_X2K2?[]U_X!S?_$T.
M#>\G][_S)Y9>7W(R]&T[5$E=9!':,Z!@ &((]>,<^V>*V1HC/_K[V5_9 %']
M3^M1?\)5I/\ ?NO_  #F_P#B:7_A*])_OW7_ (!S?_$U*P]-+:X1@TK-M_,L
MQZ)I\9!^S*[#^*0ES^M7T147:JA0.P&*Q_\ A*])_OW7_@'-_P#$T?\ "5Z5
M_?NO_ .;_P")K5)+8I12V1M45A'Q?HRR+&9K@.P)53:2Y('7'R^]/_X2O2O[
M]U_X!S?_ !-,HVJ*Q?\ A*]*_OW7_@'-_P#$T?\ "5Z3_?NO_ .;_P")H VJ
M*Q?^$KTG^_=?^ <W_P 31_PE>D_W[K_P#F_^)H VJ*Q?^$KTG^_=?^ <W_Q-
M'_"5:5_?NO\ P#F_^)H VJ*Q?^$KTK^_=?\ @'-_\33$\7Z-(6"37#%&VMBT
ME.#Z'Y?>@#=HK%_X2O2?[]U_X!S?_$T?\)7I/]^Z_P# .;_XF@#:HK%_X2K2
MO[]U_P" <W_Q-'_"5Z5_?NO_  #E_P#B: -JBL7_ (2K2O[]U_X!R_\ Q-'_
M  E>D_W[K_P#F_\ B: -JJ]]_P @^X_ZY-_*LW_A*])_OW7_ (!S?_$U7OO%
M6DFPN/WER/W3<FTE ''^[0!O0?\ 'O'_ +H_E4E16Y#6T3*<@H"#^%2T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 4(M%TZ".>.*U15G_P!8 3R,YQ].3QTYJ6VT^TLI)I;>
M(1M,VZ0@]3R?PY)/XFK5175NEW:RV\A<)*A1BC;2 1C@]J ,3_A)-%$DE['O
MDDR\+R)&2=L9RQ_W1NZ^];ZD,H92"",@URJ^"U@CE2VU"4>:95;S5WXCD"@J
M.1@C:,']*ZF-!%$L:_=4!1^% #J*** &E%;[R@_44H&!BEHI66X!1113 HZI
MJMMI$$<MP'/F.(T5%R6."?Y U6L-4TY;H:=;1/$2S8S'A=^-[+G^]\V3^-3:
MQIK:G;QHCPJR,6_?0"53D$=#WYZ@U0TWPS_9UU;LMVTEO QD1&3YMY0(26SR
M, G&.IH Z"BBB@ HHHH **** "LC4=3TW[2=,NT:0.H,@V951R1N_(UKUSVI
M^%8M1U5KQI5190@E'EY?Y,XVMGY0<X/!S0!I:;JMMJB.8!(I3:2LB%3AAE3C
MT(J_65H^DR:;YKS7(GE=4CW!-H"(,+QD\\G)K5H **** "BBB@ HHHH YY_$
M&G&_)DLKL7EO^[0- =QWY.%^H3/T%;EM<17EK%<P-OBE0.C8Z@]*R)= <J98
M;H+=_:VNA*\>X9*E=I&1D!3CKVK3TZR33M.M[.-BRP1A QZG ZT 6:*** "B
MBB@ HHHH K7][#IUF]S/NV*0,*,DDD  ?4D5EV>O:3YZK;I(ING#2/Y9 $C9
M4!CV)VX_"KVL:;_:NG-:>8$RRM\R[E.T@X8=P<8(K(M/"1M7A O 8 Z2RQB+
M&61BRA>?E49QCG@"@#IJ*** "BBB@ HHHH *R]3U2PMY/L-XKNLL?[P!,JJ,
M=N6/8$G%:E8FM^'4UFZ@DDE5$0!7&SYF 8-@'(].X/YT 6-,UBQOW-M:[U\M
M R!DVADS@,OJ,C%:=8NCZ!_9EUYSW/G;(!;0@)MVQABW//)]^.E;5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 444UW$<;.>B@DT .HJA'?7$L
M:R)I\I5@"/G7H?QIWVNZ_P"@=+_W\3_&@"[15+[7=?\ 0.E_[^)_C1]KNO\
MH'2_]_$_QH NT52^UW7_ $#Y?^_B?XT?:[K_ *!TO_?Q/\: +M%4OM=U_P!
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M+,;29Z9SA2.<=>U=?"IMXH(HM'*I @2(!D^10,8'/%/1WC.4TDK@Y&TH/ZT
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MQZ;XDCEAC$LACW-()'DW&,F9#M(R-PV@D>Q(KI_[-/\ S_7G_?P?X4?V:?\
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M46B6FHP:W<//'/Y+JV7EDSSN& ,,01C/8$=.:U_[-/\ S_7G_?P?X4?V:?\
MG^O/^_@_PK9*RL037(NSM^S/$O\ >\Q2?Y$5F>3KWV[=Y]OY&[IL/IUZ]/:K
MO]FG_G^O/^_@_P */[-/_/\ 7G_?P?X4FKF<J:D[W93U.#5Y],DMHWB,L[*F
M^,F/RT_B.<D].!CUK*M+76O[6L9KJ&8O&%CE;S/W>%R"P(;OP<%3G(Z5T/\
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M30A',6[*Y!R%).TL.F,B/4=.\2&PTJWFL))+^ULK4K=K$TTAE#?O!Y@<",J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>grk3fpqjsz23000015.jpg
<TEXT>
begin 644 grk3fpqjsz23000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &2 G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***X^Z\0^(;CQ7J&CZ-8:=(EE%$[R74[H3O!Z *?2@#L**Y3[3X\_Z!NA
M?^!<G_Q%'VGQY_T#="_\"Y/_ (B@#JZ*Y3[3X\_Z!NA?^!<G_P 11]I\>?\
M0-T+_P "Y/\ XB@#JZ*Y3[3X\_Z!NA?^!<G_ ,11]I\>?] W0O\ P+D_^(H
MZNBN4^T^//\ H&Z%_P"!<G_Q%'VGQY_T#="_\"Y/_B* .KHKE/M/CS_H&Z%_
MX%R?_$4?:?'G_0-T+_P+D_\ B* .KHKE/M/CS_H&Z%_X%R?_ !%'VGQY_P!
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MI:GXAN]%MX_#.K6RP:E#<22W"($5%)R>&/K0!W]%%% @HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBN*_XN7_ -2Q_P"1J/\ BY?_ %+'_D:@#M:*XK_BY?\ U+'_ )&H_P"+E_\
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M_P __A__ ,!Y?_BJ/(^(7_/_ .'_ /P'E_\ BJC_ .$E\9?]"(__ (,XJ/\
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M RR8M8 >90P8M\Z%%R_!SSZ#M71PNTD$;NA1F4$J>JGTKD_^$3U__H>=4_\
M >'_ .)H_P"$3U__ *'G5/\ P'A_^)H Z^BN0_X1/7_^AYU3_P !X?\ XFC_
M (1/7_\ H>=4_P# >'_XF@1U]%<A_P (GK__ $/.J?\ @/#_ /$T?\(GK_\
MT/.J?^ \/_Q- #/#UM!/XU\6M+#&[+<0;2R@X_=J?Y@?E5GQQI]DO@36RMI
M,64F,1CCY?\ ZP_(5:\-^&GT&;4+B;4[C4+F^D5Y99T53\J[1PH Z5K:C80:
MKIMQ872EK>XC,<@!P2IX/- ROH'_ "+NF?\ 7K%_Z"*T:XU/AII$<:QIJ.O*
MBC"JNJS  >GWJ7_A7&E?]!37_P#P:S?_ !5 CJ;Z&2XLY(XI&20CY65L'/UK
M%ETO4V\R1;B02!R5 F.ULYY/IQ@8JA_PKC2O^@IK_P#X-9O_ (JC_A7&E?\
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MZ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMGX;1RIX/0S030-)=7$@29"C -(Q&0>1P:ZZB@04444 %%%% !1110 4444
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MXA_Z'G4O_ >+_"G_ /"R/#W_ %$O_!=/_P#$4?\ "R/#W_42_P#!=/\ _$4
M4=&DU;2_B'_8U]X@GU.V?3C< 3(BE7\P+_"/2N\KPR5?#4GQ=C\6;M0^QB'>
MT7]GS\SC@'&WICGZBO1?^%D>'O\ J)?^"Z?_ .(H ZZBN1_X61X>_P"HE_X+
MI_\ XBM?0?$NF>)([A]-ED?[.XCE62%HV5L9QA@#TH$:]%%% !1110 4444
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MP<_2D,I:/JDVH*5GMA%(B*7()*Y(Z#(K$\(?\C3XQ_["$?\ Z)6NN5%4L54
ML<L0.IKD?"'_ "-/C'_L(1_^B5I@=A1110(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E#
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MN88+J^1XOM$+1E@(U&<,,]17;44 %%%% !1110 4444 %%%% !1110 4444
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MV<G Q)#_ /$4".SHKSZ:TU+0?$WAW'BG4M0MKVZ>*6*Y:,H0(F;^%1W KO\
M>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]
MY?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(_$H;O!
MTB;F4275NC;6*D@RJ",CGI775YI\:=8U+2/"UL]I8)=6SW47FMN(9&5PR\>A
M(Q0".B_X5UX8_P"?"3_P*E_^*H_X5UX7_P"?"3_P*E_^*K<T>XO+O1[2XU"W
M2WNY8@\D*'(0GMFKM '+?\*Z\+_\^$G_ (%2_P#Q5'_"NO"__/A)_P"!4O\
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M9_T$;3_O\O\ C0!:EBCGC,<L:2(>JNH(JO\ V7I__/C;?]^5_P *;_:^F?\
M01M/^_R_XT?VOIG_ $$;3_O\O^- #O[+T_\ Y\;;_ORO^%']EZ?_ ,^-M_WY
M7_"F_P!KZ9_T$;3_ +_+_C1_:^F?]!&T_P"_R_XT ._LO3_^?&V_[\K_ (4?
MV7I__/C;?]^5_P *;_:^F?\ 01M/^_R_XT?VOIG_ $$;3_O\O^- #O[+T_\
MY\;;_ORO^%<I\1-/LH_"FY+.W5OMEL,K$ ?]<GM74_VOIG_01M/^_P O^-<I
M\1-3L)?"FV.^MG;[9;'"RJ3_ *Y/>@:.M_LO3_\ GQMO^_*_X4?V7I__ #XV
MW_?E?\*;_:^F?]!"T_[_ "_XT?VOIG_01M/^_P O^- AW]EZ?_SXVW_?E?\
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MNF:_:M=:5>1W4".49X\X##M^M:- !1110 4444 %%%% !1110 4444 %%%%
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MMY-!F5@MU'YT 0,6^<%&'T8#\Z .B_X5QX,_Z%K3?^_ H_X5QX,_Z%K3?^_
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M#O\ T M,_P# 1/\ "M7S$_OK^='F)_?7\Z ,K_A%?#O_ $ M,_\  1/\*/\
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\ST#P9H?B*_\0WFJ6LD\ZZM/&&\]UPH(P, @5L3?#/P?!!),^F2;44L<7,I.
M!_P*I_ O7Q%_V&KC^8KJI8UFB>-QE'!4C/:@9Y[!X.\ SQ[C8R1< D/<R<9)
M Y#$=CWIT?@WX?R!#]E9=ZY&ZYE'_LU=<WAW3' W0%N<DEV))YZ\^YJCJ-CI
MMC) K:<\PP6#B3E H]STZ#\:0&--X!\"P2^4]DVX'!Q<RG'&?[WI3'\#> 8K
M;SOLN8\$C;<RDG SP-U;33Z5?W7EW5I)&9#RTCX3<.#CG&>,569M%CFEMH;*
M5UB&%9)3M(V_,0<^@_&@#.'@?P$8RYM"H'7-S+Q_X]34\%> '7=]E*C_ &KF
M4?\ LU;UM;:1J<LEHUI)&5);RW<C/;(&>XK1&@Z<#_Q[_7YCS0!SL/PT\&7$
M0EBT]V0]"+F7_P"*K#\:> _#NB>&)]0T^SDANH982CBXD.,R*.A;T->FQ1)"
MFR-<+DG'N3DURWQ)_P"1&O/^ND/_ *-2F(ZM?N#Z5P6N:#IWB+XEQ6FJ0O-!
M'I1D5!*R -YN,_*1VKO5^XOTKE#_ ,E7'_8&/_HT4 1?\*N\(_\ 0-?_ ,"9
M?_BJ#\+_  B 3_9DG'_3S+_\578U'-,EO"TLAPJCG S0!Y]'X.\ R/M^P2J1
MC.;B7C(S_>_#Z\5+_P (/\/V)'V<' R?]*EQ_P"A5N+<:";@HT312LQ09# Y
M+;OPY_E44K^'6:.(V[/&H.&PVT'OCU/-(9D'P3X '_+MD=R+J7CC/]ZIH/A]
MX&N9?*AM"[[=VT74O3C_ &O<?G6E/<Z!;E(3 Y96^Z58;?EZG/LM36,FDQ:O
MYT$LHDE&U8RI"C=CG\<#F@"A_P *N\(_] U__ F7_P"*H/PN\(X_Y!K_ /@3
M+_\ %5V-(>AIB/-]$7[/\%]5CC9@(HKY4)8D@!Y .>M6-!^&WA:[\/Z=<SZ?
M(\LMM&[M]IDY)4$G[U0Z5_R1O6O]S4/_ $9)79>&/^15TG_KTB_]!% SEIO
M/@J"X:)]*GVQC,DHN)=B<9 )W>E1Q^"_ ,DK1BR<,IP<W$O7_OKGK7;SZ9:7
M,_G2QDL0,_,0#CID=.]1'1+ RF7R2')SN5R#D]: .//@?P'NE"V+N8D+OMN)
M> ,9_B]Q4;^#?A\L19K4G R5^TRD_P#H5=9+INFZ5:SS):,RR#:X4Y)!('<^
MPJK$FC3R2VDMM]G,1_Y:/MSSP1S[T@,1_ ?@2,Q;K,@2C*'[5+SSC^]4?_"$
M^ !*8S:D87=N-S+@]>^[V-;4T^F2"**YT^41HYC$C-E0<@\MGU/Y@UK'1-.D
MBV& .AQC+$\ '&/S- ''GP3\/QG%N&(&<"ZE],_WJM6_PY\$W6_R;%GV-M;%
MS+P?^^JZ<:'IRQ&,6XVGDC)YZ?X"I;+3;73A(+6+RQ(VYN2<FF!Y]KW@[0_#
MFI^'+O2K5X)GU:*-F\]VRI#9&"2.PK;^(]O'>:+IMI,&,,^J6\<BJQ7<I;D9
M'-/\<_Z[PS_V&8?_ $%Z=X]_X\='_P"PO:_^A4 4+WX?>"; 0FXTZ51*^Q2+
MB7 .">?FXZ5$/!/@ HK?9B-V, W,N>?^!5W-S:07D82XC$BC/!]P0?T)JJFA
MZ=']VW'"[1EB<#TH XN+P=X ECB?[%*AEY56GESC!.3\WH*L1^ _ DD;2+9M
ML5@N[[3+R2,X'S5LZI8:-IJ^8]B[LR\A&.0HPOK[BBQET=XKJWBMY(X;=M^_
M<?F.2,C!SSS^=(#$/@?P "P^S99<Y47,N>/^!>XIL'@?P#<*C+:8+#(#74@/
M/_ JWHT\/PVL]RD;K&&"N^&!#'!Q]>E1(_ATPLIMY N"K*5;'IG^7/N* ,@>
M!O !?9]G&[T^U2_7^]T]Z5O O@-45OLA.6"@"YESS_P*M*-O#5PGGI!O:91,
MR\],D_3UJ:]CTV"Z>&33YI2%X/FY##&?7C@'KZ4 9$?@/P'+&[I:Y6-=SG[5
M+\HSCGYO44A\#>  JDP+AC@?Z7+_ /%5O:8NE2BXTZ*T:%7SN20\N,YR/SS5
M]M!TU@ ;9>,8.3GC('\S0!REOX"\"W5P(8+-I'*EOEN9<8&.^[W%)X8T6Q\/
M_$;5['38GBMCI\$FPR,XW%WR?F)]!796^FVEK,)88MCA=F03TX_P%<Y8_P#)
M5=7_ .P7;_\ H;TP-#QJQ7P1K;*2"+.3!!Y'RFL#2?AIX4N-&L9Y=.D:22!'
M9OM,O)*@G^*M[QO_ ,B-KG_7E+_Z":OZ%_R+^F_]>L?_ *"*!'/?\*N\(_\
M0-?_ ,"9?_BJ/^%7>$?^@:__ ($R_P#Q5=C10!Q%U\-_!MG:2W,FF2E(E+MM
MN)2<#T^:J<?@SP [2*;1DV8R6N90#D _WO<?C7<:E-%#9.9HGEC8A&5?0G'Y
M5SOF:.I(?3)8T\QHV)) '((W>Q/(^E(9D-X,^'Z1[_L;\L0!Y\H)(..[5/:>
M O M[Q!9,6R1M-S*#Q_P*M?48M&BN(YWM//WDXD23(#X)QU[_P!:=IUQI\6J
M)LMI()'3RTWD;1R=P![\T 4O^%7>$?\ H&O_ .!,O_Q5'_"KO"/_ $#7_P#
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M0D9F?P!?$L<DF6#G_P >KMJ* .-&OZJL_GCP+J(EZ;_.AS_Z%4W_  E.N_\
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MCC<NWD$=.:Q8[CQ5#CRO".E)MSC;? 8SU_@J1+_QA'GR_"VFKGKMU'&?_'*
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M8)H<9/?[]6E\4:VJA5\$ZF !@ 3P_P#Q5=6GW%^E.H$<G_PE.N_]"5J?_?\
MA_\ BJ/^$IUW_H2M3_[_ ,/_ ,57644 <!JMQKOB+4-#B/AB]LHK748[F6::
M:(J%4,#PK$]ZV/'-G?7>DV3Z?9O>36U_!<&%&"EE5LG!) KIZ* .3_X2G7?^
MA*U/_O\ P_\ Q5'_  E.N_\ 0E:G_P!_X?\ XJNLHH XR?7M6N71I? ^I,4R
M #/#C!_X%[#\J:NM:BB,B> ;]5=0K 2P<@=!]ZNUHH XO^VM2\@P?\(%?^43
MDIYL&"?^^J9_:U_@#_A7]]@-NQYL'7_OJNWHH'<X8ZG?$8'@"_7C'RRP#CT^
M]3GU:_DFDE?P!?M))C>QF@RV.F?FKMZ* .-&O:J+CSQX$U$2@8W^=#G_ -"J
M;_A*==_Z$K4_^_\ #_\ %5UE% CD_P#A*==_Z$K4_P#O_#_\54/AU-5O/&VI
M:Q?://IT$ME#!&LTB,6968G[I/J*[*B@#(\56<^H>$]5L[6/S+B>UDCC3.-S
M$<"L'3O$.OV>F6MJ_@O4F:&%(R1/#@D #^]7:T4 <G_PE.N_]"5J?_?^'_XJ
MC_A*==_Z$K4_^_\ #_\ %5UE% '(OXFUJ5"C^"-293U!GA_^*J#^V=1\MH_^
M$"O]K-N(\Z#D^OWJ[6B@#@+;Q5/J<EPD/@6^E:SD-O(#)#\C  X^]Z']:M_V
MWJ7[O_B@]0_=XV?OH>,?\"JWX/\ ^0CXH_["S_\ HM*ZF@9R?_"4Z[_T)6I_
M]_X?_BJ/^$IUW_H2M3_[_P /_P 57644".3_ .$IUW_H2M3_ ._\/_Q54H'U
MG6O'.D7]QX?NM.M;."=7DGEC;)<#&-I/I7<T4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !16!XWO;G3O!6KWEG,T-S#;LT
M<B]5/K5"'PEJ$D$;GQCKV64$_-#Z?]<Z .NKS?XTZIJ6E^#HVL[%+J"2YC68
MY.Y"&#+@#J"1C\:UD\.2R1AU\=:T5)(!\V'DC@_\LZ9<^#6N[=X[GQEK$L*D
M,RN\! *D$9_=]CB@9TVBW%Y=:+9W&H6Z6]W+$KRPH<A"1TS[5?KC/^$=D^3'
MCK63OP% EA.<\_\ //TJ1?"UT[!5\;ZVQ/0"2$Y_\<H$=?17GNOZ=JOAP:9=
MP^*=7N?,U&W@>*<QE&1W (.$!Z>]>A4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "$X4GT%<'H^M^.->TY=1L[;0TMY'=4$KR[L*Q7G ]JZW6[RZL-$
MO+NRM/M=Q#$72#?MWX[9P>:XCX,:W=ZSX-/G:<;6""9TBD+Y,I+%FXQQC.*
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M+_\ %5U5% '*_P#"N?#'_/E-_P"!<O\ \51_PKGPQ_SY3?\ @7+_ /%5U5%
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
